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INFLAMMATION AND BREAST CANCER RISK 
Gretchen L. Gierach, PhD 
University of Pittsburgh, 2006 
Mammographic density is one of the strongest risk factors for breast cancer.  Exactly how breast 
density increases breast cancer risk is unknown, although it is believed that dense breast areas 
may reflect exposure to estrogen.  Breast cancer incidence is highest in postmenopause, when 
most estrogens are produced in non-ovarian tissues.  Cyclooxygenase (COX)-2 and the cytokine 
tumor necrosis factor (TNF)-alpha may play a role in regulating estrogen synthesis in 
postmenopausal women.  The aim of the present study was to explore the association between 
inflammation and breast cancer risk in two populations of postmenopausal women.  Different 
exposures associated with inflammation (i.e. non-steroidal anti-inflammatory drug (NSAID) use, 
circulating receptors for TNF-alpha, and a polymorphism in the TNF receptor-II gene) were 
measured and tested for their association with incident breast cancer or mammographic density.  
In the first study, the Study of Osteoporotic Fractures (SOF), complete NSAID medication and 
breast cancer risk factor information was available for 6695 women, mean (SD) age 73 (5) years.  
During a mean (SD) of 13.2 (3.8) years of follow-up, 372 women were diagnosed with primary 
breast cancer.  There were no differences in incident breast cancer by NSAID use, either before 
or after adjusting for covariates.  In the second study, Mammograms and Masses (MAMS), mean 
mammographic density was lower among women in the highest quartiles of circulating soluble 
TNF receptor levels.  After adjustment for body mass index, the inverse association disappeared.  
In evaluating the TNFR2 –196 M/R polymorphism (T>G), the unadjusted mean (SD) 
mammographic density was higher in women with the TT genotype (32.3% (21.0)) as compared 
to women with the TG/GG genotypes (26.6% (17.2)), p=0.003.  The association remained 
statistically significant after adjustment for age and BMI (p=0.03); however, inclusion of 
additional covariates reduced the level of statistical significance (p=0.08).  There was no 
observable difference in circulating sTNFR2 levels between the TNFR2 genotypes.  An 
increased understanding of factors that affect mammographic density and their underlying 
iv 
mechanisms is needed, and inflammation may be involved.  An association between breast 
cancer risk and inflammation would have important pubic health implications for screening and 
primary prevention of breast cancer. 
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1.0  INTRODUCTION 
1.1 BACKGROUND AND SIGNIFICANCE 
In the following literature review, a brief description of the epidemiology of breast cancer, 
cytokines and mammographic density will be followed by a review of the potential relationship 
among these factors. 
1.1.1 Epidemiology of breast cancer 
Breast cancer incidence rates in the United States are 20%-40% higher in white women than in 
non-white women; however, U.S. incidence rates are higher in young (age < 40) black women 
than in young white women (Figure 1).  Worldwide, incidence rates for 1988-1992 were low in 
Asia, moderate in South America and Eastern Europe, and high in North America and Western 
Europe (1).  Migrant studies of increasing breast cancer rates among first-generation daughters of 
Japanese American women suggest that environmental and lifestyle factors are of greater 
significance than genetic factors in explaining international differences in breast cancer risk (1-
3).  The identification of potentially modifiable risk factors for breast cancer therefore provides 
opportunities for breast cancer prevention among women both at average and high risk. 
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Figure 1. Age-specific incidence of invasive breast cancer among US women, 2001 
 
SEER*Stat Database: 9 SEER Incidence Registries for Public-Use, National Cancer Institute, 
DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based 
on the November 2002 data (for the years 1973-2000). 
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1.1.1.1 Risk factors for breast cancer 
Few breast cancer risk factors have prevalence in the population of greater than 10% to 15%, 
although some are associated with very large relative risks (e.g., mutated genes, cellular atypia).  
Age is one of the most important risk factors for breast cancer (4).  While age-adjusted incidence 
rates continue to rise, breast cancer mortality has fallen in the past decade in the U.S (5).  The 
relationship of age to invasive breast cancer incidence in 2001 in U.S. women is also depicted in 
Figure 1.  Recently investigated epidemiologic risk factors for breast cancer are shown in Table 
1, along with the magnitude of their associated risks (6).  Traits associated with large relative 
risks are rare; common risk factors are associated with relative risks less than 2.0 so that the 
attributable risk for any particular risk factor is small (7).   
 
Table 1. Newer epidemiologic risk factors for breast cancer 
Risk factor Effect Odds ratio/relative risk (95% confidence interval) 
Anthropometry (BMI) 
Premenopausal 
 
       
      Postmenopausal 
 
Negative 
 
 
Positive 
 
For BMI ≥ 31 kg/m2 vs. BMI < 21 kg/m2: 
RR = 0.54 (0.34, 0.85) (8) 
 
For BMI ≥ 25 kg/m2 vs. BMI < 21 kg/m2: 
RR = 1.26 (1.09, 1.46) (8) 
For BMI > 22.6 kg/m2 vs. BMI ≤ 22.6 kg/m2: 
RR = 2.52 (1.62, 3.93) (9) 
Endogenous hormones Positive For increasing quintiles of free estradiol vs. 
the lowest quintile: (10)  
RR = 1.38 (0.94, 2.03) 
RR = 1.84 (1.24, 2.74) 
RR = 2.24 (1.53, 3.27) 
RR = 2.58 (1.76, 3.78) 
Estrogen metabolism  
(2:16 OHE1 Ratio [EMR])  
Negative? For EMR in the highest tertile vs. the lowest 
two-thirds: (11) 
OR = 0.71 (0.29, 1.75) 
 
By menopausal status: (12) 
OR (pre)  = 0.58 (0.25, 1.34) 
OR (post) = 1.29 (0.53, 3.10) 
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Table 1 (continued) 
Risk factor Effect Odds ratio/relative risk (95% confidence interval) 
Reproductive factors 
 
 Age at menarche 
 
Age at first live birth 
 
Parity 
 
 
Negative 
 
Positive 
 
Negative 
For breast cancer diagnosed pre- and post-
menopause: (13) 
OR (pre)  =  0.91 (0.89, 0.93)  
OR (post) =  0.96 (0.95, 0.98) 
OR (pre)  =  1.05 (1.05, 1.06) 
OR (post) =  1.03 (1.02, 1.04) 
OR (pre) =  0.97 (0.94, 0.99) 
OR (post) =  0.88 (0.86, 0.90) 
Breastfeeding Negative For every 12 months of breast-feeding: (14)  
OR = 0.96 (0.94, 0.97) 
Preeclampsia Negative ORs range from 0.27 (0.08, 0.63) to 0.81 
(0.61, 1.1) (15) 
Induced abortion Null RR = 1.00 (0.94, 1.06) (16) 
                                                                            
Bone mineral density 
 
 
 
Bone fracture  
Positive 
 
 
 
Negative 
For the highest quartile of BMD vs. the lowest 
quartile: (17) 
RR = 2.7 (1.4, 5.3)   
 
For history of fracture vs. no fracture in past 5 
years: (18) 
OR = 0.80 (0.68, 0.94) 
Biological growth factors 
TGF-β1 
 
 
 
  
 IGF-I 
 
Positive 
 
 
 
 
Positive 
 
Protective effect for women lacking the 
common TGF-β1 genetic polymorphism vs. 
women with the common variant: (19)  
Hazard ratio = 0.36 (0.17, 0.75) 
 
Top vs. bottom tertile of IGF-I: (20) 
RR = 2.9 (1.21, 6.85) 
Exogenous hormones 
Oral contraceptives 
 
 
 Hormone therapy 
 
Null? 
 
 
Positive 
 
RR = 1.24 (1.15, 1.33) (21) 
RR = 1.11 (0.94, 1.32) (22) 
 
Hazard ratio = 1.26 (1.00, 1.59) (23) 
Exercise/physical activity Negative ORs range from 0.3 to 1.6, with an average 
risk reduction of 30-40% (24) 
Alcohol consumption Positive For 12 g/day vs. nondrinkers: 
RR = 1.06 (1.00, 1.11) (25) 
 
HT for ≥ 5 years plus ≥ 20 g/day:  
RR = 1.99 (1.42, 2.79) (26)  
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Table 1 (continued) 
Risk factor Effect Odds ratio/relative risk (95% confidence interval) 
Smoking 
Premenopausal  
 
 
 Postmenopausal 
 
Positive 
 
 
Negative 
 
OR (parous) = 1.69 (1.13, 2.51) (27) 
OR (nulliparous) = 7.08 (1.63, 30.8) (27) 
 
OR = 0.49 (0.27, 0.89) (27) 
Breast implants Null? RR = 0.72 (0.61, 0.85) (28) 
Diet Null Fats compared with equivalent energy intake 
from carbohydrates for an increment of 5% of 
energy: (29) 
RR = 1.09 (1.00, 1.19), saturated 
RR = 0.93 (0.84, 1.03), monounsaturated 
RR = 1.05 (0.96, 1.16), polyunsaturated   
Dietary Micronutrients 
Beta-carotene 
Lycopene 
Total carotene 
 Folate 
 
Negative 
Negative 
Negative 
Negative? 
 
OR = 0.41 (0.22, 0.79) (30) 
OR = 0.55 (0.29, 1.06) (30) 
OR = 0.55 (0.29, 1.03) (30)                                 
For lowest 10th percentile of folate intake vs. 
≥ 50th percentile: (31) 
RR = 1.21 (0.91, 1.61) 
Among drinkers of > 4 gm per day: 
RR = 1.59 (1.05, 2.41)  
Phytoestrogens Null For the highest vs. lowest quartile: (32) 
OR = 1.0, (0.80, 1.3)  
Ionizing radiation Positive OR = 1.4 (1.2, 1.8) (33) 
RR = 4.1 (2.5, 5.7) (34) 
 
Environmental toxins 
 p,p'-bis(4-chlorophenyl)-1,1-
 dichloroethene  
 
 chlordane  
  
 dieldrin 
 
 PCB congeners 
 
Null 
 
 
Null 
 
Null 
 
Null 
 
OR = 1.20 (0.76, 1.90) (35) 
 
 
OR = 0.98 (0.62, 1.55) (35) 
 
OR = 1.37 (0.69, 2.72) (35) 
 
OR = 0.83 (0.54, 1.29) (35) 
Electromagnetic fields Null OR = 1.12 (1.09, 1.15), (36) probable bias due 
to misclassification of exposure  
HIV infection Null? OR = 0.18 (0.04, 0.76) (37)  
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1.1.1.2 Estrogens and the risk of breast cancer 
Based upon the association of hormonally related risk factors such as age at menarche and age at 
first live birth with the risk of developing breast cancer, differences in endogenous estrogen 
levels are theorized to affect the risk of breast cancer (38).  Exposure to estrogen over prolonged 
durations and higher concentrations has been consistently related to an increased risk of 
postmenopausal breast cancer in many epidemiologic studies (10, 39).  In a pooled analysis of 
nine prospective studies of endogenous hormone concentrations and breast cancer risk, serum 
estradiol concentrations predicted risk for postmenopausal breast cancer (10):  the relative risk 
(RR) for women with the highest quintile of free estradiol concentration, relative to the lowest 
quintile, was 2.58 (95% CI: 1.76-3.78).  Hence, a single measurement of bioavailable estradiol 
may be used to estimate a woman’s risk for breast cancer.  In postmenopausal women, BMI is a 
critical determinant of estrogen production (40).  Results from the Women’s Health Initiative 
(WHI) Observational Study confirmed the effect of increasing BMI on breast cancer risk among 
postmenopausal women, but only among those women who had never taken HT, with heavier 
women (baseline BMI >31.1) having an increased risk of postmenopausal breast cancer 
(RR=2.52; 95% CI: 1.62-3.93), compared to slimmer women (baseline BMI <22.6) (9).  In 
addition, bone mineral density (BMD), perhaps one of the best surrogate measures of lifetime 
estrogen exposure, is positively associated with breast cancer risk (17, 41).  Extensive data also 
link the use of HT after menopause, a major source of exogenous estrogen exposure in 
postmenopausal women, to the risk of developing breast cancer (23, 42).  Taken together, these 
studies all suggest that increased lifetime endogenous and exogenous estrogen exposure appears 
to increase breast cancer risk.  Despite the evidence implicating estrogens in breast cancer, the 
underlying mechanism by which estrogens exert their effects remains unclear.   
1.1.2 Cytokines and the risk of breast cancer  
Although data strongly implicate estrogen in breast cancer risk, increasing evidence suggests that 
cytokines may play crucial roles in postmenopausal breast cancer etiology (43).  In particular, the 
cytokine TNF-α has emerged as an important regulator of estrogen synthesis in the breast (43). 
Moreover, inflammatory cytokines induce a range of inflammatory enzymes, including 
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cyclooxygenase (COX)-2. COX-2 cyclizes and oxygenates arachidonic acid eventually 
producing prostaglandin E2 (PGE2) (44, 45).  COX-2 is believed to drive production of estrogen 
in the breast, in turn facilitating tumorigenesis (46), as evidenced by a positive correlation 
between 1) the level of COX-2 and expression of cytochrome P19 (CYP19) in human breast 
cancer (47) and 2) increased aromatase gene (P450) expression, the product of CYP19, in 
cultured breast cells (45, 48).  This paracrine loop may explain why inhibition of COX-2 activity 
could have a protective effect on breast cancer.  Indeed, studies have consistently shown that 
aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX-2 and 
thereby PGE2 production (49), hinder breast tumor cell growth in vitro and in animal models (47, 
50-53).  Consistent with this biologic mechanism, several epidemiologic studies have examined 
the association between use of NSAIDs and breast cancer risk (reviewed in (54) and (55)) with 
most, but not all (56, 57), of case-control studies finding risk reductions between ~20-40% (58-
68).  Results from prospective cohort studies have been less consistent, with seven studies 
finding no association (69-75), one study observing an increased risk (76), and five studies, 
including the WHI Observational Study, demonstrating a protective effect from use of NSAIDs 
(77-81).  Recently the Women’s Health Study, a randomized controlled trial, found that 
alternate-day use of low-dose aspirin for an average of 10 years of treatment did not reduce the 
risk of breast cancer (82).     
It is beyond the scope of this project to discuss all cytokines involved in estrogen 
synthesis and expressed in the breast.  Based upon preliminary data from the Mammograms and 
Masses Study suggesting a relationship between TNF-alpha soluble receptors and breast density 
(unpublished), as well as evidence from the literature suggesting a role for TNF-alpha in 
estrogen biosynthesis in the breast, we focused on the two soluble receptors for TNF-alpha. 
1.1.2.1 TNF-alpha  
The cytokine tumor necrosis factor (TNF)-alpha, secreted by macrophages of the immune system 
and also by adipocytes, has a central role in regulating estrogen synthesis within both normal and 
malignant breast tissue (43, 83, 84).  In fact, TNF-α can stimulate the activities of all of the 
enzymes involved in estrogen synthesis: TNF-α enhances the activities of aromatase (85), 17β-
estradiol dehydrogenase (86, 87), and estrone sulfatase (88), the three enzymes involved in the 
conversion of androstenedione to estrone (E1), the reduction of E1 to estradiol (E2), and the 
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hydrolysis of estrone sulfate to E1, respectively (84).  Furthermore, TNF-α is one of the most 
potent promoters of aromatase activity in adipose fibroblasts, resulting in the peripheral 
conversion of androgens to estrogens in the adipose tissue (89).  There is evidence that the 
production of TNF-α is also increased in obese women (90); thus, TNF-α may be one 
explanation for the positive association observed between obesity and breast cancer among 
postmenopausal women (9).  Plasma concentrations of TNF-α have also been shown to increase 
with age (91, 92), potentially influencing the development of breast tumors in some 
postmenopausal women.  Several studies have observed the regulation of estrogen production by 
TNF-α in breast fibroblasts, undifferentiated cells formed around malignant breast epithelial cells 
(83, 85, 86, 93). Thus, aberrant TNF-α function that ultimately elevates estrogens may promote 
malignant transformation in the postmenopausal breast (83); however, to date, two prospective 
epidemiologic studies have shown no association between TNF-α and breast cancer risk (94, 95).     
1.1.2.2 TNF-alpha receptor activity: Laboratory and epidemiologic observations 
TNF-α exerts its effects by binding to two transmembrane cell surface receptors: the p60 TNF 
receptor 1 (TNFR1) and the p80 TNF receptor 2 (TNFR2) (96), both of which are expressed in 
virtually all mammalian cells, including mammary epithelial cells (97).  The TNFRs have similar 
ligand-binding domains, but each differs in cytoplasmic domains, suggesting distinct signal 
transduction pathways.  TNF-α binds to the two receptors with similar affinity; when engaged, 
the extracellular domains of the soluble TNF receptors may be shed into the circulation, 
activating downstream pathways, and leading to the stimulation of pro-inflammatory cytokines 
and immunomodulatory genes (98).  In contrast, these shed sTNFRs can also compete for TNF-α 
with the cell surface receptors and thus block TNF-α activity (99).  The soluble TNF receptors 
(sTNFRs) are believed to play a central role in TNF-alpha-mediated cytotoxic (100), mitogenic 
(101), anti-proliferative (101), and apoptotic effects (102), but the specific roles of the two 
receptors are highly debated.  The functional role of sTNFRs in vivo is yet to be elucidated since 
these soluble receptors have been shown to inhibit TNF in cytotoxic assays (103, 104), and they 
have also been reported to enhance TNF-α activity in vitro (104).  Unlike TNF-α., which has a 
relatively short half-life in circulation, determination of sTNFR concentrations in healthy 
individuals at time lapses of 1 year demonstrated that the concentrations of the receptors are 
stable in each individual (correlation coefficients of 0.84 and 0.90 for sTNFR1 and sTNFR2, 
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respectively), possibly reflecting genetically determined differences (105); this observation was 
supported by studies of identical twins, who unlike discordant twins, were more likely to have 
similar levels of sTNFRs (105).  The mRNAs of both TNF receptors are up-regulated in adipose 
tissue in obese women (106, 107), and circulating levels are positively correlated with BMI and 
age (108-110).  
Excessive signaling through TNF receptors may cause severe inflammatory reactions and 
tissue damage (98).  Solid malignant tumor cell lines shed sTNFRs spontaneously, and levels of 
the receptors were elevated in the sera of cancer patients (111-115), and in the plasma (116) and 
serum (117) of breast cancer patients as compared to healthy individuals.  Deficient expression 
of TNFR2 mRNA was found in the endometrium of women at the earliest stages of 
endometriosis (118); whether low producers of soluble TNFRs may be predisposed to an over-
response to TNF in pathological conditions remains to be determined (119).  To date, only one 
nested case-control study has prospectively examined the relationship between serum levels of 
sTNFRs and breast cancer risk (95).  The investigators found no association between serum 
levels of the soluble receptors TNFR1 and TNFR2 and breast cancer risk; however, this study 
had limited power to detect an association in postmenopausal women, with only 61 
postmenopausal case-control pairs (95).   
1.1.2.3 Tumor necrosis factor receptor 2 (TNFR2) gene variations 
Polymorphic variations in the TNFR2 gene have been more extensively studied than those in 
TNFR1.  The TNFR2 gene has been localized to chromosome 1p36.2 and spans about 43kb, 
consisting of 10 exons, only three of which (exons 4, 6, and 9) contain polymorphic sites that 
lead to a non-conservative amino acid change (120, 121).  Whereas the TNFR1 gene does not 
contain any known functional variants, the TNFR2 gene contains a non-synonymous single 
nucleotide polymorphism (SNP) with potential functional significance with respect to circulating 
TNFR2 levels.  In particular, the TNFR2 –196 M/R polymorphism (T > G; Exon 6; results in 
substitution of methionine by arginine; rs1061622) is located in the extracellular region of the 
receptor, the region responsible for its proteolytic cleavage and solubilization.  This 
polymorphism appears to be functionally significant; in a cohort of patients with rheumatoid 
arthritis, the TT genotype was associated with a threefold higher chance of responding to anti-
TNF-alpha therapy as compared to patients with TG/GG genotypes (122).  (Interestingly, anti-
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TNF-alpha therapy was successfully tested for toxicity, biological activity and therapeutic 
efficacy in metastatic breast cancer (123)).  Furthermore, the –196 SNP has been found to 
influence serum TNFR2 levels in previous studies (carriers of the G allele have higher 
circulating levels) (124, 125), and has been associated with autoimmune diseases (126-130), 
hypercholesterolemia (124), hyperandrogenism (131), and polycystic ovarian syndrome (131).  
A recent study of 113 postmenopausal breast cancer cases and 157 pre- and postmenopausal 
controls in Tunisia demonstrated a significant association between the –196 M/R heterozygous 
genotype (TG) and breast carcinoma (OR=2.28, 95% CI: 1.36-3.83), yet among cases, the R 
allele was associated with increased survival after 3 years of follow-up (132); these results are to 
be interpreted with caution, as they might be specific to Tunisians, and the investigators did not 
attempt to control for potential confounding factors.  No prior studies have examined this SNP in 
relation to breast density. 
Hence, TNF-alpha and its soluble receptors may play a role in breast cancer.  Evidence 
also suggests that they are related to estrogen synthesis.  Furthermore, prospective studies 
indicate that circulating levels of sTNFRs may be genetically determined.  However, no 
adequately powered study has investigated the relationship between these cytokine levels or 
polymorphisms in the TNFR2 gene with postmenopausal mammographic density.    
1.1.3 Mammographic breast density as a breast cancer biomarker 
With the exception of age and carriage of BRCA1/2 mutations, mammographic density is the 
greatest risk factor for breast cancer (133, 134).  The histologic composition of the breast is 
reflected mammographically by density and parenchymal pattern.  The higher the fat content of 
the breast the lower the radiologic density.  Conversely, a high proportion of connective, 
ductal/epithelial, and glandular tissue increases density (135-138).  The first method to associate 
breast parenchymal patterns and breast cancer risk was proposed by Dr. John Wolfe in 1976 
(139).  His classification consisted of four patterns: N1-radiolucent breast, low risk; P1-linear 
radiographic densities or ductal prominence of lesser extent than P2, intermediate risk; P2-ductal 
prominence to a greater extent, intermediate risk; and DY-radiographically dense, risk highest 
(139).  In an effort to reduce intra- and inter-observer variability, various methods have been 
developed to quantitatively assess mammographic parenchymal patterns.  These methods 
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encompass visual estimation of dense tissue, digitized images utilizing computer-assisted 
methods, and planimetry to measure the area of density within the total breast area; the area of 
dense tissue divided by the total breast area is known as the proportion or percentage of 
mammographic density (133, 140-145).  In both case-control (146-155) and prospective cohort 
studies (156-158) using Wolfe’s method, increased breast density was associated with increased 
risk for breast cancer with ORs ranging from 1.4 to 6.2 (Table 2).  Likewise, case-control (146, 
147, 149, 151-155, 159-164) and prospective cohort studies (165) using quantitative methods 
have found similar associations, with ORs ranging from 1.8 to 6.0, and most studies yielding an 
OR of 4.0 or greater (Table 2).  These associations remain even after adjusting for factors known 
to influence breast density and breast cancer risk, such as age at menarche, menopausal status, 
parity, age at first birth, family history, HT use, and BMI (discussed further in “Breast Cancer 
Risk Factors and their Association with Mammographic Density”).  As Wolfe’s classification 
method is subjective and may vary between observers (e.g. radiologists) (166), the quantitative 
methods have been deemed more effective in identifying women at increased risk for developing 
breast cancer (167, 168).  Indeed, the majority of studies have shown a stronger association with 
breast cancer risk for the quantitative methods than for those using Wolfe’s classification (133).   
The best method of utilizing the information obtained from the dense and nondense 
components of a mammogram is currently under debate.  While the dense area itself is related to 
the risk of breast cancer (169), the percentage of breast density appears to confer a greater risk 
and is the measure reported in the vast majority of studies (134, 155, 170, 171).  Most risk 
factors for breast cancer that are related to mammographic density have the opposite relationship 
with the nondense area of the mammogram, largely comprised of fat tissue (172).  Since body 
mass index correlates strongly and positively with both the nondense and total breast areas (173), 
and thus correlates inversely with percent breast density (163, 174, 175), potential confounding 
by adiposity is of particular concern when studying factors that are related to both percent breast 
density and BMI.  Under such circumstances, investigators have argued for examination of the 
absolute area of dense breast tissue, instead of percent breast density (169, 173).   
Mammographic density has also been positively associated with breast cancer tumor 
characteristics, such as tumor size, lymph node status, and lymphatic or vascular invasion, in 
both case control studies (176, 177) and in recent case-only studies of women diagnosed  with 
screen-detected (178) and interval-detected (179) invasive breast cancer.  The positive 
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association observed between density and tumor size could be due to a delayed diagnosis of 
tumors in women with dense breasts (a “masking” effect because density impairs mammographic 
sensitivity (180)); alternatively, dense breasts may be associated with increased cell proliferation 
(discussed further in “Heritability, Genetic Variations and Breast Density”) (177).  While many 
studies have evaluated mammographic density and its association with risk of incident primary 
breast cancer, the National Surgical Adjuvant Breast and Bowel Project (NSABP) recently 
evaluated mammographic density among women with a previous diagnosis of DCIS, and who 
were prospectively followed to measure breast cancer recurrence (181).  NSABP investigators 
found that women with highly dense breasts had 2.8 (95% CI: 1.3 to 6.1) times the risk of breast 
cancer recurrence (DCIS or invasive) and three times the risk of subsequent invasive breast 
cancer (95% CI: 1.2 to 7.5) (181).  Notably, a recent retrospective study of diagnostic 
mammograms from consecutive women diagnosed with DCIS at the USC/Norris Comprehensive 
Cancer Center demonstrated that DCIS lesions occurred overwhelmingly in areas of 
mammographically dense tissue; further, the majority of lesions occurred in the mammographic 
quandrant with the highest percentage density (182).  All available pre-DCIS films showed that 
the areas in which DCIS subsequently arose were also dense at the time of the earlier 
mammogram (182).  These results strongly suggest that, indeed, some characteristic of the 
mammographically dense tissue is directly influencing the carcinogenic process in the local 
breast glandular tissue (182).  Since mammographic breast density is a non-invasive, reliable 
and quantitative measure that is strongly associated with breast cancer risk, breast density 
provides a useful intermediate marker in studies aimed at understanding breast cancer etiology 
and prevention (183). 
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Table 2.  Selected studies of breast density and breast cancer risk: Wolfe's method and quantitative methods 
First Author Study Design Participants 
Wolfe Odds Ratio* 
(95% CI) 
Quantitative 
Odds Ratio** 
(95% CI) 
Quantitative 
Method 
Threshold 
(%) Adjustments 
Boyd et al. 1982 
(146) Case-control 183 Cases 
Range of 3 reading 
radiologists 
Range of 3 read-
ing radiologists 
Visual 
Estimation <10 vs. ≥75 
Age at first 
birth, parity, 
family history 
    183 Controls 1.9-3.7  
OR 2.8-6.0 (1.4-
5.6 to 2.5-14.1)       
Brisson et al. 
1982 (147) Case-control 408 Cases OR DY vs N1 
homogeneous 
density:  
OR 5.4 (2.5-11.4) 
Visual 
Estimation 0 vs ≥60 
    1021 Controls 1.9 (1.1-3.3) 
nodular density: 
OR 3.8 (1.6, 8.7)     
Parity, age at 
first birth, 
family history, 
age at 
menopause, 
hormone use  
Tabar & Dean 
1982 (156) Prospective 21,157 women Age 60+ 0.97         
   1857 Prevalent Cases RR DY vs N1 NA     
   31 Incident Cases Prevalent 2.9      
      Incident 6.2         
Chaudry et al. 
1983 (148) Case-Control 104 Cases OR DY vs N1         
    937 Controls 1.4         
Brisson et al. 
1984 (149) Case-control 362 Cases OR DY vs N1         
    686 Controls 2.7 (1.5-4.8) OR 4.4 (2.5-7.9) 
Visual 
Estimation 0 vs ≥60 Weight, height 
Carlile et al. 
1985 (150) Case-Control 706 Cases OR DY vs N1         
    1412 Controls 3.1 NA       
Gravelle et al. 
1986 (157) Prospective 4,044 women RR DY vs N1         
    31 cancer 4.4 (0.54-36.7) NA       
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Table 2 (continued) 
First Author Study Design Participants 
Wolfe Odds Ratio* 
(95% CI) 
Quantitative 
Odds Ratio** 
(95% CI) 
Quantitative 
Method 
Threshold 
(%) Adjustments 
Wolfe et al. 
 1987 (151) Case-control 160 Cases 
OR P2/DY vs. 
N1/P1         
    160 Controls 3.3 (1.9-5.7) OR 4.3 (1.8-10.4) 
Manual 
Planimetry <25 vs. ≥70 Parity 
Brisson et al. 
1989 (152) Case-control 290 Cases OR DY vs N1         
    645 Controls 3.7 (1.8-7.4) OR 5.5 (2.3-13.2) 
Visual 
Estimation 0 vs ≥60 
Age, parity, 
education, 
weight, height 
de Stavola et al. 
1990 (158) Prospective 4,044 women RR P2/DY vs P1/N1         
    69 cancer 1.7 (0.72-4.0) NA       
Saftlas et al. 
1991 (153) N. Case-control 260 Cases OR DY vs N1         
    301 Controls 2.6 (1.3-5.4) OR 4.3 (2.1-8.8) 
Manual 
Planimetry <5 vs ≥65 
Age, weight, 
parity 
Boyd et al.  
1995 (161) N. Case-control 354 Cases   OR 4.0 (2.1, 7.7) 
Computerized 
(thresholding) 0 vs. ≥75 
    354 Controls NA OR 6.0 (2.8-13.0) 
Visual 
Estimation   
Age, parity, age 
at first birth, 
weight, height, 
age at 
menarche, 
family history  
Kato et al.  
1995 (154) N. Case-control 73 PRE Cases 
PRE women;  
OR P2/DY vs P1/N1         
   281 PRE Controls OR 6.0 (1.3-27.3) OR 3.6 (1.7-7.9) 
Manual 
Planimetry <48 vs ≥65 
BMI, parity, 
menopausal 
status 
   124 POST Cases 
POST women;  OR 
P2/DY vs P1/N1      
    240 POST Controls OR 1.9 (1.2-3.1) 2.1 (1.1, 3.8)   <28 vs ≥44   
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Table 2 (continued) 
First Author Study Design Participants 
Wolfe Odds Ratio* 
(95% CI) 
Quantitative 
Odds Ratio** 
(95% CI) 
Quantitative 
Method 
Threshold 
(%) Adjustments 
Byrne et al.  
1995 (155) N. Case-control 1880 Cases OR DY vs N1         
    2152 Controls 2.7 (2.0-3.7) OR 4.3 (3.1-6.1) 
Computerized 
Planimetry 0 vs. ≥75 
Weight, age at 
first birth, 
family history, 
education, 
alcohol use, 
prior biopsies, 
reproductive 
years 
van Gils et al. 
1999 (162) N. Case-control 108 Cases           
    400 Controls NA OR 3.3 (1.5-7.2) 
Computerized 
(automated) <5 vs >25 
Menopausal 
status, BMI 
Lam et al.  
2000 (163) N. Case-control 529 Cases           
    2116 Controls NA OR 4.5 (1.9-10.6) BIRADS 
Entirely fatty 
vs extremely 
dense Weight 
Case-control 647 Cases         
Maskarinec & 
Meng 2000 (159) 
  
  647 Controls NA OR 1.8 (1.1-3.0) 
Computerized 
(thresholding) <10 vs ≥50 
  
Age at 
menarche, 
menopausal 
status, parity, 
age at first 
birth, family 
history, 
hormone use, 
previous breast 
problems 
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Table 2 (continued) 
First Author Study Design Participants 
Wolfe Odds Ratio* 
(95% CI) 
Quantitative 
Odds Ratio** 
(95% CI) 
Quantitative 
Method 
Threshold 
(%) Adjustments 
Ursin et al. 2003 
(171) Case-control 622 Cases     
  443 Controls NA OR 5.2 (1.7-16.1) 
Computerized 
(thresholding) <1 vs ≥75 
Age, BMI, age 
at menarche, 
family history 
of breast cancer, 
# full-term 
pregnancies, 
menopausal 
status, hormone 
therapy use, age 
at first birth 
Vacek & Geller 
2004 (165) Prospective 24,238 PRE women           
   337 PRE cancer NA RR 4.6 (1.7, 12.6) BIRADS 
Entirely fatty 
vs extremely 
dense 
these are 
unadjusted 
estimates 
   37,606 POST women       
    854 POST cancer NA RR 3.9 (2.6, 5.8) BIRADS 
Entirely fatty 
vs extremely 
dense 
these are 
unadjusted 
estimates 
Kerlikowske et 
al. 2005 (160) N. Case-control 200 Cases           
    431 Controls NA OR 2.7 (1.4-5.4) 
Computerized 
(thresholding) 
<23.9 vs. 
≥66.8 
(lowest vs. 
highest 
sextile) 
Age, family 
history, age at 
first birth, hip 
BMD, race, 
BMI 
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Table 2 (continued) 
 
   
First Author Study Design Participants 
Wolfe Odds Ratio* 
(95% CI) 
Quantitative 
Odds Ratio** 
(95% CI) 
Quantitative 
Method 
Threshold 
(%) Adjustments 
Maskarinec et al. 
2005 (164) N. Case-control 607 Cases     
  667 Controls NA OR 3.1 (2.0-4.9) 
Computerized 
(thresholding) <10 vs ≥50 
Ethnicity, age at 
mammogram, 
BMI, age at 
first live birth, # 
children, age at 
menarche and 
menopause, 
family history 
of breast cancer 
*Wolfe’s Method: N1-radiolucent breast, low risk; P1-linear radiographic densities or ductal prominence of lesser extent than P2, intermediate risk; P2-ductal 
prominence to a greater extent, intermediate risk; and DY-radiographically dense, risk highest 
**ORs shown for total density unless otherwise specified 
BIRADS=Breast Imaging Reporting and Data System; BMD=bone mineral density; BMI=body mass index; CI=confidence interval; N.=nested; NA=not 
applicable; OR=odds ratio; PRE=premenopausal; POST=postmenopausal 
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1.1.3.1 Breast cancer risk factors and their association with breast density      
Several reproductive and hormonal factors are known to influence both the mammographic 
appearance of the breast and the risk of breast cancer in a similar fashion.  For instance, 
mammographic density is inversely related to parity, and increased mammographic density is 
observed in nulliparous women, and in women with a later age at first birth and later age at 
menopause (133, 158, 184-192); the same negative and positive relationships have been 
observed for these reproductive factors with respect to breast cancer risk (193).  However, while 
breast cancer risk increases with age (4), breast density decreases with age (194-197).  This 
apparent inconsistency can be explained by comparing breast density to breast cancer incidence 
rates in the population (167, 198).  The rate of increase in breast cancer incidence begins to slow 
around age 50 (199); around the same time, glandular and ductal tissue decreases and fibrous 
connective tissue is replaced by fat (194-196).  In contrast to its inverse relationship with age, 
breast density is very hormonally responsive and is positively associated with hormone therapy 
use (133, 200-203); elevated breast cancer risk has also been found with HT use in the WHI 
clinical trial (23).  In addition, selective estrogen receptor modulators have been associated with 
both a reduction in breast density and breast cancer risk (143, 204-207).  Studies of BMD, a 
proxy measure of lifetime estrogen exposure, and breast density have been equivocal.  One 
cross-sectional analysis from the Postmenopausal Estrogen/Progestin Interventions Study (PEPI) 
showed a positive association between BMD and breast density only among women who had not 
recently used HT (208).  Although BMD is positively associated with breast cancer risk (17, 41), 
additional studies have not observed an association between BMD and breast density (160, 209, 
210).  Finally, breast density potentially may be influenced by lifestyle and anthropometric 
factors.  Evidence for an association between diet, physical activity, and breast cancer is not 
entirely consistent (24, 29); these relationships remain unclear for breast density as well (211-
218).  BMI has been inversely associated with breast density in several studies (163, 174, 175), 
while breast cancer risk has been shown to be positively associated with BMI in postmenopausal 
non-HT users (9).  Taken together, these observations suggest that variations in exposure to both 
endogenous and exogenous hormones may be responsible for the variations in breast tissue 
composition that are reflected in inter-individual differences in the extent of mammographic 
density.  Hence, the associations between other breast cancer risk factors and breast density, as 
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well as the responsiveness of breast density to hormones, further supports breast density as a 
surrogate marker of breast cancer risk. 
1.1.3.2 Heritability, genetic variations and breast density 
The amount of breast density may be due in part to genetic heredity (219).  A cohort study of 
families with a history of breast cancer demonstrated evidence for a genetic effect as sister-sister 
correlations in breast density were significant (r=0.16-0.27) (220), and these results were further 
clarified in a sib-pair linkage analysis (221).  A twin study conducted in Australia and North 
America estimated that genetic factors likely account for 63% of the unexplained variance in 
mammographic density in all twins studied (219).  In contrast to women at low risk for 
developing breast cancer, women with known BRCA1 or BRCA2 mutations have been shown to 
have denser breast tissue (222).  A study of 6146 women in the San Francisco Mammography 
Registry demonstrated an association between increased breast density with a positive family 
history of breast cancer (223).   
Despite the findings which suggest that genetics plays a strong role in breast density, 
relatively few studies to date have demonstrated strong, consistent relationships between 
polymorphisms in genes and breast density in postmenopausal women (224-227).  In a study of 
breast cancer patients, longer CAG repeat lengths of the androgen receptor gene were associated 
with higher mean breast density only among postmenopausal women who were current HT users 
(228).  In a cross-sectional study of 328 healthy women (only 60 of which were 
postmenopausal), carriers of the catechol-O-methyl transferase (COMT) and CYP1A1 variant 
alleles had lower mammographic density as compared to women with the common alleles, 
although this result was in the opposite of what is commonly hypothesized with respect to the 
enzyme function of these genes involved in estrogen synthesis (229).  A study of healthy women 
in Toronto found a strong relationship between polymorphisms in the IGFBP-3 gene in 
premenopausal women only (230); while the IGF-1 19 repeat allele was positively associated 
with breast density among postmenopausal women, this polymorphic locus was not related to 
serum levels of IGF-1 in this population (230).  A study in postmenopausal women, who had 
participated in one of two clinical trials with hormone therapy, demonstrated that polymorphisms 
in genes involved in the metabolism of estrogen (cytochrome P450 1B1, CYP1B1) and 
progesterone (aldo-keto reductase 1C4, AKR1C4) were associated with mammographic density 
19 
changes between baseline and 12 months in the group of women using estrogen plus progestin 
therapy (EPT) (231).  These findings suggest that the increase in breast density in women using 
combined hormone therapy may be greater in those with genetically determined lower activity of 
enzymes that metabolize estrogen and progesterone; however, these data should be considered 
preliminary as they are based on small numbers (EPT group: n=33 genotyped for CYP1B1 and 
n=32 genotyped for AKR1C4) (231).  Other genetic associations that have not yet been 
replicated include polymorphisms in the estrogen receptor alpha (ESR1) and progesterone 
receptor (PGR) genes, which modified the association between hormone therapy use and 
mammographic density (232, 233), along with two SNPs in the pituitary growth hormone gene 
(GH1), one of which was also associated with serum growth hormone levels (234). 
In spite of the paucity of data relating genetic polymorphisms to breast density, the 
factors known to influence density suggest that genes related to sex steroid hormone regulation 
may be involved, and no prior study has analyzed breast density in relation to polymorphisms in 
the TNF receptor-II gene.  Genes regulating cytokine production are ideal candidates to assess 
whether breast density may vary by particular polymorphisms.  
1.1.4 Association between endogenous hormones, cytokines, and breast density      
Despite the relationship between breast cancer and breast density, and their associations with 
estrogen exposure, relatively few studies have examined the association between endogenous 
hormones and breast density in postmenopausal women.  The relationship between insulin-like 
growth factors (IGFs) and mammographic density is complex; similar to the observed relations 
between IGFs and breast cancer risk (20, 235), associations with breast density vary by 
menopausal status and history of hormone therapy use, and may be confounded by body mass 
index (173).  In a cross-sectional analysis of the Nurses’ Health Study, mammographic density 
was significantly associated with insulin-like growth factors in premenopausal but not 
postmenopausal women (236).  In contrast, among postmenopausal women who were former 
hormone therapy users, mammographic density was inversely associated with the IGF-1/IGFBP-
3 ratio (237).  In a study of healthy premenopausal women, IGF binding protein-3 was inversely 
related to breast density, and the IGF-1/IGFBP-3 ratio was positively associated with breast 
density (238), and these results were subsequently confirmed (239).  Breast tissue from healthy 
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women with little or no density compared to breast tissue from healthy women with dense 
breasts has increased IGF-1, matched for age at biopsy (240).  Lastly, among healthy pre- and 
postmenopausal women, levels of C-peptide, a marker of insulin secretion, are not associated 
with breast density after adjustment for adiposity (241).   
In postmenopausal women, variations in mammographic density have been associated 
with blood levels of prolactin in a dose-response fashion (242), although not consistently (243, 
244).  Bioavailable estradiol has been negatively associated with breast density in several studies 
of postmenopausal women (237, 242, 244).  However, in the Nurses’ Health Study negative 
associations between circulating estrogens and mammographic density were attenuated after 
adjustment for BMI (244), and in PEPI significant positive associations between circulating 
estrogens and mammographic density were observed despite adjustment for potential 
confounders, including BMI and prior use of hormone therapy (245).     
Sex hormone binding globulin (SHBG) has been positively related to postmenopausal 
percent density (242), albeit inconsistently.  Positive associations between SHBG and breast 
density disappeared after adjustment for BMI in pre- (246) and postmenopausal women (244).  
Riza et al (247) evaluated the role of urinary estrogen metabolites and their relationship with 
mammographic density in 70 postmenopausal women with high-density Wolfe mammographic 
parenchymal patterns (P2/DY) and 70 women with low-density patterns (N1).  The ratio of 2-
hydroxyestrone (OHE1):16α-OHE1 was 35% higher (p=0.005) in women with a P2/DY pattern.  
These data are not consistent with observed associations between low 2-OHE1:16α-OHE1 ratios 
and increased breast cancer risk (11, 12); additional larger studies are needed.   
Thus, several studies have demonstrated associations between levels of breast mitogens 
and mammographic density, perhaps suggesting a biological basis for the associated risk of 
breast density with breast cancer.  However, no studies have investigated the association between 
cytokines and breast density, and studies are needed to understand this relationship. 
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1.1.5 Summary of Background and Significance 
The association between estrogen and breast cancer risk is well-established.  However, few 
studies have investigated the underlying biological mechanisms mediating the inflammation-
breast cancer relationship, despite the evidence that cytokines play a role in estrogen synthesis in 
the breast.  The association between breast cancer risk factors and mammographic breast density 
suggests that the radiologic features of breast tissue may provide an index of exposure of breast 
tissue to current and past endocrine events that influence breast cancer susceptibility (183).  
These radiologic features can be quantitatively measured and are directly related to the risk of 
breast cancer.  Thus, mammographic breast density can be used as a surrogate marker for breast 
cancer risk.  Despite evidence linking inflammation to breast cancer and breast density to breast 
cancer, to the best of our knowledge this project is the first to investigate the association between 
TNF receptors and breast density.  It is our hope that this study may provide us with a deeper, 
more comprehensive understanding of the role of cytokines in breast cancer risk. 
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2.1 ABSTRACT 
Purpose:  To test reported use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs 
(NSAIDs) for their effect on incident breast cancer among older women.  We further 
investigated whether the relationship between NSAIDs and breast cancer incidence differed by 
hormone receptor status and tumor type at diagnosis.   
Methods: The Study of Osteoporotic Fractures is a multi-center, prospective cohort study of 
white women recruited from four U.S. centers, 1986-1988.  Complete NSAID medication and 
breast cancer risk factor information was available for 6695 women, mean (SD) age 73 (5) years.   
Results:  During a mean (SD) of 13.2 (3.8) years of follow-up, 372 women were diagnosed with 
primary breast cancer: in situ (14%), invasive (81%), or unknown stage (5%).  Weekly use of 
any NSAID during the past 12 months was reported by 3646 (54%) women.  Daily use of any 
NSAID for at least one year was reported by 2097 (31%) women.  There were no differences in 
the risk of incident breast cancer by use of aspirin, non-aspirin NSAID, or any NSAID, before 
and after adjusting for age, current use of estrogen therapy, body mass index, surgical 
menopause, total hip bone mineral density, smoking, family history of breast cancer, study 
center, walking for exercise, nulliparity, and hypertension.  Further, we observed no difference in 
breast cancer risk by frequency and duration of NSAID use.  Results were similar irrespective of 
hormone receptor status and tumor type.  
Conclusions:  Our results do not support a protective effect of nonprescription NSAIDs among 
older postmenopausal women.   
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2.2 INTRODUCTION 
Breast cancer is the most common cancer in women around the world; in the United States this 
year, it is expected that breast cancer alone will account for 31% (212,920) of all new cancer 
cases among women and 40,970 women are expected to die from the disease (1).  Estrogen is 
believed to be a key contributor to breast cancer development (2).  Most breast tumors are 
initially dependent on estrogen for survival; paradoxically, the highest incidence of breast cancer 
occurs in postmenopausal women when ovarian production of estrogens is minimal (3).  In 
postmenopausal women, estrogens continue to be produced in non-ovarian sites, such as adipose 
tissue, as well as in normal and cancerous breast tissues (4).  In fact, the more biologically active 
form of estrogen, estradiol, has been detected in breast tumors at 50 to 100 times the 
concentration of that found in sera of postmenopausal women (5).  Further, postmenopausal 
breast cancer is largely estrogen receptor (ER) or progesterone receptor (PR) positive, and is 
more responsive to anti-estrogen therapy and aromatase inhibitors, even after controlling for 
stage and other prognostic factors (6).  Increased understanding of the mechanism by which 
estrogens are synthesized in the postmenopausal breast may inform preventative strategies. 
In breast tissue, estrogen biosynthesis increases with over-expression of the 
cyclooxygenase-2 (COX-2) gene and subsequent deregulation of prostaglandin E2 (PGE2) 
production (7), which may facilitate tumorigenesis (8).  COX-2-driven production of estrogen in 
the breast is evidenced by a positive correlation between 1) the level of COX-2 and expression of 
cytochrome P19 (CYP19) in human breast cancer (9) and 2) increased aromatase gene (P450) 
expression, the product of CYP19, in cultured breast cells (10).  This paracrine loop may explain 
why inhibition of COX-2 activity could have a protective effect on breast cancer.  Indeed, studies 
have consistently shown that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), 
which inhibit COX-2 and thereby PGE2 production (7), hinder breast tumor cell growth in vitro 
and in animal models (9, 11-14).  Epidemiologic studies have examined the association between 
use of NSAIDs and breast cancer risk (reviewed in (15) and (16)) with most, but not all (17, 18), 
of case-control studies finding risk reductions between ~20-40% (19-29).  Results from 
prospective cohort studies have been less consistent, with seven studies finding no association 
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(30-36), one study observing an increased risk (37), and five studies demonstrating a protective 
effect from use of NSAIDs (38-42).  Recently the Women’s Health Study, a randomized 
controlled trial, found that alternate-day use of low-dose aspirin for an average of 10 years of 
treatment did not reduce the risk of breast cancer (43).   
Relatively few studies have examined the effect of NSAIDs on breast cancer risk by 
hormone receptor status (28, 29, 37) or carcinoma type (in situ (stage 0) vs. stages 1-4) at 
diagnosis (30, 37, 40, 41), and these also present conflicting results.  In particular, results from 
the Long Island Breast Cancer Prevention Project (LIBCP), a population-based case control 
study, demonstrated that the protective effect of NSAIDs was greater for hormone receptor-
positive than for hormone receptor negative breast cancer (28).  Furthermore, the protective 
effect of NSAIDs was significant for postmenopausal but not for premenopausal women; these 
results persisted after considering potential confounding by numerous variables, including 
medical conditions not considered in previous studies (e.g. hypertension and myocardial 
infarction) (28).  In contrast, in a hospital-based case-control study the protective effect of 
NSAIDs was not modified by hormone receptor status (29), and one cohort study found that 
long-term daily aspirin use was associated with an increased risk of hormone receptor-negative 
breast cancer (37).  Of the four studies assessing the association between NSAID use and stage 
of breast cancer, three cohort studies have found no relationship (30, 37, 40), and one nested 
case-control study reported a decreased risk of distant, but not regional, lymph node metastasis 
(41).  Finally, interpretation of prior research is complicated by a paucity of attention to the 
effect of individual NSAIDs, with few studies providing separate risk estimates for ibuprofen 
and aspirin (16).  As these two types of NSAIDs may be associated with different biologic 
effects, separate evaluation is needed (39, 44).  Hence, we undertook a study to test reported use 
of aspirin and non-aspirin NSAIDs (ibuprofen and naproxen) for their effect on incident breast 
cancer among older women participating in the Study of Osteoporotic Fractures (SOF) cohort.  
We further investigated whether the relationship between NSAIDs and breast cancer incidence 
differed by hormone receptor status and tumor type at diagnosis. 
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2.3 METHODS 
The complete SOF study design and methodology have been described in detail (45-47). Briefly, 
SOF is a multi-center, prospective cohort study of risk factors for osteoporotic fractures.  As part 
of the study, SOF has also tracked cases of incident breast cancer.  Women were recruited 
between 1986 and 1988 from four centers in the United States (Baltimore, Pittsburgh, 
Minneapolis and Portland), resulting in a cohort of 9704 community-dwelling, primarily white 
(99.7%) women age ≥65 years.  Women were excluded from the study if they reported a bilateral 
hip replacement or were unable to walk unassisted.  The procedures followed were in accordance 
with each clinic’s institutional guidelines, and all participants gave informed consent for 
participation.   
In this report, we used the information on aspirin and non-aspirin NSAID (ibuprofen or 
naproxen) use that was collected at the second clinical examination (visit 2: 1989-1990) and 
incident breast cancers that occurred after this examination until June, 2004, representing an 
average follow-up period of 13.2 years.  For the analyses presented here, only women with 
complete NSAID medication and breast cancer risk factor information were considered.  Of the 
9339 women who attended visit two, 522 were excluded because of prevalent breast cancer, and 
114 women were excluded due to unavailable information on their breast cancer status during 
follow-up.  Reported aspirin or non-aspirin NSAID use was missing for 438 women, and 1570 
women had missing breast cancer risk factor data; these women were also excluded.  Thus, 6695 
women were included in the present analyses.  
2.3.1 Ascertainment of breast cancer 
Breast cancer incidence was captured by self-report on annual follow-up questionnaires and by 
review of death records obtained from state health departments.  All women who reported that 
they had been diagnosed with breast cancer (or for decedents, the next-of-kin) were asked for 
permission to obtain relevant hospital records and histopathology reports.  Date of breast cancer 
diagnosis, stage at diagnosis, and estrogen and progesterone-receptor status were confirmed by 
medical record and pathology report review by a study physician.  Cases of breast cancer were 
staged according to the American Joint Committee on Cancer (AJCC) methodology using 
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standard tumor-node-metastasis (TNM) staging criteria.  An expert breast pathologist reviewed a 
random sample of 10% of the cases.   
2.3.2 Non-steroidal anti-inflammatory drug exposure 
At the second clinical examination, trained clinic staff asked participants to look at three lists of 
medications for pain, arthritis, headaches and other discomforts, and then to answer the question, 
“In the past 12 months, have you taken any of these at least once a week?”  Separate lists were 
shown for aspirin (Aspirin, Aspirin Plus Codeine, Anacin, Ascriptin, Bufferin, Another Aspirin 
Product), acetaminophen (Tylenol, Tylenol Plus Codeine, Anacin III, No Aspirin, 
Acetaminophen, Another Aspirin Substitute), and non-aspirin NSAIDs (e.g. Advil, Nuprin, 
Ibuprofen, Motrin, Naproxen, etc.).  If the answer was yes, participants were asked to indicate 
for how many days per week (1-4 or 5-7), on average, they took each type of medication.   
Participants were also asked, “Have you taken any of the medications on this list every day or 
almost every day for a year or longer?”  If the answer was yes, participants were asked to 
indicate for how many years they took each type of medication; this question was not specific to 
recent use, but rather captured the number of total years during the lifespan that the particular 
medication was taken on an almost daily basis for a year or longer.  We created categories for 
duration of use (no regular use, <5 years, and ≥5 years) based on previous epidemiologic 
investigations which suggest that continuing daily intake of aspirin or ibuprofen for at least five 
years reduces breast cancer risk by ~25-30% or 50-60%, respectively (16).  In this report, “any 
NSAID” combines the use of aspirin and non-aspirin NSAIDs.  Acetaminophen does not inhibit 
COX-2 gene expression (48); however, since lifestyle factors and response patterns may be 
similar between NSAIDs and acetaminophen use, we analyzed both NSAIDs and acetaminophen 
to assess whether any observed associations were specific to NSAIDs.   
2.3.3 Demographic and risk factor data 
All measures were collected by trained clinic staff at visit 2 unless noted otherwise (Tables 3-6).  
Weight was measured in light clothes with a balance beam scale, and height was measured on a 
Harpenden Stadiometer (Dyved, U.K.).  Weight and height were used to calculate body mass 
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index (BMI, weight in kilograms divided by height in meters squared), and BMI was categorized 
according to national guidelines: underweight or normal weight (<25 kg/m2) vs. overweight or 
obese (≥25 kg/m2) (49).  Lifestyle and reproductive history were obtained by questionnaire and 
interview, including education (<high school vs. high school graduate), parity, age at menopause, 
type of menopause (surgical vs. natural), estrogen therapy use (current, former, never), number 
of alcoholic drinks per week, cigarette smoking (current, former, never), takes walks for 
exercise, self-reported diagnosis by a physician of stroke or myocardial infarction, and family 
history of breast cancer.  A family history of breast cancer was defined as a report of breast 
cancer in a participant’s mother or sister.  Cut points for age at menarche (<12, 12-13, ≥14 years) 
and age at first live birth (≤20 vs. >20 years) were determined based on those used in the Gail 
Model for 5-year risk of breast cancer (50).  Blood pressure was measured during the baseline 
clinic visit (1986-1988), and hypertension was defined as systolic blood pressure >160 mmHg, 
or diastolic blood pressure >90 mmHg, or use of thiazide at baseline.  At visit 3 (1990-1992) 
participants were asked if they had ever had a mammogram.  Total hip bone mineral density 
(BMD) was measured by dual energy x-ray absorptiometry (DEXA, QDR 1000; Hologic Inc., 
Waltham, Massachusetts).   
2.3.4 Statistical analysis  
Characteristics of women reporting use of the medication of interest (any NSAID, aspirin, non-
aspirin NSAID, acetaminophen) were compared to women not regularly using that medication 
by the Wilcoxon rank-sum test for continuous measures and the chi-square test for discrete 
measures.  Fisher’s exact test for discrete measures was used when expected cell counts were 
less than five.  Cox proportional hazards models were used to estimate hazard ratios and 95% 
confidence intervals for the associations between medication type (any NSAID, aspirin, non-
aspirin NSAID, acetaminophen) and breast cancer.  To test the hypotheses that the relationship 
between NSAIDs and breast cancer incidence differs by hormone receptor status and tumor type, 
we conducted subgroup analyses, modeling the incidence of breast cancer separately for 
hormone receptor positive breast cancer (ER+PR+, ER+PR-, or ER-PR+) and after excluding in 
situ cases.  For most medication types, cell sizes were too sparse to model the incidence of 
hormone receptor negative (ER-PR-) breast cancer and in situ breast cancer separately. 
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 Cox proportional hazards models were used to estimate hazard ratios and 95% confidence 
intervals for the associations between NSAID type (any NSAID, aspirin, non-aspirin NSAIDs, 
acetaminophen) and breast cancer, initially adjusting for age.  Due to anonymized high extreme 
values for age in the public release SOF database, age was dichotomized at the median (≤72 vs. 
>73 years) in order to avoid having missing covariate information for these women (n=26).    
Subsequent models controlled for covariates that were shown to differ between users and non-
users of NSAIDs in univariate analyses, in addition to those that are known to be associated with 
breast cancer risk.  These were included in multivariate modeling as follows: current use of 
estrogen therapy, BMI, surgical menopause, total hip BMD, cigarette smoking, family history of 
breast cancer, study center, takes walks for exercise, nulliparity, and hypertension.  As 
hypertension was highly collinear with self-reported myocardial infarction and stroke, only 
hypertension was included in multivariate analyses.  In subsequent models, we also adjusted 
individually for several risk factors for breast cancer, including age at menarche, first birth, and 
menopause, and mammogram at visit 3; results were essentially the same and are not shown 
here.   
 Several approaches were used to check the proportional hazards assumption.  We 
regressed Schoenfeld residuals for each medication variable on follow-up time; probability 
values ranged from 0.33 to 0.99, suggesting no departure from proportionality.  To test the 
proportional hazards assumption for our final multivariate model, we generated time dependent 
covariates by including interactions of each predictor with the natural log of follow-up time in 
the model; probability values for all time dependent covariates were >0.05, consistent with 
hazards that are proportional.  Probability values of ≤ 0.05 were considered statistically 
significant.  All tests of statistical significance were two-tailed.  Analyses were performed using 
SAS software release 8.02 (SAS Institute Inc., Cary, NC). 
2.4 RESULTS 
Among the 6695 mostly white (99.8%) SOF participants in this report, weekly use of any 
NSAID during the past 12 months was reported by 3646 (54%) women.  Among weekly users of 
any NSAID, 752 (21%) reported using both aspirin and a non-aspirin NSAID, 1876 (51%) 
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reported using aspirin, and 1018 (28%) reported using a non-aspirin NSAID; 1047 (29%) women 
reported using both an NSAID and acetaminophen on a weekly basis.  Among weekly users of 
any NSAID, 1445 (40%) took an NSAID 5-7 days/week.  Daily use of any NSAID for at least 
one year during the lifespan was reported by 2097 (31%) women, including 279 (13%) users of 
both aspirin and a non-aspirin NSAID, 1206 (58%) users of aspirin, and 612 (29%) users of a 
non-aspirin NSAID; 300 women reported using both an NSAID and acetaminophen on a daily 
basis for at least one year (14%).  Among daily users of any NSAID, 884 (42%) used an NSAID 
for 5 or more years.  Reported mean (SD) duration of daily use was 6 (8) years for any NSAID, 7 
(9) years for aspirin, 4 (4) years for a non-aspirin NSAID, and 5 (7) years for acetaminophen.  
The shorter duration for daily non-aspirin NSAID use is consistent with a more limited time of 
availability, as ibuprofen was licensed for over-the-counter use in 1984 (four years prior to visit 
2) in the United States (51). 
Table 3 shows the characteristics of the population by reported NSAID use.  Women who 
used any NSAID on a regular basis (≥1/week) in the past 12 months were slightly older, had a 
higher BMI, and were more likely to be hypertensive, have a history of heart attack or stroke, to 
be former smokers, and to have been enrolled at clinic A than were nonusers.  In addition, 
regular users of NSAIDs were more likely to have a younger age at first birth, currently use 
estrogen therapy, and have a greater total hip BMD; and were less likely to be nulliparous and 
walk for exercise.  Similar differences were observed between daily users and nonusers of any 
NSAID for ≥1 year with the exception of the following variables:  daily users of any NSAID for 
≥1 year tended to have an earlier age at menarche and menopause and were no different with 
respect to parity.   
In contrast to women who used any NSAID on a regular basis in the past 12 months, 
regular users and nonusers of acetaminophen were no different with respect to age and were 
more likely to have a mammogram at visit three (Table 4).  Regular acetaminophen users also 
had an earlier age at menopause; were more likely to have had a surgical menopause; were less 
likely to be high school graduates; and were no different from non-users with respect to walking 
for exercise and total hip BMD.  For the most part, daily users of acetaminophen for ≥1 year 
were similar to women who used acetaminophen on a regular basis in the past 12 months, except 
that daily users tended to be older; were less likely to take walks for exercise; and were no 
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different with respect to cigarette smoking, nulliparity, and having a mammogram as compared 
to nonusers (Table 4). 
In general, aspirin and non-aspirin NSAID users shared similar characteristics, although 
daily aspirin users were more likely to be high school graduates, while weekly and daily non-
aspirin NSAID users were less likely to have graduated from high school (Tables 5 and 6).  In 
addition, weekly and daily users of non-aspirin NSAID were more likely to have had a surgical 
menopause, while no such difference was observed for aspirin use.   
During a mean (SD) of 13.2 (3.8) years of follow-up, 372 women were diagnosed with 
primary in situ (14%) or invasive (81%) breast cancer (Tables 7 and 8).  Because axillary 
dissection was not performed in all cases of invasive cancer, staging could not be determined in 
17 (4.6%) women and was missing in 2 (0.05%) cases.  Clinical characteristics of cases did not 
differ by NSAID (Table 7) or acetaminophen use (Table 8). 
2.4.1 Non-steroidal anti-inflammatory drug use and breast cancer 
There were no differences in the risk of incident breast cancer by weekly use of aspirin, non-
aspirin NSAID, any NSAID, or acetaminophen in SOF (Table 9).  In multivariable analyses, the 
hazard ratios for incident breast cancer associated with reported use of aspirin, non-aspirin 
NSAID, or any NSAID, respectively, for ≥1/week in the past 12 months were as follows: 0.96 
(95% CI: 0.78, 1.18); 0.96 (95% CI: 0.76, 1.21); and 0.89 (95% CI: 0.73, 1.10).  Further 
evaluation of weekly aspirin, non-aspirin NSAID, NSAID, and acetaminophen use by frequency 
(no regular use, 1-4 days/week, 5-7 days/week) did not reveal any differences in breast cancer 
risk.  Likewise, there were no differences in the risk of incident breast cancer by daily use of 
aspirin, non-aspirin NSAID, or any NSAID for ≥1 year, with multivariable hazard ratios of 0.90 
(0.70, 1.16), 0.95 (0.70, 1.29), and 0.89 (0.71, 1.12) for aspirin, non-aspirin NSAID, and any 
NSAID, respectively.  Women who reported using acetaminophen daily for ≥1 year had a 
decreased age-adjusted risk of breast cancer of borderline significance (HR=0.58, 95% CI: 0.34, 
0.99); however, only 14 women with breast cancer reported using acetaminophen daily for ≥1 
year and contributed to this analysis.  Again, there were no apparent differences in breast cancer 
risk when evaluating daily use of aspirin, non-aspirin NSAID, and any NSAID by duration (no 
regular use, <5 years, ≥5 years).  Cell sizes were too small to evaluate daily acetaminophen use 
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by duration.  Results were similar when we modeled the incidence of breast cancer separately for 
hormone receptor positive breast cancer (Table 10) and after excluding in situ cases (Table 11).   
2.5 DISCUSSION 
In this prospective study of postmenopausal, mostly white, women we found no association 
between NSAID use and incident breast cancer.  Further, we observed no difference in breast 
cancer risk by frequency and duration of NSAID use.  Results were similar irrespective of 
hormone receptor status and tumor type.  
 Previously, thirteen prospective studies and one randomized controlled trial have 
evaluated the influence of NSAIDs on breast cancer risk.  Our results are consistent with seven 
large prospective studies finding no association (30-36), and with null results from the 
randomized controlled trial of alternate-day low-dose aspirin (43).  However, our results are not 
consistent with five prospective studies demonstrating a protective effect from use of NSAIDs 
(38-42) and one suggesting an increased risk. (37).   
Although the reason for these differing results is unclear, one explanation may be due to 
differences in exposure assessment across studies.  Among the seven prior prospective studies 
with null results, four studies assessed exposure of aspirin or non-aspirin NSAIDs using self-
reported questionnaire data (30, 33, 34, 36), with none verifying use against pill bottles; one used 
a general practitioners’ database containing information on aspirin use (32); and two used 
databases of prescribed low-dose aspirin (31) or non-aspirin NSAIDs (35).  In contrast, the 
Women’s Health Initiative Observational Study, which observed a 21% reduction in breast 
cancer incidence with regular NSAID use (≥2 tablets/week) for 5-9 years, validated self-reported 
use with pill bottle labels and prescription records (39).  In the present study, a medication 
inventory was not conducted until visit 4, at which time patients were asked to bring all 
medications to the clinic for verification of use; however, the questions regarding frequency and 
duration of aspirin and non-aspirin NSAID use were only asked at visit two.  Further, at visit two 
only non-prescription NSAID use was captured.  This is an important limitation, especially given 
that a recent case-control study demonstrated a 71% reduction in breast cancer risk associated 
with use of selective COX-2 inhibitors (11).  If in the present analysis users of prescription 
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NSAIDs were included in the referent group (i.e. non-NSAID users), results would be biased 
toward the null.   
Nevertheless, this study has several strengths.  Its prospective design and assessment of 
NSAID use before cancer diagnosis eliminate recall bias.  We controlled for many factors that 
differed among NSAID users and nonusers.  In addition, we examined the effect of individual 
NSAIDs on breast cancer risk, and the prevalence of aspirin and non-aspirin NSAID use in SOF 
is consistent with that observed in other studies (28, 30, 40).  While acetaminophen does not 
inhibit COX-2 gene expression (48), we analyzed both NSAIDs and acetaminophen to assess 
whether any observed associations were specific to NSAIDs.  Weekly acetaminophen use was 
not associated with incident breast cancer; however, daily use of acetaminophen for 1 year or 
more at an unknown period during the lifespan appeared to be associated with a decrease in 
breast cancer risk.  This finding is to be interpreted with caution as it is likely due to small cell 
sizes; only 14 cases reported daily use of acetaminophen.  In addition, when we excluded in situ 
breast cancer cases, the age-adjusted relative hazard associated with acetaminophen use was no 
longer significant (HR=0.56, 95% CI: 0.31, 1.03).  Lastly, we attempted to separately examine 
the effect of NSAIDs on hormone receptor positive and invasive breast cancer.  To date, only 
one other prospective study has evaluated the association by hormone receptor status, finding 
that long-term daily aspirin use was associated with an increased risk of hormone receptor-
negative breast cancer (37).  Only 31 cases were ER/PR negative in SOF, a subgroup of too 
small a size to evaluate separately.  Our non-significant findings for invasive breast cancer are 
consistent with three out of four prospective studies evaluating the association between NSAID 
use and stage of breast cancer (30, 37, 40).   
In conclusion, our results do not support a protective effect of nonprescription NSAIDs 
among older postmenopausal women.  Given the potential public health impact should NSAIDs 
be successful chemopreventive agents for breast cancer, these findings warrant further 
investigation in larger populations with carefully defined exposure assessment.
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Table 3. Characteristics of women by NSAID use in the Study of Osteoporotic Fractures, 1989-90 
  
Regular use of any NSAID in past 
12 months  
Daily use of any NSAID for at least 1 
year  
 
Overall 
n=6695 No (n=3049) Yes (n=3646)  No (n=4598) Yes (n=2097)  
Variable n % n % n % p-value n % n % p-value 
Clinic*       <0.0001     0.003 
   A 1781 27 739 24 1042 29  1174 26 607 29  
   B 1635 24 729 24 906 25  1104 24 531 25  
   C  1489 22 768 25 721 20  1051 23 438 21  
   D 1790 27 813 27 977 27  1269 28 521 25  
Age (±SD), years 73 (5) 73 (5) 73 (5) 0.2 73 (5) 74 (5) <0.0001 
Age (years)       0.05     0.0015 
   ≤72 3528 53 1647 54 1881 52  2483 54 1045 50  
   73+ 3167 47 1402 46 1765 48  2115 46 1052 50  
Education*       0.38     0.94 
   <High school 1431 21 637 21 794 22  984 21 447 21  
   High school graduate 5264 79 2412 79 2852 78  3614 79 1650 79  
Family history of breast 
cancer*       0.54     0.23 
  No 5809 87 2637 86 3172 87  3974 86 1835 88  
  Yes 886 13 412 14 474 13  624 14 262 12  
Age at first Menses       0.38     0.02 
     <12 794 12 350 12 444 12  511 11 283 14  
    12-13 3541 54 1636 55 1905 53  2452 55 1089 53  
     14+ 2192 34 979 33 1213 34  1520 34 672 33  
  Missing 168  84  84   115  53   
Parity*       0.04     0.51 
   Nulliparous 1246 19 612 20 634 17  845 18 401 19  
   1 922 14 431 14 491 13  632 14 290 14  
   2 1828 27 830 27 998 27  1252 27 576 27  
   3 1363 20 590 19 773 21  929 20 434 21  
   4 697 10 310 10 387 11  502 11 195 9  
   5+ 639 9 276 9 363 10  438 10 201 10  
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Table 3 (continued) 
 
Regular use of any NSAID in past 
12 months  
Daily use of any NSAID for at least 1 
year  
 
Overall 
n=6695 No (n=3049) Yes (n=3646)  No (n=4598) Yes (n=2097)  
Variable n % n % n % p-value n % n % p-value 
Nulliparous*       0.005     0.47 
   No 5449 81 2437 80 3012 83  3753 82 1696 81  
   Yes 1246 19 612 20 634 17  845 18 401 19  
Age at first live birth       0.004     0.002 
   ≤20 836 15 336 14 500 17  538 14 298 18  
   >20 4603 85 2098 86 2505 83  3209 86 1394 82  
  Missing 1256  615  641   851  405   
Age (years) at menopause*       0.36     0.03 
   ≤40 580 10 250 10 330 11  376 10 204 12  
   41-45 1082 19 511 20 571 19  769 20 313 18  
   46-50 2144 38 975 38 1169 38  1467 37 677 39  
   ≥51 1834 32 856 33 978 32  1294 33 540 31  
  Missing 1055  457  598   692  363   
Surgical menopause*       0.13     0.12 
   No 5873 88 2695 88 3178 87  4053 88 1820 87  
   Yes 822 12 354 12 468 13  545 12 277 13  
Estrogen only therapy 
(Oral)*       <0.0001     <0.0001 
   Never use 3835 57 1864 61 1971 54  2766 60 1069 51  
   Past use 1883 28 805 26 1078 30  1258 27 625 30  
   Current use 977 15 380 12 597 16  574 12 403 19  
Estrogen only therapy 
(Any Current)*       <0.0001     <0.0001 
   No 5718 85 2669 87 3049 84  4024 87 1694 81  
   Yes 977 15 380 12 597 16  574 12 403 19  
Average no. of alcoholic 
drinks/week (±SD)* 2 (4) 2 (4) 2 (4) 0.82 2 (4) 2 (4) 0.26 
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Table 3 (continued) 
 
Regular use of any NSAID in past 
12 months  
Daily use of any NSAID for at least 1 
year  
 
Overall 
n=6695 No (n=3049) Yes (n=3646)  No (n=4598) Yes (n=2097)  
Variable n % n % n % p-value n % n % p-value 
Average no. of alcoholic 
drinks/week*       0.77     0.53 
   None 1932 29 887 29 1045 29  1341 29 591 28  
   <1 2265 34 1043 34 1222 33  1571 34 694 33  
   1-2 830 12 361 12 469 13  559 12 271 13  
   2-7 1106 16 500 16 606 17  754 16 352 17  
   >7 562 8 258 8 304 8  373 8 189 9  
Cigarette Smoking       0.05     0.12 
  Never 4047 60 1874 61 2173 60  2810 61 1237 59  
  Former 2128 32 925 30 1203 33  1425 31 703 33  
  Current 520 8 250 8 270 7  363 8 157 7  
Walks for exercise*       0.02     0.001 
  No 3174 47 1398 46 1776 49  2118 46 1056 50  
  Yes 3521 53 1651 54 1870 51  2480 54 1041 50  
Body mass index §       <0.0001     <0.0001 
   <25 2999 45 1528 50 1471 40  2161 47 838 40  
   25+ 3696 55 1521 50 2175 60  2437 53 1259 60  
Hypertension*       <0.0001     <0.0001 
   Never 4186 62 2057 67 2129 58  3033 66 1153 55  
   Ever 2509 37 992 32 1517 42  1565 34 944 45  
Hip bone mineral density 
(±SD), g/cm² 0.76 (0.13) 0.75 (0.13) 0.76 (0.13) <0.0001 0.75 (0.13) 0.76 (0.14) 0.002 
Stroke       <0.0001     <0.0001 
   Never 6378 96 2947 97 3431 95  4440 97 1938 93  
   Ever 276 4 89 3 187 5  133 3 143 7  
  Missing 41  13  28   25  16   
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Table 3 (continued) 
 
Regular use of any NSAID in past 
12 months  
Daily use of any NSAID for at least 1 
year  
 
Overall 
n=6695 No (n=3049) Yes (n=3646)  No (n=4598) Yes (n=2097)  
Variable n % n % n % p-value n % n % p-value 
Heart Attack       <0.0001     <0.0001 
   Never 5375 93 2548 95 2827 91  3755 94 1620 90  
   Ever 396 7 133 5 263 9  222 6 174 10  
  Missing 924  368  556   621  303   
Mammogram at visit 3       0.91     0.91 
   No 875 20 410 20 465 20  606 20 269 20  
   Yes 3484 80 1640 80 1844 80  2406 80 1078 80  
  Missing 2336  999  1337   1586  750   
*Information collected at baseline clinical visit; † History of breast cancer in a mother or sister; § Weight (kg)/height² (m²). 
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Table 4. Characteristics of women by acetaminophen use in the Study of Osteoporotic 
Fractures, 1989-90 
 
Regular use of 
acetaminophen in past 12 
months  
Daily use of acetaminophen 
for at least 1 year  
 
No 
(n=5173) 
Yes 
(n=1513)  No (n=6234) Yes (n=446)  
Variable n % n % p-value n % n % p-value 
Clinic*     <0.0001     0.003 
   A 1369 26 409 27  1642 26 135 30  
   B 1241 24 394 26  1505 24 129 29  
   C  1218 24 269 18  1410 23 76 17  
   D 1345 26 441 29  1677 27 106 24  
Age (±SD), years 73 (5) 73 (5) 0.46 73 (5) 74 (5) 0.0009 
Age (years)     0.50     0.008 
   ≤72 2715 52 809 53  3312 53 208 47  
   73+ 2458 47 704 47  2922 47 238 53  
Education*     0.0002     0.004 
   <High school 1053 20 376 25  1306 21 119 27  
   High school grad 4120 80 1137 75  4928 79 327 73  
Family history of breast 
cancer*     0.86     0.06 
  No 4487 87 1315 87  5398 87 400 90  
  Yes 686 13 198 13  836 13 46 10  
Age at first Menses     0.39     0.08 
     <12 621 12 171 12  726 12 67 15  
    12-13 2742 54 796 54  3312 55 221 50  
     14+ 1669 33 519 35  2036 33 150 34  
  Missing 141  27   160  8   
Parity*     0.31     0.17 
   Nulliparous 990 19 255 17  1159 19 82 18  
   1 722 14 200 13  876 14 46 10  
   2 1395 27 426 28  1700 27 125 28  
   3 1052 20 311 20  1265 20 94 21  
   4 530 10 166 11  651 10 45 10  
   5+ 484 9 155 10  583 9 54 12  
Nulliparous*     0.04     0.91 
   No 4183 81 1258 83  5075 81 364 82  
   Yes 990 19 255 17  1159 19 82 18  
Age at first live birth     0.002     <0.0001 
   ≤20 607 14 227 18  749 15 83 23  
   >20 3569 85 1028 82  4316 85 281 77  
  Missing 997  258   1169  82   
Age (years) at 
menopause*     0.007     0.01 
   ≤40 420 10 156 13  524 10 55 15  
   41-45 839 19 241 20  1010 19 72 20  
   46-50 1690 38 453 37  2009 38 129 36  
   ≥51 1458 33 375 31  1725 33 105 29  
  Missing 766  288   966  85   
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Table 4 (continued) 
 
Regular use of 
acetaminophen in past 12 
months  
Daily use of acetaminophen 
for at least 1 year  
 
No 
(n=5173) 
Yes 
(n=1513)  No (n=6234) Yes (n=446)  
Variable n % n % p-value n % n % p-value 
Surgical menopause*     <0.0001     <0.0001 
   No 4592 89 1276 84  5494 88 365 82  
   Yes 581 11 237 16  740 12 81 18  
Estrogen only therapy 
(Oral)*     0.0006     0.006 
   Never use 3022 58 808 53  3597 58 233 52  
   Past use 1433 28 446 29  1749 28 126 28  
   Current use 718 14 259 17  888 14 87 20  
Estrogen only therapy 
(Any Current)*     0.002     0.002 
   No 4455 86 1254 83  5346 86 359 80  
   Yes 718 14 259 17  888 14 87 20  
Avg. no. of alcoholic 
drinks/week (±SD)* 2 (4) 2 (5) 0.12 2 (4) 2 (6) 0.99 
Avg. no. of alcoholic 
drinks/week*     0.50     0.43 
   None 1483 29 444 29  1798 29 125 28  
   <1 1730 33 532 35  2101 34 161 36  
   1-2 652 13 177 12  785 13 45 10  
   2-7 872 17 234 15  1032 17 72 16  
   >7 436 8 126 8  518 8 43 10  
Cigarette Smoking     0.06     0.41 
  Never 3124 60 917 61  3757 60 281 63  
  Former 1626 31 499 33  1993 32 129 29  
  Current 423 8 97 6  484 8 36 8  
Walks for exercise*     0.16     0.003 
  No 2428 47 741 49  2925 47 242 54  
  Yes 2745 53 772 51  3309 53 204 46  
Body mass index §     <0.0001     0.008 
   <25 2412 47 583 39  2821 45 173 39  
   25+ 2761 53 930 61  3413 55 273 61  
Hypertension*     0.0008     0.0002 
   Never 3289 64 890 59  3938 63 242 54  
   Ever 1884 36 623 41  2296 37 204 46  
Hip bone mineral 
density (±SD), g/cm² 0.76 (0.13) 0.76 (0.13) 0.055 0.76 (0.13) 0.74 (0.14) 0.07 
Stroke     0.001     <0.0001 
   Never 4948 96 1421 94  5960 96 406 92  
   Ever 191 4 85 6  236 4 37 8  
  Missing 34  7   38  3   
62 
Table 4 (continued) 
 
Regular use of 
acetaminophen in past 12 
months  
Daily use of acetaminophen 
for at least 1 year  
 
No 
(n=5173) 
Yes 
(n=1513)  No (n=6234) Yes (n=446)  
Variable n % n % p-value n % n % p-value 
Heart Attack     0.0003     0.02 
   Never 4197 94 1173 91  5020 93 345 90  
   Ever 277 6 117 9  357 7 37 10  
  Missing 699  223   857  64   
Mammogram at visit 3     0.02     0.29 
   No 703 21 169 17  822 20 52 18  
   Yes 2681 79 803 83  3234 80 242 82  
  Missing 1789  541   2178  152   
*Information collected at baseline clinical visit.       
† History of breast cancer in a mother or sister.       
§ Weight (kg)/height² (m²).           
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Table 5. Characteristics of women by aspirin use in the Study of Osteoporotic Fractures, 
1989-90  
 
Regular use of asiprin in 
past 12 months  
Daily use of aspirin for 
at least 1 year  
 
No 
(n=4067) 
Yes 
(n=2628)  
No 
(n=5210) 
Yes 
(n=1485)  
Variable n % n % p-value n % n % p-value 
Clinic*     <0.0001     0.0003 
   A 1001 25 780 30  1335 26 446 30  
   B 1013 25 622 24  1264 24 371 25  
   C  967 24 522 20  1163 22 326 22  
   D 1086 27 704 27  1448 28 342 23  
Age (±SD), years 73 (5) 73 (5) 0.45 73 (5) 74 (5) 0.004 
Age (years)     0.12     0.003 
   ≤72 2174 53 1354 52  2796 54 732 49  
   73+ 1893 47 1274 48  2414 46 753 51  
Education*     0.28     0.02 
   <High school 887 22 544 21  1147 22 284 19  
   High school graduate 3180 78 2084 79  4063 78 1201 81  
Family history of breast 
cancer*     0.07     0.11 
  No 3504 86 2305 88  4502 86 1307 88  
  Yes 563 14 323 12  708 14 178 12  
Age at first Menses     0.09     0.44 
     <12 472 12 322 13  605 12 189 13  
    12-13 2190 56 1351 53  2771 54 770 53  
     14+ 1296 32 896 35  1703 34 489 34  
  Missing 109  59   131  37   
Parity*     0.59     0.2 
   Nulliparous 775 19 471 18  954 18 292 20  
   1 564 14 358 14  712 14 210 14  
   2 1113 27 715 27  1426 27 402 27  
   3 800 20 563 21  1051 20 312 21  
   4 428 10 269 10  568 11 129 9  
   5+ 387 9 252 10  499 10 140 9  
Nulliparous*     0.24     0.24 
   No 3292 81 2157 82  4256 82 1193 80  
   Yes 775 19 471 18  954 18 292 20  
Age at first live birth     0.39     0.17 
   ≤20 494 15 342 16  638 15 198 17  
   >20 2792 85 1811 84  3611 85 992 83  
  Missing 781  475   961  295   
Age (years) at menopause*     0.37     0.21 
   ≤40 351 10 229 10  445 10 135 11  
   41-45 656 19 426 19  858 19 224 18  
   46-50 1283 37 861 39  1647 37 497 40  
   ≥51 1147 33 687 31  1450 33 384 31  
  Missing 630  425   810  245   
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Table 5 (continued) 
 
Regular use of asiprin in 
past 12 months  
Daily use of aspirin for 
at least 1 year  
 
No 
(n=4067) 
Yes 
(n=2628)  
No 
(n=5210) 
Yes 
(n=1485)  
Variable n % n % p-value n % n % p-value 
Surgical menopause*     0.52     0.29 
   No 3576 88 2297 87  4582 88 1291 87  
   Yes 491 12 331 13  628 12 194 13  
Estrogen only therapy (Any 
Current)*     0.05     <0.0001 
   No 3501 86 2217 84  4498 86 1220 82  
   Yes 566 14 411 16  712 14 265 18  
Average no. of alcoholic 
drinks/week (±SD)* 2 (4) 2 (4) 0.09 2 (4) 2 (4) 0.04 
Average no. of alcoholic 
drinks/week*     0.37     0.07 
   None 1197 29 735 28  1517 29 415 28  
   <1 1388 34 877 33  1790 34 475 32  
   1-2 500 12 330 12  646 12 184 12  
   2-7 646 16 460 17  837 16 269 18  
   >7 336 8 226 9  420 8 142 9  
Cigarette Smoking     0.59     0.5 
  Never 2478 61 1569 60  3169 61 878 59  
  Former 1275 31 853 32  1640 31 488 33  
  Current 314 8 206 8  401 8 119 8  
Walks for exercise*     0.58     0.1 
  No 1917 47 1257 48  2442 47 732 49  
  Yes 2150 53 1371 52  2768 53 753 51  
Body mass index §     <0.0001     0.04 
   <25 1900 47 1099 42  2369 45 630 42  
   25+ 2167 53 1529 58  2841 55 855 58  
Hypertension*     <0.0001     <0.0001 
   Never 2627 65 1559 59  3362 65 824 55  
   Ever 1440 35 1069 41  1848 35 661 45  
Hip bone mineral density 
(±SD), g/cm² 0.75 (0.13) 0.76 (0.13) 0.005 0.76 (0.13) 0.76 (0.14) 0.13 
Stroke     <0.0001     <0.0001 
   Never 3927 97 2451 94  5025 97 1353 92  
   Ever 121 3 155 6  158 3 118 8  
  Missing 19  22   27  14   
Heart Attack     <0.0001     <0.0001 
   Never 3384 95 1991 90  4255 94 1120 89  
   Ever 181 5 215 10  255 6 141 11  
  Missing 502  422   700  224   
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Table 5 (continued) 
 
Regular use of asiprin in 
past 12 months  
Daily use of aspirin for 
at least 1 year  
 
No 
(n=4067) 
Yes 
(n=2628)  
No 
(n=5210) 
Yes 
(n=1485)  
Variable n % n % p-value n % n % p-value 
Mammogram at visit 3     0.13     0.77 
   No 521 19 354 21  676 20 199 20  
   Yes 2172 81 1312 79  2708 80 776 80  
  Missing 1374  962   1826  510   
*Information collected at baseline clinical visit.     
† History of breast cancer in a mother or sister.     
§ Weight (kg)/height² (m²).       
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Table 6. Characteristics of women by non-aspirin NSAID use in the Study of Osteoporotic 
Fractures, 1989-90 
 
Regular use of a non-
aspirin NSAID in past 12 
months  
Daily use of a non-
aspirin NSAID for at 
least 1 year  
 
No 
(n=4925) 
Yes 
(n=1770)  
No 
(n=5804) 
Yes 
(n=891)  
Variable n % n % p-value n % n % p-value 
Clinic*     <0.0001     0.0002 
   A 1290 26 491 28  1528 26 253 28  
   B 1163 24 472 27  1391 24 244 27  
   C  1171 24 318 18  1340 23 149 17  
   D 1301 26 489 28  1545 27 245 27  
Age (±SD), years 73 (5) 73 (5) 0.87 73 (5) 73 (5) 0.36 
Age (years)     0.79     0.91 
   ≤72 2600 53 928 52  3060 53 468 53  
   73+ 2325 47 842 48  2744 47 423 47  
Education*     <0.0001     0.01 
   <High school 992 20 439 25  1213 21 218 24  
   High school graduate 3933 80 1331 75  4591 79 673 76  
Family history of breast 
cancer*     0.26     0.66 
  No 4287 87 1522 86  5040 87 769 86  
  Yes 638 13 248 14  764 13 122 14  
Age at first Menses     0.85     0.007 
     <12 577 12 217 12  663 12 131 15  
    12-13 2603 54 938 54  3069 54 472 54  
     14+ 1616 34 576 33  1927 34 265 31  
  Missing 129  39   145  23   
Parity*     0.01     0.27 
   Nulliparous 952 19 294 17  1098 19 148 17  
   1 691 14 231 13  809 14 113 13  
   2 1353 27 475 27  1582 27 246 28  
   3 991 20 372 21  1179 20 184 21  
   4 488 10 209 12  592 10 105 12  
   5+ 450 9 189 11  544 9 95 11  
Nulliparous*     0.01     0.10 
   No 3973 81 1476 83  4706 81 743 83  
   Yes 952 19 294 17  1098 19 148 17  
Age at first live birth     0.0002     0.03 
   ≤20 565 14 271 18  702 15 134 18  
   >20 3402 86 1201 82  3996 85 607 82  
  Missing 958  298   1106  150   
Age (years) at menopause*     0.64     0.06 
   ≤40 419 10 161 11  486 10 94 13  
   41-45 808 19 274 19  948 19 134 19  
   46-50 1598 38 546 37  1872 38 272 38  
   ≥51 1349 32 485 33  1615 33 219 30  
  Missing 751  304   883  172   
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Table 6 (continued) 
 
Regular use of a non-
aspirin NSAID in past 12 
months  
Daily use of a non-
aspirin NSAID for at 
least 1 year  
 
No 
(n=4925) 
Yes 
(n=1770)  
No 
(n=5804) 
Yes 
(n=891)  
Variable n % n % p-value n % n % p-value 
Surgical menopause*     0.05     0.04 
   No 4343 88 1530 86  5110 88 763 86  
   Yes 582 12 240 14  694 12 128 14  
Estrogen only therapy (Any 
Current)*     <0.0001     <0.0001 
   No 4266 87 1452 82  5027 87 691 78  
   Yes 659 13 318 18  777 13 200 22  
Average no. of alcoholic 
drinks/week (±SD)* 2 (4) 2 (4) 0.20 2 (4) 2 (4) 0.38 
Average no. of alcoholic 
drinks/week*     0.56     0.67 
   None 1404 29 528 30  1677 29 255 29  
   <1 1673 34 592 33  1953 34 312 35  
   1-2 600 12 230 13  712 12 118 13  
   2-7 826 17 280 16  969 17 137 15  
   >7 422 9 140 8  493 8 69 8  
Cigarette Smoking     0.05     0.33 
  Never 2992 61 1055 60  3520 61 527 59  
  Former 1533 31 595 34  1827 31 301 34  
  Current 400 8 120 7  457 8 63 7  
Walks for exercise*     0.006     0.0004 
  No 2285 46 889 50  2702 47 472 53  
  Yes 2640 54 881 50  3102 53 419 47  
Body mass index §     <0.0001     <0.0001 
   <25 2364 48 635 36  2700 46 299 33  
   25+ 2561 52 1135 64  3104 53 592 66  
Hypertension*     <0.0001     <0.0001 
   Never 3190 65 996 56  3713 64 473 53  
   Ever 1735 35 774 44  2091 36 418 47  
Hip bone mineral density 
(±SD), g/cm² 0.75 (0.13) 0.77 (0.13) <0.0001 0.75 (0.13) 0.77 (0.14) <0.0001 
Stroke     0.49     0.006 
   Never 4696 96 1682 96  5544 96 834 94  
   Ever 198 4 78 4  224 4 52 6  
  Missing 31  10   36  5   
Heart Attack     0.57     0.18 
   Never 3966 93 1409 93  4662 93 713 92  
   Ever 287 7 109 7  334 7 62 8  
  Missing 672  252   808  116   
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Table 6 (continued) 
 
Regular use of a non-
aspirin NSAID in past 12 
months  
Daily use of a non-
aspirin NSAID for at 
least 1 year  
 
No 
(n=4925) 
Yes 
(n=1770)  
No 
(n=5804) 
Yes 
(n=891)  
Variable n % n % p-value n % n % p-value 
Mammogram at visit 3     0.17     0.86 
   No 670 21 205 19  764 20 111 20  
   Yes 2590 79 894 81  3034 80 450 80  
  Missing 1665  671   2006  330   
*Information collected at baseline clinical visit.      
† History of breast cancer in a mother or sister.      
§ Weight (kg)/height² (m²).        
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Table 7. Clinical characteristics of breast cancer cases by regular NSAID use, the Study of Osteoporotic Fractures, 1986-1993 
 
Regular use of any NSAID in 
past 12 months  
Daily use of any NSAID for 
at least 1 year  
 
Overall 
n=372 No (n=177) Yes (n=195)  No (n=265) Yes (n=107)  
Characteristics n % n % n % p-value n % n % p-value 
Age at diagnosis, mean (SD), y   78 (5) 79 (5) 0.16 78 (5) 78 (6) 0.34 
Estrogen receptor status, No. (%)†       §     § 
   Positive 269 72 129 73 140 72  188 71 81 76  
   Negative 37 10 16 9 21 11  27 10 10 9  
   Borderline 1 0.3 0 0 1 1  1 0 0 0  
   Unknown 65 17 32 18 33 17  49 18 16 15  
Estrogen receptor status, No. (%)†       0.6     0.71 
   Positive ║ 270 88 129 89 140 86  189 87 81 89  
   Negative 37 12 16 11 21 13  27 12 10 11  
   missing 65  0 0 1 1  49  16   
Progesterone receptor status, No. (%)†       §     § 
   Positive 209 56 99 56 110 56  152 57 57 53  
   Negative 88 24 40 23 48 25  55 21 33 31  
   Borderline 7 2 3 2 4 2  6 2 1 1  
   Unknown 68 18 35 20 33 17  52 20 16 15  
Progesterone receptor status, No. (%)†       0.78     0.07 
   Positive ║ 216 71 102 72 114 70  158 74 58 64  
   Negative  88 29 40 28 48 30  55 26 33 36  
   missing 68  35  33   52  16   
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Table 7 (continued) 
 
Regular use of any NSAID 
in past 12 months  
Daily use of any NSAID for at 
least 1 year  
 
Overall 
n=372 No (n=177) Yes (n=195)  No (n=265) Yes (n=107)  
Characteristics n % n % n % p-value n % n % p-value 
Cancer stage at diagnosis, No. (%)‡       0.84     0.82 
  O (in situ) 52 14 27 15 25 13  38 14 14 13  
   I 206 55 98 55 108 55  150 57 56 52  
  II (no nodes) 41 11 20 11 21 11  29 11 12 11  
  II (+ nodes) 36 10 20 11 16 8  24 9 12 11  
  III 14 4 4 2 10 5  10 4 4 4  
  IV 4 1 1 1 3 1  3 1 1 1  
  Unknown 19 5 7 4 12 6   11 4 8 8   
†Women with unknown estrogen receptor status were excluded in statistical tests.       
‡The p value compares women with stage II cancer or greater at diagnosis with other cases.  Women with unknown cancer stage at diagnosis were excluded 
from this analysis. 
║ Borderline recoded to positive             
§ Cell sizes too sparse to use chi square test to compare clinical characteristic by medication use.     
71 
Table 8. Clinical characteristics of breast cancer cases by regular acetaminophen use, the Study of Osteoporotic Fractures, 
1986-1993 
 
Regular use of acetaminophen in past 
12 months  
Daily use of acetaminophen for at 
least 1 year  
 No (n=295) Yes (n=76)  No (n=358) Yes (n=14)  
Characteristics n % n % p-value n % n % p-value 
Age at diagnosis, mean (SD), y 78 (5) 78 (6) 0.29 78 (5) 77 (6) 0.24 
Estrogen receptor status, No. (%)†     §     § 
   Positive 210 71 58 76  260 73 9 64  
   Negative 29 10 8 11  36 10 1 7  
   Borderline 1 0 0 0  1 0 0 0  
   Unknown 55 19 10 13  61 17 4 29  
Estrogen receptor status, No. (%)†     0.99     1.00 
   Positive ║ 211 88 58 88  261 88 9 90  
   Negative 29 12 8 12  36 12 1 10  
   missing 55  10   61  4   
Progesterone receptor status, No. (%)†     §     § 
   Positive 160 54 48 63  204 57 5 36  
   Negative 71 24 17 22  83 23 5 36  
   Borderline 7 2 0 0  7 2 0 0  
   Unknown 57 19 11 14  64 18 4 29  
Progesterone receptor status, No. (%)†     0.56     0.16 
   Positive ║ 167 70 48 74  211 72 5 50  
   Negative  71 30 17 26  83 28 5 50  
   missing 57  11   64  4   
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Table 8 (continued) 
 
Regular use of acetaminophen in past 
12 months  
Daily use of acetaminophen for at 
least 1 year  
 No (n=295) Yes (n=76)  No (n=358) Yes (n=14)  
Characteristics n % n % p-value n % n % p-value 
Cancer stage at diagnosis, No. (%)‡     0.25     § 
  O (in situ) 45 15 7 9  50 14 2 14  
   I 158 53 47 62  200 56 6 43  
  II (no nodes) 35 12 6 8  40 11 1 7  
  II (+ nodes) 30 10 6 8  33 9 3 21  
  III 10 3 4 5  13 4 1 7  
  IV 3 1 1 1  4 1 0 0  
  Unknown 14 5 5 7   18 5 1 7   
†Women with unknown estrogen receptor status were excluded in statistical tests.      
‡The p value compares women with stage II cancer or greater at diagnosis with other cases.  Women with unknown cancer stage at diagnosis were excluded 
from this analysis. 
 ║ Borderline recoded to positive           
§ Cell sizes too sparse to use chi square test to compare clinical characteristic by medication use.   
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Table 9. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use in the Study of Osteoporotic Fractures, 1986-1993 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Controls 
(n=6323) 
Cases 
(n=372) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Aspirin ≥ 1/week in 
past 12 months         
   No 3838 229 1.00  1.00  1.00  
   Yes 2485 143 0.98 0.80, 1.21 0.98 0.80, 1.21 0.96 0.78, 1.18 
Aspirin frequency:         
        No regular use 3838 229 1.00  1.00  1.00  
        1-4 days/week 995 62 1.02 0.77, 1.35 1.02 0.77, 1.35 1.00 0.76, 1.33 
        5-7 days/week 1418 72 0.89 0.68, 1.16 0.90 0.69, 1.17 0.87 0.66, 1.13 
        Missing 72 9       
Aspirin ~daily for ≥ 
1 year         
   No 4913 297 1.00  1.00  1.00  
   Yes 1410 75 0.93 0.72, 1.19 0.93 0.72, 1.20 0.90 0.70, 1.16 
Aspirin duration:         
        No regular use 4913 297 1.00  1.00  1.00  
        < 5 years 771 40 0.90 0.65, 1.25 0.90 0.65, 1.26 0.89 0.64, 1.23 
        5+ years 632 35 0.97 0.68, 1.37 0.97 0.69, 1.38 0.92 0.65, 1.31 
        Missing 7 0       
Non-aspirin NSAID 
≥ 1/week in past 12 
months         
   No 4652 273 1.00  1.00  1.00  
   Yes 1671 99 1.01 0.80, 1.27 1.01 0.80, 1.27 0.96 0.76, 1.21 
Non-aspirin NSAID 
frequency:         
        No regular use 4652 273 1.00  1.00  1.00  
        1-4 days/week 540 35 1.08 0.76, 1.54 1.08 0.76, 1.54 1.05 0.74, 1.50 
        5-7 days/week 1080 60 0.96 0.72, 1.26 0.96 0.72, 1.27 0.90 0.68, 1.19 
        Missing 51 4       
Non-aspirin NSAID 
~daily for ≥ 1 year         
   No 5481 323 1.00  1.00  1.00  
   Yes 842 49 1.02 0.75, 1.38 1.02 0.76, 1.38 0.95 0.70, 1.29 
Non-aspirin NSAID 
duration:         
        No regular use 5481 323 1.00  1.00  1.00  
        < 5 years 565 34 1.06 0.75, 1.51 1.07 0.75, 1.52 1.02 0.71, 1.46 
        5+ years 271 15 0.95 0.57, 1.60 0.95 0.57, 1.59 0.85 0.50, 1.43 
        Missing 6 0       
Any NSAIDs ≥ 
1/week in past 12 
months         
   No 2872 177 1.00  1.00  1.00  
   Yes 3451 195 0.93 0.76, 1.14 0.94 0.76, 1.15 0.89 0.73, 1.10 
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Table 9 (continued) 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Controls 
(n=6323) 
Cases 
(n=372) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs 
frequency:         
        No regular use 2872 177 1.00  1.00  1.00  
        1-4 days/week 2014 105 0.88 0.69, 1.12 0.89 0.70, 1.13 0.83 0.65, 1.07 
        5-7 days/week 1364 81 0.95 0.73, 1.24 0.95 0.73, 1.24 0.92 0.71, 1.20 
        Missing 73 9       
Any NSAIDs ~daily 
for ≥ 1 year         
   No 4333 265 1.00  1.00  1.00  
   Yes 1990 107 0.93 0.74, 1.16 0.93 0.74, 1.17 0.89 0.71, 1.12 
NSAIDs duration:         
        No regular use 4333 265 1.00  1.00  1.00  
        < 5 years 1143 62 0.93 0.71, 1.23 0.94 0.71, 1.24 0.91 0.69, 1.20 
        5+ years 839 45 0.92 0.67, 1.26 0.93 0.68, 1.27 0.86 0.63, 1.19 
        Missing 8 0       
Acetaminophen ≥ 
1/week in past 12 
months         
   No 4878 295 1.00  1.00  1.00  
   Yes 1437 76 0.89 0.69, 1.15 0.87 0.70, 1.07 0.87 0.67, 1.12 
   Missing 8 1       
Acetaminophen 
frequency:         
        No regular use 4878 295 1.00  1.00  1.00  
        1-4 days/week 842 47 0.92 0.68, 1.26 0.92 0.68, 1.25 0.90 0.66, 1.22 
        5-7 days/week 495 19 0.68 0.43, 1.08 0.68 0.43, 1.09 0.67 0.42, 1.07 
        Missing 108 11       
Acetaminophen 
~daily for ≥ 1 year         
   No 5876 358 1.00  1.00  1.00  
   Yes 432 14 0.58 0.34, 0.99 0.58 0.34, 0.99 0.57 0.33, 0.97 
   Missing 15 0       
Acetaminophen 
duration: §         
        No regular use 5876 358 1.00  1.00  1.00  
        < 5 years 276 6       
        5+ years 152 8       
        Missing 19 0             
*Proportional hazards regression models.       
**Age-adjusted hazard ratio       
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval.       
§ Too few breast cancer cases to estimate relative hazard associated with medication use. 
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Table 10. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use by hormone receptor status in the SOF, 1986-1993 
 Unadjusted* Adjusted** Adjusted*** 
Cases:  
≥ 1 
Positive 
Hormone 
Receptor 
(n=275) HR‡ 95% CI HR‡ 95% CI 
Controls 
(n=6323) Risk Factor HR‡ 95% CI 
Aspirin ≥ 1/week in 
past 12 months         
   No 3838 170 1.00  1.00  1.00  
   Yes 2485 105 0.97 0.76, 1.24 0.97 0.76, 1.24 0.94 0.74, 1.21 
Aspirin frequency:          
        No regular use 3838 170 1.00  1.00  1.00  
        1-4 days/week 995 46 1.02 0.74, 1.41 1.02 0.73, 1.41 1.00 0.72, 1.39 
        5-7 days/week 1418 52 0.87 0.64, 1.18 0.87 0.64, 1.19 0.84 0.61, 1.15 
        Missing 72 7       
Aspirin ~daily for ≥ 
1 year          
   No 4913 216 1.00  1.00  1.00  
   Yes 1410 59 1.00 0.75, 1.33 1.01 0.75, 1.34 0.96 0.72, 1.29 
Aspirin duration:          
        No regular use 4913 216 1.00  1.00  1.00  
        < 5 years 771 30 0.93 0.63, 1.36 0.93 0.64, 1.36 0.90 0.62, 1.33 
        5+ years 632 29 1.10 0.74, 1.62 1.11 0.75, 1.63 1.04 0.71, 1.54 
        Missing 7 0       
Non-aspirin NSAID 
≥ 1/week in past 12 
mos          
   No 4652 200 1.00  1.00  1.00  
   Yes 1671 75 1.04 0.80, 1.36 1.04 0.80, 1.36 1.00 0.76, 1.30 
Non-aspirin NSAID 
frequency:          
        No regular use 4652 200 1.00  1.00  1.00  
        1-4 days/week 540 28 1.18 0.79, 1.75 1.18 0.79, 1.75 1.15 0.78, 1.72 
        5-7 days/week 1080 45 0.98 0.71, 1.35 0.98 0.71, 1.36 0.92 0.66, 1.28 
        Missing 51 2       
Non-aspirin NSAID 
~daily for ≥ 1 year          
   No 5481 237 1.00  1.00  1.00  
   Yes 842 38 1.08 0.76, 1.51 1.08 0.76, 1.52 1.01 0.71, 1.42 
Non-aspirin NSAID 
duration:           
        No regular use 5481 237 1.00  1.00  1.00  
        < 5 years 565 26 1.11 0.74, 1.66 1.11 0.74, 1.67 1.06 0.71, 1.60 
        5+ years 271 12 1.03 0.58, 1.85 1.03 0.58, 1.84 0.92 0.51, 1.65 
        Missing 6 0       
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Table 10 (continued) 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Controls 
(n=6323) 
Cases:  
≥ 1 
Positive 
Hormone 
Receptor 
(n=275) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs ≥ 
1/week in past 12 
months         
   No 2872 131 1.00  1.00  1.00  
   Yes 3451 144 0.93 0.73, 1.18 0.93 0.74, 1.18 0.89 0.70, 1.13 
Any NSAIDs 
frequency:          
        No regular use 2872 131 1.00  1.00  1.00  
        1-4 days/week 2014 76 0.86 0.65, 1.14 0.87 0.65, 1.15 0.81 0.61, 1.08 
        5-7 days/week 1364 62 0.98 0.73, 1.33 0.98 0.72, 1.33 0.95 0.70, 1.29 
        Missing 73 6       
Any NSAIDs ~daily 
for ≥ 1 year          
   No 4333 193 1.00  1.00  1.00  
   Yes 1990 82 0.97 0.75, 1.26 0.98 0.76, 1.27 0.93 0.71, 1.20 
NSAIDs duration:          
        No regular use 4333 193 1.00  1.00  1.00  
        < 5 years 1143 46 0.95 0.69, 1.31 0.96 0.69, 1.32 0.92 0.67, 1.27 
        5+ years 839 36 1.01 0.71, 1.44 1.01 0.71, 1.45 0.94 0.66, 1.35 
        Missing 8 0       
Acetaminophen ≥ 
1/week in past 12 
months          
   No 4878 215 1.00  1.00  1.00  
   Yes 1437 59 0.94 0.71, 1.26 0.94 0.71, 1.26 0.92 0.69, 1.23 
   Missing 8 1       
Acetaminophen 
frequency:          
        No regular use 4878 215 1.00  1.00  1.00  
        1-4 days/week 842 37 0.99 0.70, 1.41 0.99 0.70, 1.40 0.96 0.68, 1.37 
        5-7 days/week 495 14 0.68 0.40, 1.17 0.69 0.40, 1.18 0.67 0.39, 1.15 
        Missing 108 9       
Acetaminophen 
~daily for ≥ 1 year †         
   No 5876 266 1.00  1.00  1.00  
   Yes 432 9 0.50 0.26, 0.97 0.50 0.26, 0.98 0.48 0.25, 0.93 
   Missing 15 0       
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Table 10 (continued) 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Controls 
(n=6323) 
Cases:  
≥ 1 
Positive 
Hormone 
Receptor 
(n=275) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Acetaminophen 
duration: †         
        No regular use 5876 266 1.00  1.00  1.00  
        < 5 years 276 4       
        5+ years 152 5       
        Missing 19 0             
*Proportional hazards regression models; **Age-adjusted hazard ratio 
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval.   
† Too few hormone receptor-positive breast cancer cases to estimate HR associated with medication use. 
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Table 11. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use by tumor type at diagnosis in the SOF (1986-1993) 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Cases  
Stages I 
to IV 
(n=301) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Aspirin ≥ 1/week in past 12 
months        
   No 184 1.00  1.00  1.00  
   Yes 117 1.00 0.79, 1.26 1.00 0.76, 1.26 0.97 0.77, 1.22 
Aspirin frequency:         
        No regular use 184 1.00  1.00  1.00  
        1-4 days/week 52 1.07 0.78, 1.45 1.06 0.78, 1.44 1.04 0.76, 1.41 
        5-7 days/week 59 0.91 0.68, 1.22 0.91 0.68, 1.23 0.88 0.65, 1.18 
        Missing 6       
Aspirin ~daily for ≥ 1 year        
   No 242 1.00  1.00  1.00  
   Yes 59 0.89 0.67, 1.19 0.90 0.68, 1.19 0.86 0.65, 1.15 
Aspirin duration:         
        No regular use 242 1.00  1.00  1.00  
        < 5 years 30 0.83 0.57, 1.21 0.83 0.57, 1.22 0.81 0.55, 1.19 
        5+ years 29 0.98 0.67, 1.44 0.99 0.67, 1.45 0.93 0.63, 1.37 
        Missing 0       
Non-aspirin NSAID ≥ 
1/week in past 12 months        
   No 221 1.00  1.00  1.00  
   Yes 80 1.01 0.78, 1.30 1.01 0.78, 1.30 0.96 0.74, 1.24 
Non-aspirin NSAID 
frequency:         
        No regular use 221 1.00  1.00  1.00  
        1-4 days/week 29 1.11 0.75, 1.63 1.11 0.75, 1.63 1.08 0.73, 1.59 
        5-7 days/week 49 0.96 0.71, 1.31 0.97 0.71, 1.32 0.90 0.66, 1.23 
        Missing 2       
Non-aspirin NSAID ~daily 
for ≥ 1 year         
   No 261 1.00  1.00  1.00  
   Yes 40 1.03 0.74, 1.44 1.03 0.74, 1.44 0.96 0.68, 1.34 
Non-aspirin NSAID 
duration:         
        No regular use 261 1.00  1.00  1.00  
        < 5 years 28 1.08 0.73, 1.60 1.09 0.74, 1.61 1.03 0.70, 1.53 
        5+ years 12 0.94 0.53, 1.68 0.94 0.53, 1.68 0.83 0.45, 1.49 
        Missing 0       
Any NSAIDs ≥ 1/week in 
past 12 months        
   No 143 1.00  1.00  1.00  
   Yes 158 0.93 0.75, 1.17 0.94 0.75, 1.18 0.89 0.71, 1.12 
Any NSAIDs frequency:        
        No regular use 143 1.00  1.00  1.00  
        1-4 days/week 86 0.89 0.68, 1.16 0.90 0.69, 1.17 0.84 0.64, 1.10 
        5-7 days/week 67 0.97 0.73, 1.30 0.97 0.73, 1.30 0.94 0.70, 1.26 
        Missing 5       
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Table 11 (continued) 
 Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
Cases  
Stages I 
to IV 
(n=301) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs ~daily for ≥ 1 
year        
   No 216 1.00  1.00  1.00  
   Yes 85 0.90 0.70, 1.16 0.91 0.71, 1.17 0.86 0.66, 1.10 
NSAIDs duration:         
        No regular use 216 1.00  1.00  1.00  
        < 5 years 48 0.89 0.65, 1.21 0.89 0.65, 1.22 0.86 0.63, 1.18 
        5+ years 37 0.93 0.65, 1.31 0.93 0.66, 1.32 0.86 0.60, 1.22 
        Missing 0       
Acetaminophen ≥ 1/week 
in past 12 months         
   No 236 1.00  1.00  1.00  
   Yes 64 0.94 0.71, 1.23 0.93 0.71, 1.23 0.90 0.68, 1.19 
   Missing 1       
Acetaminophen frequency:         
        No regular use 236 1.00  1.00  1.00  
        1-4 days/week 40 0.98 0.70, 1.37 0.98 0.70, 1.37 0.95 0.68, 1.33 
        5-7 days/week 16 0.71 0.43, 1.18 0.72 0.43, 1.19 0.69 0.41, 1.15 
        Missing 9       
Acetaminophen ~daily for 
≥ 1 year         
   No 290 1.00  1.00  1.00  
   Yes 11 0.56 0.31, 1.02 0.56 0.31, 1.03 0.53 0.29, 0.98 
   Missing 0       
Acetaminophen duration: 
†         
        No regular use 290 1.00  1.00  1.00  
        < 5 years 4       
        5+ years 7       
        Missing 0       
*Proportional hazards regression models. 
**Age-adjusted hazard ratio 
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval. 
† Too few invasive breast cancer cases to estimate relative hazard associated with medication use. 
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3.1  ABSTRACT 
Background: Mammographic density is one of the strongest risk factors for breast cancer.  
Exactly how mammographic density increases breast cancer risk is unknown, although it has 
been posited that dense breast areas may reflect exposure to estrogen.  The cytokine tumor 
necrosis factor (TNF)-alpha has a central role in regulating estrogen synthesis in the breast.  
Circulating TNF receptors may block TNF-α activity, thereby preventing induction of COX-2 
gene expression, thus resulting in decreased aromatase activity, and ultimately suppression of 
estrogen biosynthesis in the breast. 
Methods:  The association between mammographic density and plasma levels of soluble TNF 
receptors (sTNFR1 and sTNFR2) was examined among 376 cancer-free, mostly white, 
postmenopausal women, participating in a cross-sectional study of mammographic density 
(Pittsburgh, PA, 2001-2005).  Women were not taking hormone therapy at the time of blood 
collection.  Percent breast density was calculated using a quantitative method (planimetry).       
Results:  The mean percent mammographic density was lower among women in the highest 
quartiles of circulating levels of sTNFR1 and sTNFR2.  After adjustment for BMI, the inverse 
association initially observed between the circulating sTNFRs and percent mammographic 
density disappeared.  While not the primary aim of the study, recent NSAID use reported at 
blood collection was associated with lower percent mammographic density. 
Conclusion:  Our findings suggest that mammographic density is independent of circulating 
sTNFRs in postmenopausal women. 
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3.2 INTRODUCTION 
Breast cancer is the most common cancer in women around the world; in the United States this 
year, it is expected that breast cancer alone will account for 31% (212,920) of all new cancer 
cases among women and 40,970 women are expected to die from the disease (1).  
Mammographic density is a known risk factor for breast cancer (2, 3).  The histologic 
composition of the breast is reflected mammographically by density and parenchymal pattern.  
The higher the fat content of the breast the lower the radiologic density.  Conversely, a high 
proportion of connective, ductal/epithelial, and glandular tissue increases density (4-7).  Notably, 
the risk associated with mammographic density is greater than that associated with almost all 
other risk factors for breast cancer (3, 8).  Therefore, understanding factors that affect breast 
density and their underlying mechanism is an important research question.   
Many reproductive and hormonal factors associated with breast cancer (9-12) are also 
associated with breast density.  For instance, increased mammographic density is observed in 
nulliparous women, and in women with a later age at first birth and later age at menopause (3, 9, 
10, 13-20); similar relationships have been observed for these reproductive factors with respect 
to breast cancer risk (21).  A positive association between hormone therapy (HT) and density 
further supports a hormonal influence on breast density (3, 11, 22).  Together, these observations 
suggest that the radiologic features of breast tissue may provide an index of breast tissue 
exposure to current and past endocrine events that influence breast cancer susceptibility (23).  
The cytokine tumor necrosis factor (TNF)-alpha, secreted by macrophages of the immune 
system and also by adipocytes, has a central role in regulating estrogen synthesis within both 
normal and malignant breast tissue (24-26).  Further, TNF-α is one of the most potent promoters 
of the aromatase gene, CYP19, resulting in the peripheral conversion of androgens to estrogens 
in adipose tissue (27).  TNF-α induces a range of inflammatory enzymes, including 
cyclooxygenase (COX)-2. COX-2 cyclizes and oxygenates arachidonic acid eventually 
producing prostaglandin E2 (PGE2) (28, 29).  COX-2 is believed to drive production of estrogen 
in the breast, in turn facilitating tumorigenesis (30), as evidenced by  a positive correlation 
between 1) the level of COX-2 and expression of CYP19 in human breast cancer (31) and 2) 
88 
increased aromatase gene (P450) expression, the product of CYP19, in cultured breast cells (29, 
32). This paracrine loop may explain why inhibition of COX-2 activity could have a protective 
effect on breast cancer (33) and quite possibly, mammographic density.  TNF-α exerts its effects 
by binding to two transmembrane cell surface receptors: TNF receptor 1 (TNFR1, also referred 
to as p55, p60, TNFRSF1A) and the TNF receptor 2 (TNFR2, p75, p80, TNFRSF1B) (34, 35), 
both of which are expressed in virtually all mammalian cells, including mammary epithelial cells 
(36).  The TNFRs have similar ligand-binding domains, but each differs in cytoplasmic domains, 
suggesting distinct signal transduction pathways.  TNF-α binds to the two receptors with similar 
affinity; when engaged, the extracellular domains of the soluble TNF receptors (sTNFRs) may be 
shed into the circulation (35).  These shed sTNFRs can compete for TNF-α with cell surface 
receptors and thus block TNF-α activity (37).   
 To date, only one nested case-control study has prospectively examined the relationship 
between serum levels of sTNFRs and breast cancer risk (38).  The investigators found no 
association between serum levels of the soluble receptors TNFR1 and TNFR2 and breast cancer 
risk; however, this study had limited power to detect an association in postmenopausal women, 
with only 61 postmenopausal case-control pairs (38).  In light of the evidence linking TNF-α  to 
estrogen synthesis and cellular proliferation in the breast, and the potential for sTNFRs to inhibit 
TNF-α, we sought to examine the association between circulating sTNFR1 and sTNFR2 levels 
with mammographic density among cancer-free postmenopausal women.  
3.3 METHODS 
The Mammograms and Masses Study (MAMS) is a cross-sectional study of correlates of 
mammographic density.  Pre- and postmenopausal women were recruited between 2001 and 
2005 through the Magee Womens Hospital Mammographic Screening and Diagnostic Imaging 
Program in the greater Pittsburgh area (Pennsylvania, USA).  Women were excluded from the 
study if they reported a previous personal history of any cancer (except nonmelanoma skin 
cancer).  Volunteers arose from two sources: 1) women undergoing outpatient needle breast 
biopsy through the Breast Biopsy Service at Magee-Womens Hospital (Pittsburgh, PA) and 2) 
women receiving screening mammography through Magee-Womens Hospital or through a 
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suburban Pittsburgh Magee Womancare Center.  To identify and recruit eligible participants, a 
trained research assistant personally solicited patients visiting the Breast Biopsy Service between 
September 2001 and May 2005 and women visiting Magee-Womencare Center North (Wexford, 
PA) and East (Monroeville, PA) between July 2002 and September 2003.  To boost recruitment, 
Magee-Womens Hospital attached study flyers to screening result reports mailed to Magee-
Womancare Center patients with negative mammography between November 2003 and April 
2005.  The procedures followed were in accordance with both the Magee-Womens Hospital and 
the University of Pittsburgh’s Institutional Review Boards, and all participants gave informed 
consent. 
 For this ancillary study, only cancer-free postmenopausal women were considered 
because both cytokine levels (39) and mammographic density (40) vary with the menstrual cycle.  
In addition, we excluded women who were taking hormone therapy at study enrollment, the time 
of blood draw, as HT use is related to elevations in mammographic density (3, 11, 22), and the 
relationship between HT and circulating sTNFR levels has not been well-established (41).  We 
further restricted the population to women with completed study questionnaires and available 
sTNFR and mammographic density results.  Of 856 Breast Biopsy Service patients approached, 
573 (67%) women lacked a personal cancer history, provided informed consent, completed a 
personal interview, and provided a blood sample.  A subsequent review of breast biopsy 
pathology reports verified non-breast cancer outcomes in 311 (54% of 573) women and 
confirmed primary breast cancer in 262 (46% of 573) women; breast cancer cases were excluded 
from this report.  Of the 311 cancer-free women, 109 (35% of 311) were postmenopausal and not 
taking HT at study enrollment.  Of these, 69 (63% of 109) had available questionnaire, sTNFR 
and mammographic density results.  Of approximately 100 Magee-Womancare Center North and 
East patients approached directly, 86 women lacked a personal cancer history, provided informed 
consent, completed a personal interview, and provided a blood sample.  Subsequent follow-up 
verified non-breast cancer outcomes in 85 (99%) women and a primary breast cancer in one 
remaining woman; this breast cancer case was excluded.  Of the 85 cancer-free women, 43 
(51%) were postmenopausal and not taking HT at study enrollment; of these, 30 (70%) had 
available questionnaire, sTNFR and mammographic density results.  Finally, mailing study flyers 
to 21,606 women with negative mammography produced 1,025 responses (5%), including 857 
(84% of 1,025) responses from women without a personal cancer history.  Of 451 (53% of 857) 
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women providing informed consent and a blood sample, 297 (66% of 451) were postmenopausal 
and not taking HT at study enrollment.  Of the 297 women, 277 (93%) had available 
questionnaire, sTNFR and mammographic density results.  Thus, 376 women, consisting of 69 
(18%) from the Breast Biopsy Service, 30 (8%) from Magee-Womancare Center North/East, and 
277 (74%) from the mass mailings, were included in the present analysis.  The 376 women were 
similar to the 73 women who were excluded due to missing questionnaire and/or mammographic 
density results with respect to age and body mass index; however, women excluded from the 
present study were less likely to attend post-secondary education, to walk for exercise, and to be 
nulliparous, and they were more likely to have been enrolled in the Breast Biopsy Service.  
Women excluded from the study due to missing questionnaire data were very similar to the 376 
women with respect to mammographic density.    
3.3.1 Data collection 
At study enrollment, trained clinical staff conducted a personal interview and recorded 
information on standardized study forms including age, race, menopausal status, history of 
hormone therapy use, aspirin or other anti-inflammatory drug use in the last 48 hours, weight 
without shoes or heavy clothing (measured in kilograms with a standard balance beam scale), 
and height without shoes at full inspiration (measured in centimeters with a stadiometer).  
Weight and height were used to calculate body mass index (BMI, weight in kilograms divided by 
height in meters squared).   
Lifestyle and reproductive history were obtained through a standardized self-
administered take-home questionnaire, including education (high school graduate vs. any post-
secondary education), cigarette smoking (current, former, never), number of alcohol drinks per 
week (among those who reported consuming alcohol ≥1/week for ≥6 months), takes walks for 
exercise ≥10 minutes without stopping (rarely/1-3 times per month vs. at least 2-3 times per 
week), parity, breastfeeding duration (never or ≤1 month, 1-12 months, 13+ months), type of 
menopause (surgical vs. natural), and number of breast biopsies prior to study enrollment (0, 1, 
2+).  Current alcohol use was defined as reported consumption of beer, wine, or spirits for 
≥1/week for ≥6 months during the year prior to study enrollment.  Ethanol exposure in 
grams/day was calculated and standardized across the different types of alcoholic beverages as 
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previously reported (42).  Current alcohol consumption was defined as: no current use, <12 g/day 
(the equivalent of ~1 alcoholic beverage/day), ≥12 g/day.  A family history of breast cancer was 
defined as a report of breast cancer in a participant’s mother or sister.  Age at menarche (<12, 12-
13, ≥14) and age at first live birth (<30 vs. ≥30 or nulliparous) were categorized according to the 
Gail Model for 5-year risk of breast cancer (43).  Age at menopause was defined according to 
methods outlined by the Women’s Health Initiative (44), where age at menopause was the 
minimum age at which the participant last had any natural menstrual bleeding, had a bilateral 
oophorectomy, or began using HT.  For a hysterectomized woman without a bilateral 
oophorectomy, age at menopause was the earliest age at which she began using HT or first had 
menopausal symptoms.  If neither occurred and her age at hysterectomy was 50 years or older, 
then age at menopause was her age at hysterectomy (44).  In this report, one participant has a 
missing value for her age at menopause because she: 1) did not have a hysterectomy, and 2) has 
a missing value for age last had any menstrual bleeding, and 3) has a missing value for age of 
bilateral oophorectomy, and 4) has a missing value for age beginning HT.  An additional nine 
participants have a missing value for their age at menopause because they: 1) had a 
hysterectomy, but not a bilateral oophorectomy, and 2) had their hysterectomy when <50 years 
of age, and 3) had a missing value for age beginning HT, and 4) had a missing value for age at 
which she first experienced menopausal symptoms.  All ten women missing age at menopause 
were age 51 or greater at study enrollment.  Years since menopause was calculated by 
subtracting age at menopause from age at study enrollment.    
3.3.2 Non-steroidal anti-inflammatory drug exposure 
Non-steroidal anti-inflammatory drug use among MAMS participants was recorded in three 
different ways.  First, at study enrollment, trained clinical staff asked participants if they had 
used aspirin or another anti-inflammatory agent within the last 48 hours (yes/no).  Second, 
medication use was self-reported in the study questionnaire, with an open-ended question asking 
participants to list all medications they were currently taking.  Lastly, in February 2005, IRB-
approval was obtained to send a follow-up questionnaire to capture medications participants may 
have taken for pain or inflammation prior to study enrollment.  The follow-up survey was sent to 
all MAMS participants who indicated on their study consent form that they agreed to be 
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contacted by researchers at a future time to answer additional questions.  All 376 women included in 
the present study had agreed to follow-up.  To date, 304 (81%) of the follow-up surveys for 
participants included in this report have been returned, reviewed, and entered into the MAMS 
database.  Each mini-survey was accompanied with a personalized cover letter explaining that 
investigators were interested in learning about medications taken for pain or inflammation before 
study enrollment, and each woman’s enrollment date was clearly specified in the cover letter and 
throughout the mini-survey in bold face type.  Participants were asked to look at three lists of 
medications and then to answer the question, “During the year before you joined our study, did 
you ever take any of these products on a regular basis—that is, for at least once a week, every 
week, for 6 months or more?”  Separate lists were shown for aspirin (e.g. Aspirin, Anacin, 
Ascriptin, Bayer, Bufferin, Ecotrin, Emprin, Another Aspirin Product), acetaminophen (e.g. 
Tylenol, Anacin III, Acetaminophen, APAP), and non-aspirin NSAIDs (e.g. Advil, Nuprin, 
Ibuprofen, Motrin, Naproxen).  If the answer was yes, participants were asked to indicate for 
how many days per week (1, 2-4, or 5-7), on average, they took each type of medication.   
Participants were also asked for duration of use (in months) for each type of medication.  We 
used information from both questions to create a new variable indicating daily use of each 
medication for one year or more (yes/no).  In this report, “any NSAID” combines the use of 
aspirin and non-aspirin NSAIDs.  After editing study questionnaires for completeness and 
consistency, a trained research assistant telephoned subjects, when necessary, to retrieve missing 
information and to resolve inconsistencies.  
3.3.3 Mammographic density assessment 
Copies of screen-film mammograms completed within ~4.5 months of study enrollment (95% 
completed within 3 months; mean (SD) =33 (24) days), were assessed by a consultant expert 
reader (M Salane), initially trained by Wolfe in both Wolfe’s method and planimetry (7).  With 
respect to women enrolled through the Breast Biopsy Service, the unaffected side was sent for 
evaluation, with the exception of five women, for whom only the affected side was available and 
assessed.  The cranio-caudal view of one breast chosen at random was evaluated for each 
participant.  For two women, only the medio-lateral view was available and assessed.  Density 
measurements from both sides and views have shown a high degree of symmetry (45).   
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Both a qualitative method, Wolfe’s classification, and a quantitative method were used to 
assess breast density.  As Wolfe’s classification method is subjective and may vary between 
observers (46), the quantitative measurements have been deemed more effective in identifying 
women at increased risk for developing breast cancer (47, 48).  Indeed, the majority of studies 
have shown a stronger association with breast cancer risk for the quantitative methods than for 
those using Wolfe’s classification (3).  For this analysis, we therefore chose to examine the 
quantitative measures only.  Using the mammogram image and excluding biopsy scars, Cooper’s 
ligaments, and breast masses, the reader used a wax pencil to outline the entire breast and the 
portions of breast containing radio-densities. The reader used a compensating polar planimeter 
(LASICO, Los Angeles, CA) and traced the outline of the entire breast and outlines of dense 
breast to compute total breast area and dense breast area, respectively.  Percentage breast density 
was calculated by dividing the dense breast area by the total area.  Nondense area was calculated 
by subtracting dense breast area from total breast area.  All films were relabeled with a study ID 
so that the reader remained masked to the participant’s identity.  We assessed the internal 
reliability of the reader’s readings by randomly sending a masked set of 28 mammograms (8 
from the lowest tertile of percent breast density, and 10 each from the remaining two tertiles of 
percent breast density) for re-review.  The intraclass correlation coefficient (ICC) for intra-
observer agreement was ρ=0.86 for the continuous measurement of area of dense tissue, ρ=0.99 
for total area of the breast, and ρ=0.89 for the measurement of percent breast density.  Our ICC 
estimate for percent breast density is consistent with estimates reported by Boyd et al. (49), who 
observed an ICC of ρ=0.897 for 150 sets of films in the Canadian National Breast Screening 
Study, and Byrne et al. (50), who reported an ICC of ρ=0.93 for computer-assisted breast density 
measurements in the Nurses’ Health Study.  In addition, the reader’s reproducibility in our study 
is comparable to her reliability as evaluated in the Breast Cancer Detection Demonstration 
Project (BCDDP), with an ICC of ρ=0.915 (adjusted for case status, age, weight, and film type) 
for measurement of percent breast density in 193 sets of films (51).  
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3.3.4 Biological specimen collection 
At study enrollment, trained clinical staff drew 40 mL of peripheral blood using standardized 
phlebotomy procedures; 20 mL was collected with EDTA anticoagulant, which provided 8 mL 
of plasma. The blood was processed immediately according to standardized protocols at the 
Magee Womens Hospital Satellite Clinical Research Center.  Plasma was separated and placed 
into individually-labeled 1 mL cryovials and stored at –70°C until analyzed.   
3.3.5 Soluble TNFR1 and TNFR2 assays 
We used the Laboratory for Clinical Biochemistry Research at the University of Vermont (RP 
Tracy) and commercially available sTNFR1 and sTNFR2 antibody bead kits for human plasma 
(BioSource International, Camarillo, CA, USA) to measure sTNFR1 and sTNFR2 plasma levels.  
Multiplex immunoassays, combining the principle of a sandwich immunoassay with fluorescent-
bead-based technology, were conducted according to the manufacturer’s specifications.  To 
minimize inter-assay variability, all assays were performed with a single lot of sTNFR kits for 
human plasma.  The plates were read on a Bio-Rad Bio-Plex instrument (Hercules, CA) using 
Bio-Plex Manager Software Version 3.0, with the instrument calibrated using a low RP1 setting, 
and gates adjusted to 3000 and 10000.  The standard curve ranges were 23,400 to 30 pg/mL and 
11,400 to 20 pg/mL for sTNFR1 and sTNFR2, respectively.  All samples read well within the 
standard curve range, with the exception of one potential outlier point for sTNFR1 (23,442.3 
pg/mL).  Assays were run in duplicate and were preformed by two different technicians, who 
were masked to the mammographic density results.  Using control plasma, the laboratory 
reported within-assay coefficients of variation of 17.5% and 17.4% for sTNFR1 and sTNFR2 
concentrations, respectively.  The inter-assay coefficients of variation calculated from the 
analytic results for 40 masked duplicate plasma samples were 30.0% and 22.4% for sTNFR1 and 
sTNFR2 concentrations, respectively. 
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3.3.6 Statistical analysis 
Descriptive statistics for all baseline measures were calculated (means for continuous measures 
and frequencies for nominal variables) to assess the distribution of demographic variables and 
potential confounding variables.  Baseline characteristics were compared across quartiles of 
percent mammographic density, sTNFR1, and sTNFR2 using generalized linear models (analysis 
of variance) for continuous measures and the chi-squared test for discrete measures.  Fisher’s 
exact test for discrete measures was used when expected cell counts were less than five.  
Pearson’s correlation was used to examine the magnitude of the relationship between sTNFR1, 
sTNFR2 and percent mammographic density.  Fisher’s z transformation was used to estimate 
95% confidence limits for the correlation coefficients.  Although percent mammographic density 
was the primary focus of this study, the best method of utilizing the information obtained from 
the dense and nondense components of a mammogram is currently under debate (52).  We 
therefore report the associations between the sTNFRs and dense breast area, total breast area, and 
nondense breast area for descriptive purposes only, as we did not account for these multiple 
comparisons a priori. 
Age at enrollment, BMI (kg/m2), history of breast biopsy prior to study enrollment 
(yes/no), former hormone therapy use (yes/no), current alcohol use (yes/no), age at first birth 
(<30 vs. ≥30 or nulliparous), education (high school graduate vs. any post-secondary education), 
aspirin or other anti-inflammatory drug use with 48 hrs of blood draw (yes/no), age at 
menopause (continuous), years since menopause (continuous), site of enrollment (Breast Biopsy 
Service vs. screening mammography), number of live births (0, 1, 2, 3, 4, or 5+; continuous), 
nulliparity (yes/no), current bisphosphonate use (e.g. Risedronate, Alendronate; yes/no), and 
laboratory technician (tech #1 vs. #2) were all evaluated as potential confounding variables due 
to their known associations with breast density or with sTNFRs, evidence for a difference in the 
covariate across quartiles of percent breast density or sTNFRs (p<0.10), or concerns about 
possible bias due to use of two different laboratory technicians.  Since age and BMI have been 
previously shown to be positively associated with circulating sTNFR levels (53-55) and 
negatively associated with percent mammographic density (56-62), the multivariate linear 
regression models assessing the relation between the sTNFRs and percent mammographic 
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density were first adjusted for age, and then for age and BMI.  We then used forward, stepwise 
multivariable linear regression to develop a model describing the factors associated with percent 
breast density (excluding sTNFR1 and sTNFR2). The model building process proceeded as 
follows.  First, we separately regressed on the outcome variable (percent mammographic density) 
each potential confounding variable.  The variable that explained the largest proportion of the 
variation in percent breast density (R2) was then selected as the first variable to be entered into 
the regression equation.  Each remaining explanatory variable was then regressed on percent 
breast density jointly with the first variable, and partial F statistics were determined.  The 
variable with the largest partial F statistic (providing the largest gain in explanatory power) was 
then added as the second variable in the multiple regression equation (p-value to enter 
model=0.10), and this process was repeated for the remaining variables until the final model was 
reached (e.g. the test for the partial F statistic was not significant for the variables not yet in the 
model).  Finally, multiple linear regression was used to assess the relation of the sTNFRs with 
percent breast density controlling for: 1) age, 2) age and BMI, 3) covariates determined to 
explain the largest proportion of variation in percent breast density in the stepwise linear 
regression process described above, and 4) any other covariate shown to be significantly 
associated (p<0.05) with percent breast density in separate linear regression models.  Nine 
women reported using hormone therapy within 3 months, but not within the 2 weeks, prior to 
study enrollment (blood draw); analyses were run with and without these women, and results 
remained essentially the same.  Likewise, analyses were run with and without the potential 
outlier for sTNFR1; again, results remained essentially the same, and the participant was not 
excluded from analyses.  sTNFR1 levels were natural logarithm transformed to meet correlation 
and regression assumptions.  Both mammographic density and sTNFR2 levels were normally 
distributed and analyses were conducted with these variables in the natural scale.  Bonferroni 
correction was used to control for Type I error across the 2 cytokine comparisons; a p-value of 
less than 0.025 (0.05/2) was required for statistical significance.  All tests of statistical 
significance were two-tailed.  Analyses were performed using SAS software release 8.02 (SAS 
Institute Inc., Cary, NC). 
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3.4 RESULTS 
Among the 376 MAMS participants in this report, the mean (SD) age was 62 (8) years, ranging 
from 42-85 (Table 12).  The majority of the population was Caucasian (94%) and attended post-
secondary education (75%).  The mean (SD) years since menopause was 14 (10), ranging from 
1-43.  The mean (SD) percent breast density was 29.7% (19.5), ranging from 0-94.9%.  sTNFR1 
and sTNFR2 levels were positively correlated with one another (r=0.49, p<0.0001).  One 
hundred sixty three (44%) of this population reported taking aspirin or another anti-inflammatory 
agent within 48 hours of blood draw, a proportion similar to those who reported current use of 
aspirin and non-aspirin NSAIDs medications in their original study questionnaire (40%), and 
slightly less than those who reported any NSAID use at least once a week in the 12 months prior 
to study enrollment in their follow-up questionnaire (51%) (Table 13).   
Table 14 shows the characteristics of the study population by quartiles of percent 
mammographic density.  Women with higher percent mammographic density were younger, and 
thus had fewer years since menopause; had a lower BMI; were more likely to have attended post-
secondary education, to report current consumption of alcohol, to be nulliparous and/or have a 
later age at first birth, to be former hormone therapy users, and to report a history of breast 
biopsy; and were less likely to have taken aspirin or another anti-inflammatory agent at blood 
draw than women with lower percent mammographic density.  No other self-reported medication 
use was related to percent mammographic density.   
In contrast, women with higher sTNFR1 and sTNFR2 levels had a higher BMI than 
women with lower sTNFR levels (Tables 15 and 16).  Women with higher sTNFR1 were more 
likely to be enrolled in the Breast Biopsy Service, and tended to be less likely to have a family 
history of breast cancer than women with lower sTNFR1 levels, although this difference was not 
statistically significant.  Women with higher sTNFR2 levels were older, had a greater number of 
years since menopause and were less educated than women with lower sTNFR2 levels.  Self-
reported current use of bisphosphonates in the study questionnaire differed across quartiles of 
sTNFR2, but no clear pattern emerged.    
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Before adjusting for covariates, both sTNFR1 and sTNFR2 were inversely correlated 
with percent mammographic density to a similar degree (r = -0.14, p=0.007, and r = -0.13, 
p=0.01, respectively) (Table 17).  As expected, the opposite relationship was observed for total 
breast area and nondense breast area, which were both positively correlated with sTNFR1 and 
sTNFR2 levels (Tables 19 and 20).  However, sTNFR levels did not appear to be associated with 
the dense area of the breast (r= -0.05, p=0.31 and r = -0.02, p=0.65) (Table 18). 
Results of the multivariable linear regression analyses are shown in Tables 21-24.  The 
inverse associations observed between the sTNFRs and percent mammographic density remained 
after adjustment for age (Table 21); however, age and each sTNFR explained only 3% of the 
variation in percent mammographic density (R2=0.03).  After adjustment for BMI, 24% of the 
variation in percent mammographic density was explained, but the inverse association between 
the sTNFRs and percent mammographic density diminished and was no longer statistically 
significant.  The covariates associated with percent mammographic density in the stepwise 
model were age, BMI, ever had breast biopsy prior to enrollment, nulliparity and current alcohol 
consumption.  Addition of these covariates, along with others individually associated with 
percent breast density, did not further influence the relationship between the sTNFRs and percent 
mammographic density, and increased the R2 to 28% and 30%, respectively.  No association was 
observed between the sTNFRs and dense breast area (Table 22), while positive age-adjusted 
associations resulted between the sTNFRs and both total and nondense breast areas (Tables 23 
and 24).  Again, these associations were no longer apparent after adjustment for BMI.    
3.5 DISCUSSION 
In this cross-sectional study of cancer-free, postmenopausal women, we investigated the 
association between circulating soluble TNF-alpha receptors-I and II with percent 
mammographic density.  Although previous studies have suggested distinct signal transduction 
pathways for sTNFR1 and sTNFR2 (35), both receptors had similar relationships with 
mammographic density.  The mean percent mammographic density was lower among women in 
the highest quartiles of circulating levels of sTNFR1 and sTNFR2.  After adjustment for BMI, 
the inverse association initially observed between the circulating sTNFRs and percent 
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mammographic density disappeared.  Thus, these data do not support an independent association 
between sTNFR1, sTNFR2, and percent mammographic density. 
 To our knowledge, this is the first study to examine the association between circulating 
sTNFRs and percent mammographic density.  We chose to evaluate percent mammographic 
density, as the percentage appears to confer a greater risk and is the measure reported in the vast 
majority of studies (8, 63-65).  Our initial findings of an inverse correlation between the sTNFRs 
and percent breast density were consistent with the idea that circulating sTNFRs may block 
TNF-α activity (37), thereby preventing induction of COX-2 gene expression (33), resulting in 
decreased biosynthesis of estrogen and ultimately reducing mammographic density, a marker of 
breast cancer risk.  Furthermore, we observed positive correlations between the sTNFRs and the 
nondense area of the breast; most risk factors for breast cancer that are related to mammographic 
density have the opposite relationship with the nondense area of the mammogram, largely 
comprised of fat tissue (66).  However, since body mass index correlates strongly and positively 
with both the nondense and total breast areas (52), and thus correlates inversely with percent 
breast density (60-62), potential confounding by adiposity is of particular concern when studying 
factors, such as circulating sTNFRs, which are positively correlated with BMI.  Under such 
circumstances, investigators have recently argued for examination of the absolute area of dense 
breast tissue, instead of percent breast density (52, 67).  Indeed, circulating sTNFRs were not 
associated with dense breast area, both before and after adjustment for potential confounding 
factors in our population.   
 In spite of the lack of a BMI-adjusted association between sTNFRs and mammographic 
density in this report, we cannot rule out the hypothesis that inflammation plays a role in 
mammographic density.  Notably, MAMS participants who reported use of aspirin or another 
anti-inflammatory agent within 48 hours of blood collection were significantly more likely to 
have lower percent mammographic density.  Consistent with this biologic mechanism, several 
epidemiologic studies have examined the association between use of NSAIDs and breast cancer 
risk (reviewed in (68) and (69)) with most, but not all (70, 71), of case-control studies finding 
risk reductions between ~20-40% (72-82).  Results from prospective cohort studies have been 
less consistent, with seven studies finding no association (83-89), one study observing an 
increased risk (90), and five studies, including the WHI Observational Study, demonstrating a 
protective effect from use of NSAIDs (91-95).  Recently the Women’s Health Study, a 
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randomized controlled trial, found that alternate-day use of low-dose aspirin for an average of 10 
years of treatment did not reduce the risk of breast cancer (96).  Hence, while our finding may be 
biologically plausible, it is equally likely that this single association may have been a spurious 
finding due to multiple statistical comparisons.  In addition, we observed no association between 
percent mammographic density and any of our other measures of NSAID exposure.  Although 
previous studies have not evaluated the effect of aspirin and non-aspirin NSAIDs on 
mammographic density, several clinical trials are underway.        
Some limitations of this study deserve consideration.  The main limitation of this study is 
its cross sectional design.  We only obtained one mammogram, and used a single measure of 
circulating sTNFRs, measured with fair reproducibility.  Unlike TNF-α, however, which has a 
relatively short half-life in circulation, determination of sTNFR concentrations in healthy 
individuals at time lapses of one year demonstrated that the concentrations of the receptors are 
stable in each individual (correlation coefficients of 0.84 and 0.90 for sTNFR1 and sTNFR2, 
respectively), possibly reflecting genetically determined differences (97); this observation is 
supported by studies of identical twins, who unlike discordant twins, are more likely to have 
similar levels of sTNFRs (97).  In addition, medication use was self-reported, and with the 
exception of a general question about use of “aspirin or anti-inflammatory agents in the last 48 
hours” elicited by trained clinical staff, detailed use and dosage of specific medications were not 
recorded at the time of blood collection nor were they verified against pill bottles or prescription 
records.  Self-reported information on duration and past use of NSAIDs in the MAMS follow-up 
survey is also subject to recall bias.  For example, participants at a higher risk of breast cancer 
(and thus with greater breast density) may have been more likely to report NSAID use prior to 
study enrollment with greater frequency and duration; however, we did not observe any 
difference in mammographic density with self-reported use of any of the medications listed in 
follow-up survey.  Finally, the lack of ethnic diversity within MAMS, in combination with the 
postmenopausal study population, reduces the generalizability of our findings to other ethnic 
groups and to younger women.  Strengths of the study include the use of a quantitative, highly 
reproducible measure of mammographic density.  Further, we assessed several reproductive and 
anthropometric variables potentially related to mammographic density and/or sTNFRs, and the 
relationships between these factors were consistent with previous studies of breast density (3, 9-
11, 13-20, 22, 56-62, 98, 99) and sTNFR levels (53-55).   
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While the mechanism by which mammographic density increases breast cancer risk is 
unknown, it is thought that dense areas may be associated with increased cell proliferation (100).  
A recent retrospective study of diagnostic mammograms from women diagnosed with DCIS 
demonstrated that DCIS lesions occurred overwhelmingly in areas of mammographically dense 
tissue, suggesting that some characteristic of the dense tissue is directly influencing the 
carcinogenic process in the breast (101).  While our findings suggest that mammographic density 
is independent of circulating sTNFRs in postmenopausal women, these findings should be 
replicated with improved measurement of sTNFRs in larger populations.  We hope this report 
will encourage other investigators to examine potential mechanisms by which inflammation may 
be related to mammographic density and breast cancer risk. 
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Table 12. Characteristics of the study population, Mammograms and Masses Study (2001-
2005) 
Variable n=376 % or (range) 
Clinic, %   
   Biopsy 69 18 
   Screening clinic 307 82 
Age (years), mean (SD) 62 (8) (42-85) 
Race (%)   
   White 353 94 
   Other 23 6 
Education level (%)   
   High school 93 25 
   > High school 274 75 
   Missing 9  
Body mass index §, mean (SD) 28.4 (6.1) (16.8-46.6) 
Cigarette Smoking (%)   
  Never 219 58 
  Former 133 35 
  Current 23 6 
  Missing 1  
Cigarette Smoking (%)   
  Never 219 58 
  Ever 156 42 
  Missing 1  
Current alcohol use ≥ 1/week for ≥ 6 months 
(%)   
  No 263 72 
  Yes 104 28 
   Missing 9  
Current alcohol consumption ≥1/week for ≥6 
months (%)   
  No 263 72 
  Yes   
   <12g/day 68 19 
   ≥12g/day 35 9 
   Missing 10  
Walks for exercise (%)   
  Rarely/1-3 times/month 148 40 
  At least 2-3 times/week 219 60 
  Missing 9  
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Table 12 (continued) 
Variable n=376 % or (range) 
Age at menarche (years), %   
  <12 72 19 
  12-13 223 59 
  ≥14 80 21 
   Missing 1  
Nulliparous (%)   
  No 295 78 
  Yes 81 21 
Parity (%)   
   Nulliparous 81 21 
  1 43 11 
  2 113 30 
  3 79 21 
  4 32 9 
  5+ 28 7 
Age at first birth (years), %   
  <30 249 66 
  ≥30 or nulliparous 127 34 
Breastfeeding (%)   
  Never or ≤1 month 226 60 
  Ever 149 40 
  Missing 1  
Breastfeeding (%)   
  Never or ≤1 month 226 60 
  Ever   
    1-12 months 97 26 
    ≥13 months  52 14 
   Missing 1  
Age at menopause (years), mean (SD) 48 (5) (26-60) 
   Missing 10  
Years since menopause, mean (SD) 14 (10) (1-43) 
   Missing 10  
Surgical menopause (%)   
   No 340 93 
   Yes 26 7 
   Missing 10  
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Table 12 (continued) 
Variable n=376 % or (range) 
Hormone therapy (%)   
   Never use 151 40 
   Past use 225 60 
Family history of breast cancer † (%)   
  No 318 85 
  Yes 54 14 
   Missing 4  
Breast biopsy prior to enrollment (%)   
  Never 305 81 
  Ever 70 19 
  Missing 1  
Breast biopsy prior to enrollment (%)   
  0 305 81 
  1 48 13 
  2+ 22 6 
  Missing 1  
Dense breast area, mean (SD) 40.9 (26.2) (0-188.1) 
Total breast area, mean (SD) 162.5 (76.4) (31.6-442.0) 
Nondense breast area, mean (SD) 121.5 (78.0) (3.6-389.0) 
% Breast density, mean (SD) 29.7 (19.5) (0-94.9) 
TNFR1 pg/mL, mean (SD) 2794.7 (2314.9) (107.6-23442.29) 
TNFR2 pg/mL, mean (SD) 2662.6 (1202.8) (84.3-8517.8) 
† History of breast cancer in a mother or sister.   
§ Weight (kg)/height² (m²).   
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Table 13. Self-reported medication use in the Mammograms and Masses Study (MAMS), 
2001-2005 
Variable n=376 % 
Aspirin or other anti-inflammatory agent within 48 hours of blood 
draw   
  % yes 163 44 
  Missing 2  
Self-reported current medication use in study questionnaire:   
Aspirin, % yes 111 29 
Non-aspirin NSAID, % yes 53 14 
Acetaminophen, % yes 22 6 
Any NSAID, % yes 150 40 
Cox-2 inhibitors, % yes 14 4 
Selective Estrogen Receptor Modulator (Raloxifene or Tamoxifen),  
% yes 31 8 
Bisphosphonates (Risedronate or Alendronate), %  yes 51 14 
Self-reported medication use in NSAIDs follow-up questionnaire:   
Aspirin ≥ 1/week in past 12 months, % yes 122 40 
  Missing 72  
Aspirin ~daily for 1 year or more, % yes 74 24 
  Missing 72  
Non-aspirin NSAID ≥ 1/week in past 12 months, % yes 69 23 
  Missing 72  
Non-aspirin NSAID ~daily for 1 year or more, % yes 19 6 
  Missing 72  
Acetaminophen ≥ 1/week in past 12 months, % yes 79 26 
  Missing 73  
Acetaminophen ~daily for 1 year or more, % yes 15 5 
  Missing 73  
Any NSAID ≥ 1/week in past 12 months, % yes 155 51 
  Missing 72  
Any NSAID ~daily for 1 year or more, % yes 88 29 
  Missing 72   
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Table 14. Characteristics of the study population by percentage of mammographic density 
quartiles (Q), Mammograms and Masses Study (2001-2005), n=376 
 Mammographic density (%)   
Variable 
Q1 
(0-14.0) 
Q2 
(14.1-27.4) 
Q3 
(27.5-42.0) 
Q4 
(42.2-94.9) p-value 
Median % mammographic density 8.6 20.4 34.1 56.6   
Median sTNFR1 pg/mL 2612.9 2522.7 2188.9 1961.5   
Median sTNFR2 pg/mL 2541.0 2680.6 2497.5 2433.9   
Mean (SD)       
Age (years) 62 (8) 63 (8) 63 (8) 60 (8) 0.03 
Body mass index § 32.0 (6.1) 29.7 (5.9) 27.2 (5.1) 24.7 (4.6) <0.0001 
Age at menopause (years) 48 (5) 48 (5) 48 (6) 48 (5) 0.83 
   Missing 4 5 1 0   
Years since menopause 14 (9) 15 (10) 15 (10) 11 (9) 0.05 
   Missing 4 5 1 0   
Dense breast area 15.8 (10.9) 36.4 (15.8) 45.9 (17.8) 65.6 (28.1) <0.0001 
Total breast area 213.3 (79.9) 183.6 (78.4) 134.3 (52.4) 118.7 (49.3) <0.0001 
Nondense breast area 197.6 (76.3) 147.2 (64.8) 88.4 (36.0) 53.1 (28.8) <0.0001 
Frequency, n (%)       
Enrolled in biopsy clinic 12 (13) 14 (15) 19 (20) 24 (26) 0.10 
White 88 (94) 86 (91) 90 (96) 89 (95) 0.65 
> High school 62 (67) 63 (68) 72 (78) 77 (85) 0.02 
   Missing 2 2 2 3   
Ever smoker 40 (43) 39 (41) 43 (46) 34 (37) 0.64 
  Missing 0 0 0 1   
Current alcohol consumption  
≥1/week for ≥6 months 15 (16) 24 (26) 31 (34) 34 (37) 0.01 
   Missing 2 3 2 2   
Walks for exercise at least 2-3 
times/week 53 (58) 47 (51) 58 (63) 61 (67) 0.14 
  Missing 2 2 2 3   
Age at menarche (years)     0.68 
  <12 21 (22) 19 (20) 19 (20) 13 (14)   
  12-13 53 (56) 52 (56) 59 (63) 59 (63)   
  ≥14 20 (21) 22 (24) 16 (17) 22 (23)   
   Missing 0 1 0 0   
Nulliparous 15 (16) 15 (16) 20 (21) 31 (33) 0.01 
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Table 14 (continued) 
 Mammographic density (%)   
Variable 
Q1 
(0-14.0) 
Q2 
(14.1-27.4) 
Q3 
(27.5-42.0) 
Q4 
(42.2-94.9) p-value 
Age at first birth ≥30 years or 
nulliparous 27 (29) 26 (28) 32 (34) 42 (45) 0.05 
Ever breastfed 37 (39) 36 (38) 38 (40) 38 (41) 0.98 
  Missing 0 0 0 1   
Surgical menopause 8 (9) 10 (11) 4 (4) 4 (4) 0.17 
   Missing 4 5 1 0   
Former hormone therapy use  44 (47) 56 (60) 69 (73) 56 (60) 0.003 
Family history of breast cancer †  17 (18) 13 (14) 8 (9) 16 (17) 0.25 
   Missing 1 1 2 0   
Breast biopsy prior to enrollment 7 (7) 14 (15) 22 (23) 27 (29) 0.001 
  Missing 0 1 0 0   
Aspirin or other anti-inflammatory 
agent within 48 hours of blood 
draw 53 (56) 39 (41) 39 (42) 32 (34) 0.02 
  Missing 0 0 1 1   
Self-reported current medication 
use in study questionnaire:       
Any NSAID 39 (41) 39 (41) 37 (39) 35 (37) 0.92 
Selective Estrogen Receptor 
Modulator 8 (9) 8 (9) 8 (9) 7 (7) 0.99 
Bisphosphonates 9 (10) 11 (12) 18 (19) 13 (14) 0.25 
† History of breast cancer in a mother or sister.  
§ Weight (kg)/height² (m²).       
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Table 15. Characteristics of the study population by sTNFR1 quartiles (Q), Mammograms 
and Masses Study (2001-2005), n=376 
 sTNFR1 (pg/mL)   
Variable 
Q1 
(107.6-
1526.2) 
Q2 
(1530.7-
2348.3) 
Q3  
(2371.0-
3361.7) 
Q4 
(3369.7-
23442.3) p-value 
Median % mammographic 
density 34.1 25.0 27.2 21.2   
Median sTNFR1 pg/mL 1070.9 1865.7 2757.3 4322.2   
Median sTNFR2 pg/mL 1813.5 2280.2 2630.8 3243.1   
Mean (SD)       
Age (years) 61 (8) 62 (8) 62 (8) 62 (8) 0.39 
Body mass index § 26.5 (5.2) 28.1 (5.2) 28.7 (5.9) 30.3 (7.3) 0.0003 
Age at menopause (years) 49 (5) 48 (6) 48 (5) 49 (6) 0.79 
   Missing 1 2 2 5   
Years since menopause 12 (9) 15 (10) 14 (10) 14 (10) 0.31 
   Missing 1 2 2 5   
Dense breast area 44.2 (25.3) 37.7 (23.0) 41.7 (29.4) 40.1 (26.9) 0.39 
Total breast area 138.2 (60.5) 161.1 (72.1) 165.7 (76.4) 184.9 (87.7) 0.0004 
Nondense breast area 94.0 (56.9) 123.4 (70.3) 124.0 (80.5) 144.8 (92.3) 0.0001 
Frequency, n (%)       
Enrolled in biopsy clinic 10 (11) 14 (15) 20 (21) 25 (27) 0.03 
White 89 (95) 88 (94) 88 (94) 88 (94) 0.99 
> High school 76 (81) 69 (76) 67 (73) 62 (69) 0.29 
   Missing 0 3 2 4   
Ever smoker 39 (41) 40 (43) 38 (40) 39 (41) 0.99 
  Missing 0 1 0 0   
Current alcohol consumption  
≥1/week for ≥6 months 31 (33) 25 (27) 27 (30) 21 (23) 0.47 
   Missing 1 2 3 3   
Walks for exercise at least 2-3 
times/week 57 (61) 56 (61) 60 (65) 46 (51) 0.25 
  Missing 0 3 2 4   
Age at menarche (years)     0.96 
  <12 18 (19) 16 (17) 18 (19) 20 (22)   
  12-13 57 (61) 55 (59) 55 (59) 56 (60)   
  ≥14 19 (20) 23 (24) 21 (22) 17 (18)   
   Missing 0 0 0 1   
Nulliparous 24 (26) 17 (18) 20 (21) 20 (21) 0.67 
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Table 15 (continued) 
 sTNFR1 (pg/mL)   
Q1 
(107.6-
1526.2) 
Q2 
(1530.7-
2348.3) 
Q3  
(2371.0-
3361.7) 
Q4 
(3369.7-
23442.3) Variable p-value 
Age at first birth ≥30 years or 
nulliparous 37 (39) 31 (33) 29 (31) 30 (32) 0.6 
Ever breastfed 36 (39) 38 (40) 34 (36) 41 (44) 0.76 
  Missing 1 0 0 0   
Surgical menopause 6 (6) 8 (9) 8 (9) 4 (4) 0.64 
   Missing 1 2 2 5   
Former hormone therapy use  61 (65) 54 (57) 58 (62) 52 (55) 0.54 
Family history of breast cancer †  17 (18) 18 (19) 8 (9) 11 (12) 0.1 
   Missing 2 1 1 0   
Breast biopsy prior to enrollment 17 (18) 19 (20) 16 (17) 18 (19) 0.94 
  Missing 0 1 0 0   
Aspirin or other anti-
inflammatory agent within 48 
hours of blood draw 45 (48) 47 (50) 33 (35) 38 (41) 0.17 
  Missing 0 0 1 1   
Self-reported current 
medication use in study 
questionnaire:       
Any NSAID 42 (45) 45 (48) 33 (35) 30 (32) 0.08 
Selective Estrogen Receptor 
Modulator 9 (10) 6 (6) 9 (10) 7 (7) 0.81 
Bisphosphonates 15 (16) 12 (13) 14 (15) 10 (11) 0.72 
† History of breast cancer in a mother or sister.  
§ Weight (kg)/height² (m²).       
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Table 16. Characteristics of the study population by sTNFR2 quartiles (Q), Mammograms 
and Masses Study (2001-2005), n=376 
 sTNFR2 (pg/mL)   
Variable 
Q1 
(84.3-
1839.0) 
Q2 
(1845.0-
2523.8) 
Q3 
(2529.7-
3254.7) 
Q4 
(3260.2-
8517.8) p-value 
Median % mammographic 
density 32.4 24.4 27.2 24.3  
Median sTNFR1 pg/mL 1520.3 1989.3 2677.0 3325.0  
Median sTNFR2 pg/mL 1456.5 2232.8 2856.7 3958.2  
Mean (SD)      
Age (years) 60 (7) 61 (7) 63 (9) 64 (8) 0.009 
Body mass index § 26.8 (5.3) 28.6 (5.9) 28.4 (6.1) 29.7 (6.7) 0.01 
Age at menopause (years) 49 (5) 49 (5) 49 (5) 47 (6) 0.08 
   Missing 1 3 1 5  
Years since menopause 12 (9) 12 (9) 14 (10) 17 (10) 0.0008 
   Missing 1 3 1 5  
Dense breast area 42.3 (25.2) 39.6 (24.0) 41.5 (25.1) 40.3 (30.4) 0.90 
Total breast area 139.0 (53.8) 170.6 (83.7) 164.4 (70.0) 175.8 (89.0) 0.005 
Nondense breast area 96.8 (56.0) 131.0 (86.9) 122.9 (70.8) 135.4 (88.9) 0.003 
Frequency, n (%)      
Enrolled in biopsy clinic 13 (14) 19 (20) 17 (18) 20 (21) 0.56 
White 87 (93) 87 (93) 90 (96) 89 (95) 0.74 
> High school 79 (86) 72 (77) 62 (67) 61 (68) 0.01 
   Missing 2 1 2 4  
Ever smoker 39 (41) 40 (43) 37 (40) 40 (43) 0.98 
  Missing 0 0 1 0  
Current alcohol consumption  
≥1/week for ≥6 months 33 (35) 29 (31) 22 (24) 20 (22) 0.17 
   Missing 1 0 4 4  
Walks for exercise at least 2-3 
times/week 58 (63) 61 (66) 54 (59) 46 (51) 0.21 
  Missing 2 1 2 4  
Age at menarche (years)     0.92 
  <12 19 (20) 19 (20) 15 (16) 19 (20)  
  12-13 55 (59) 56 (60) 55 (59) 57 (61)  
  ≥14 20 (21) 19 (20) 24 (26) 17 (18)  
   Missing 0 0 0 1  
Nulliparous 19 (20) 15 (16) 26 (28) 21 (22) 0.27 
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Table 16 (continued) 
 sTNFR2 (pg/mL)   
Variable 
Q1 
(84.3-
1839.0) 
Q2 
(1845.0-
2523.8) 
Q3 
(2529.7-
3254.7) 
Q4 
(3260.2-
8517.8) p-value 
Age at first birth ≥30 years or 
nulliparous 32 (34) 31 (33) 36 (38) 28 (30) 0.67 
Ever breastfed 45 (48) 30 (32) 39 (41) 35 (37) 0.13 
  Missing 1 0 0 0  
Surgical menopause 3 (3) 10 (11) 8 (9) 5 (6) 0.19 
   Missing 1 3 1 5  
Former hormone therapy use  58 (62) 57 (61) 55 (59) 55 (59) 0.96 
Family history of breast cancer †  19 (20) 11 (12) 13 (14) 11 (12) 0.31 
   Missing 0 1 2 1  
Breast biopsy prior to enrollment 19 (20) 15 (16) 22 (23) 14 (15) 0.42 
  Missing 0 1 0 0  
Aspirin or other anti-
inflammatory agent within 48 
hours of blood draw 44 (47) 43 (46) 41 (44) 35 (37) 0.53 
  Missing 0 1 1 0  
Self-reported current 
medication use in study 
questionnaire:      
Any NSAID 38 (40) 41 (44) 39 (41) 32 (34) 0.57 
Selective Estrogen Receptor 
Modulator 8 (9) 6 (6) 7 (7) 10 (11) 0.75 
Bisphosphonates 16 (17) 9 (10) 7 (7) 19 (20) 0.03 
† History of breast cancer in a mother or sister. 
§ Weight (kg)/height² (m²).      
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Table 17. Correlation between circulating sTNFR levels and percent mammographic 
density, Mammograms and Masses Study (2001-2005) 
 
Pearson correlation 
coefficient* 95% CI p-value 
sTNFR1 pg/mL (n=376) -0.14 (-0.24, -0.04) 0.007 
sTNFR2 pg/mL  (n=376) -0.13 (-0.23, -0.03) 0.01 
*Pearson's correlation between the continuous measure of percentage of breast density 
and the continuous levels of log transformed values for sTNFR1 and raw values for 
sTNFR2. 
 
 
Table 18. Correlation between circulating sTNFR levels and dense breast area, 
Mammograms and Masses Study (2001-2005) 
 
Pearson correlation 
coefficient* 95% CI p-value 
sTNFR1 pg/mL  (n=376) -0.05 (-0.15, 0.05) 0.31 
sTNFR2 pg/mL  (n=376) -0.02 (-0.12, 0.08) 0.65 
*Pearson's correlation between the continuous measure of dense breast area and the 
continuous levels of log transformed values for sTNFR1 and raw values for sTNFR2. 
 
 
Table 19. Correlation between circulating sTNFR levels and total breast area, 
Mammograms and Masses Study (2001-2005) 
 
Pearson correlation 
coefficient* 95% CI p-value 
sTNFR1 pg/mL  (n=376) 0.19 (0.09, 0.29) 0.0003 
sTNFR2 pg/mL  (n=376) 0.17 (0.07, 0.27) 0.0009 
*Pearson's correlation between the continuous measure of total breast area and the 
continuous levels of log transformed values for sTNFR1 and raw values for sTNFR2. 
 
 
Table 20. Correlation between circulating sTNFR levels and nondense breast area, 
Mammograms and Masses Study (2001-2005) 
 
Pearson correlation 
coefficient* 95% CI p-value 
sTNFR1 pg/mL  (n=376) 0.20 (0.10, 0.29) <0.0001
sTNFR2 pg/mL  (n=376) 0.17 (0.07, 0.27) 0.0007 
*Pearson's correlation between the continuous measure of nondense breast area and the 
continuous levels of log transformed values for sTNFR1 and raw values for sTNFR2. 
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Table 21. Relationship between circulating sTNFR levels and percent mammographic 
density, Mammograms and Masses Study (2001-2005) 
 β (%) SE p-value R2† 
sTNFR1 pg/mL     
   +Age  (n=376) -3.60 1.39 0.01 0.03 
   +BMI (n=376) -0.77 1.26 0.54 0.24 
   +MV § (n=366) -1.00 1.23 0.42 0.28 
   +MV2 *   (n=347) -0.63 1.46 0.66 0.30 
sTNFR2 pg/mL     
   +Age        (n=376) -0.002 0.001 0.03 0.03 
   +BMI       (n=376) -0.0003 0.001 0.70 0.24 
   +MV §     (n=366) -0.0003 0.001 0.68 0.28 
   +MV2 *   (n=347) -0.0004 0.001 0.65 0.30 
BMI=body mass index, MV=multivariable     
†R2 based on regression models of continuous levels of log transformed values for 
sTNFR1 and raw values for sTNFR2 on the continuous measure of percentage of 
breast density. 
§ Adjusted for the following variables: age (continuous), BMI (continuous), ever 
had breast biopsy prior to study enrollment (yes/no), nulliparous (yes/no), and 
current alcohol consumption (yes/no). 
* Adjusted for the following variables: age (continuous), BMI (continuous), ever 
had breast biopsy prior to study enrollment (yes/no), nulliparous (yes/no), current 
alcohol consumption (yes/no), prior use of hormone therapy (yes/no), post-
secondary education (yes/no), aspirin use within 48 hrs of blood draw (yes/no), 
laboratory technician (1/2), years since menopause (continuous), and site of 
enrollment (biopsy vs. screening). 
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Table 22. Relationship between circulating sTNFR levels and dense breast area, 
Mammograms and Masses Study (2001-2005) 
 β (%) SE p-value R2† 
sTNFR1 pg/mL     
   +Age        (n=376) -1.81 1.89 0.34 0.005
   +BMI     (n=376) -1.45 1.94 0.45 0.007
   +MV §   (n=366) -1.73 1.90 0.36 0.09 
sTNFR2 pg/mL     
   +Age        (n=376) -0.0003 0.001 0.78 0.003
   +BMI     (n=376) -0.0001 0.001 0.94 0.006
   +MV §   (n=366) -0.0003 0.001 0.82 0.09 
BMI=body mass index, MV=multivariable     
†R2 based on regression models of continuous levels of log transformed values for sTNFR1 
and raw values for sTNFR2 on the continuous measure of dense breast area. 
§ Adjusted for the following variables: age (continuous), BMI (continuous), ever had breast 
biopsy prior to study enrollment (yes/no), nulliparous (yes/no), and post-secondary 
education (yes/no). 
 
 
Table 23. Relationship between circulating sTNFR levels and total breast area, 
Mammograms and Masses Study (2001-2005) 
 β (%) SE p-value R2† 
sTNFR1 pg/mL     
   +Age        (n=376) 19.58 5.4 0.0003 0.04 
   +BMI     (n=376) 3.08 3.97 0.44 0.51 
sTNFR2 pg/mL     
   +Age        (n=376) 0.01 0.003 0.002 0.03 
   +BMI     (n=376) 0.001 0.002 0.55 0.51 
BMI=body mass index    
†R2 based on regression models of continuous levels of log transformed values for sTNFR1 
and raw values for sTNFR2 on the continuous measure of total breast area. 
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Table 24. Relationship between circulating sTNFR levels and nondense breast area, 
Mammograms and Masses Study (2001-2005) 
 β (%) SE p-value R2† 
sTNFR1 pg/mL     
   +Age        (n=376) 21.39 5.5 0.0001 0.04 
   +BMI     (n=376) 4.54 4.02 0.26 0.51 
sTNFR2 pg/mL     
   +Age        (n=376) 0.01 0.003 0.001 0.03 
   +BMI     (n=376) 0.001 0.002 0.54 0.51 
BMI=body mass index     
†R2 based on regression models of continuous levels of log transformed values for sTNFR1 
and raw values for sTNFR2 on the continuous measure of nondense breast area. 
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4.1 ABSTRACT 
Background:  Studies have demonstrated a strong heritability component for both 
mammographic density and circulating soluble tumor necrosis factor-alpha (TNF-α) receptor 
levels.  Exactly how mammographic density increases breast cancer risk is unknown, although it 
has been posited that dense breast areas may reflect exposure to estrogen.  TNF-α has a central 
role in regulating estrogen synthesis in the breast, and circulating TNF receptors may block 
TNF-α activity.  The TNFR2 gene contains a non-synonymous SNP with potential functional 
significance with respect to circulating sTNFR2 levels.   
Methods:  We examined the association between percent mammographic density and the 
TNFR2 –196 M/R polymorphism (T>G) among 376 cancer-free, mostly white, postmenopausal 
women participating in a cross-sectional study of mammographic density (Pittsburgh, PA, 2001-
2005).  Women were not taking hormone therapy at the time of blood collection.  Percent breast 
density was calculated using a quantitative method (planimetry).  We also evaluated whether 
plasma levels of sTNFR2 varied by TNFR2 genotype. 
Results: The unadjusted mean (SD) percent breast density was higher in women with the TT 
genotype (32.3% (21.0)) as compared to women with the TG/GG genotypes (26.6% (17.2)), 
p=0.003.  The association remained statistically significant after adjustment for age and body 
mass index (p=0.03); however, inclusion of additional confounding factors reduced the level of 
statistical significance (p=0.08).  There was no observable difference in circulating sTNFR2 
levels between the TNFR2 genotypes, either before or after adjustment for covariates. 
Conclusion: Our findings offer little evidence for an independent association between the 
TNFR2 –196 M/R polymorphism and percent mammographic density among postmenopausal, 
white women.   
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4.2 INTRODUCTION 
Early detection of breast cancer is critical for reducing mortality.  Mammography is currently the 
primary screening tool available for early detection, with a reduction of ~25% in mortality 
associated with routine screening in women over age 50 (1).  However, mammograms typically 
miss more than 15% of cancers (2).  Notably, over 67% of the decrease in mammographic 
sensitivity is attributed to breast density (2).  The histologic composition of the breast is reflected 
mammographically by density and parenchymal pattern.  The higher the fat content of the breast 
the lower the radiologic density.  Conversely, a high proportion of connective, ductal/epithelial, 
and glandular tissue increases density (3-6).  In addition to its effect on mammographic 
sensitivity, mammographic density is a known risk factor for breast cancer (7, 8), and the risk 
associated with mammographic density is greater than that associated with almost all other risk 
factors for breast cancer (8, 9).  Identifying factors that are associated with mammographic 
density can inform preventative strategies.   
Many reproductive and hormonal factors associated with breast cancer (10-13) are also 
associated with breast density (8, 10-12, 14-23).  However, these factors only account for ~20-
30% of the variation observed in breast density in the population (9, 14).  In fact, studies have 
demonstrated that breast density has a strong hereditary component (7).  A cohort study of 
families with a history of breast cancer demonstrated evidence for a genetic effect as sister-sister 
correlations in breast density were significant (r=0.16-0.27) (24), and these results were further 
clarified in a sib-pair linkage analysis (25).  A twin study conducted in Australia and North 
America estimated that genetic factors likely account for 63% of the unexplained variance in 
mammographic density in all twins studied (7).  In contrast to women at low risk for developing 
breast cancer, women with known BRCA1 or BRCA2 mutations have been shown to have 
denser breast tissue (26).  In addition, a study of 6146 women in the San Francisco 
Mammography Registry demonstrated an association between increased breast density with a 
positive family history of breast cancer (27).   
Studies have investigated the association between mammographic density and 
polymorphisms in specific genes involved in regulating steroid hormone synthesis and 
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metabolism with varied results (28-38).  The gene encoding for tumor necrosis factor-alpha 
receptor-II (TNFR2) has not yet been studied with respect to mammographic density.  The 
cytokine tumor necrosis factor (TNF)-alpha, secreted by macrophages of the immune system and 
also by adipocytes, has a central role in regulating estrogen synthesis within both normal and 
malignant breast tissue (39-41).  Moreover, TNF-α induces a range of inflammatory enzymes, 
including cyclooxygenase (COX)-2.  COX-2 cyclizes and oxygenates arachidonic acid, 
eventually producing prostaglandin E2 (PGE2) (42, 43).  PGE2 is believed to drive production of 
estrogen in the breast, in turn facilitating tumorigenesis (44).  TNF-α exerts its effects by binding 
to two transmembrane cell surface receptors: TNF receptor 1 and TNFR2 (also known as p75, 
p80, TNFRSF1B) (45, 46), both of which are expressed in virtually all mammalian cells, 
including mammary epithelial cells (47).  TNF-α binds to the two receptors with similar affinity; 
when engaged, the extracellular domains of the soluble TNF receptors (sTNFRs) may be shed 
into the circulation (46).  These shed sTNFRs can compete for TNF-α with cell surface receptors 
and thus block TNF-α activity (48).   
Whereas the TNFR1 gene does not contain any known functional variants, the TNFR2 
gene contains a non-synonymous single nucleotide polymorphism (SNP).  The TNFR2 –196 
M/R polymorphism (T > G; chromosome 1p36.2, exon 6; results in substitution of methionine by 
arginine; rs1061622) is located in the extracellular region of the receptor, the region responsible 
for its proteolytic cleavage and solubilization.  Carriers of the G allele have been found to have 
higher circulating levels of sTNFR2 in previous studies (49, 50).  We aimed to examine the 
association of the TNFR2 –196 M/R polymorphism with mammographic density and with 
plasma levels of sTNFR2 in cancer-free postmenopausal women. 
4.3 METHODS 
The Mammograms and Masses Study (MAMS) is a cross-sectional study of correlates of 
mammographic density.  Pre- and postmenopausal women were recruited between 2001 and 
2005 through the Magee Womens Hospital Mammographic Screening and Diagnostic Imaging 
Program in the greater Pittsburgh area (Pennsylvania, USA).  Women were excluded from the 
study if they reported a previous personal history of any cancer (except nonmelanoma skin 
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cancer).  Volunteers arose from two sources: 1) women undergoing outpatient needle breast 
biopsy through the Breast Biopsy Service at Magee-Womens Hospital (Pittsburgh, PA) and 2) 
women receiving screening mammography through Magee-Womens Hospital or through a 
suburban Pittsburgh Magee Womancare Center.  To identify and recruit eligible participants, a 
trained research assistant personally solicited patients visiting the Breast Biopsy Service between 
September 2001 and May 2005 and women visiting Magee-Womencare Center North (Wexford, 
PA) and East (Monroeville, PA) between July 2002 and September 2003.  To boost recruitment, 
Magee-Womens Hospital attached study flyers to screening result reports mailed to Magee-
Womancare Center patients with negative mammography between November 2003 and April 
2005.  The procedures followed were in accordance with both the Magee-Womens Hospital and 
the University of Pittsburgh’s Institutional Review Boards, and all participants gave informed 
consent. 
 For this ancillary study, only cancer-free postmenopausal women were considered 
because both cytokine levels (51) and mammographic density (52) vary with the menstrual cycle.  
In addition, we excluded women who were taking hormone therapy at study enrollment, the time 
of blood draw, as HT use is related to elevations in mammographic density (8, 12, 23), and the 
relationship between HT and circulating sTNFR2 levels has not been well-established (53).  We 
further restricted the population to women with completed study questionnaires and available 
TNFR2 genotype, sTNFR2 and mammographic density results.  Of 856 Breast Biopsy Service 
patients approached, 573 (67%) women lacked a personal cancer history, provided informed 
consent, completed a personal interview, and provided a blood sample.  A subsequent review of 
breast biopsy pathology reports verified non-breast cancer outcomes in 311 (54% of 573) women 
and confirmed primary breast cancer in 262 (46% of 573) women; breast cancer cases were 
excluded from this report.  Of the 311 cancer-free women, 109 (35% of 311) were 
postmenopausal and not taking HT at study enrollment.  Of these, 69 (63% of 109) had available 
questionnaire, TNFR2 genotype, sTNFR2 and mammographic density results.  Of approximately 
100 Magee-Womancare Center North and East patients approached directly, 86 women lacked a 
personal cancer history, provided informed consent, completed a personal interview, and 
provided a blood sample.  Subsequent follow-up verified non-breast cancer outcomes in 85 
(99%) women and a primary breast cancer in one remaining woman; this breast cancer case was 
excluded.  Of the 85 cancer-free women, 43 (51%) were postmenopausal and not taking HT at 
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study enrollment; of these, 30 (70%) had available questionnaire, TNFR2 genotype, sTNFR2 and 
mammographic density results.  Finally, mailing study flyers to 21,606 women with negative 
mammography produced 1,025 responses (5%), including 857 (84% of 1,025) responses from 
women without a personal cancer history.  Of 451 (53% of 857) women providing informed 
consent and a blood sample, 297 (66% of 451) were postmenopausal and not taking HT at study 
enrollment.  Of the 297 women, 277 (93%) had available questionnaire, TNFR2 genotype, 
sTNFR2 and mammographic density results.  Thus, 376 women, consisting of 69 (18%) from the 
Breast Biopsy Service, 30 (8%) from Magee-Womancare Center North/East, and 277 (74%) 
from the mass mailings, were included in the present analysis.  The 376 women were similar to 
the 73 women who were excluded due to missing questionnaire and/or mammographic density 
results with respect to age and body mass index; however, women excluded from the present 
study were less likely to attend post-secondary education, to walk for exercise, and to be 
nulliparous, and they were more likely to have been enrolled in the Breast Biopsy Service.  
Women excluded from the study due to missing questionnaire data were very similar to the 376 
women with respect to mammographic density.    
4.3.1 Data collection 
At study enrollment, trained clinical staff conducted a personal interview and recorded 
information on standardized study forms including age, race, menopausal status, history of 
hormone therapy use, aspirin or other anti-inflammatory drug use in the last 48 hours, weight 
without shoes or heavy clothing (measured in kilograms with a standard balance beam scale), 
and height without shoes at full inspiration (measured in centimeters with a stadiometer).  
Weight and height were used to calculate body mass index (BMI, weight in kilograms divided by 
height in meters squared).   
Lifestyle and reproductive history were obtained through a standardized self-
administered take-home questionnaire, including education (high school graduate vs. any post-
secondary education), cigarette smoking (current, former, never), number of alcohol drinks per 
week (among those who reported consuming alcohol ≥1/week for ≥6 months), takes walks for 
exercise ≥10 minutes without stopping (rarely/1-3 times per month vs. at least 2-3 times per 
week), parity, breastfeeding duration (never or ≤1 month, 1-12 months, 13+ months), type of 
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menopause (surgical vs. natural), and number of breast biopsies prior to study enrollment (0, 1, 
2+).  Current alcohol use was defined as reported consumption of beer, wine, or spirits for 
≥1/week for ≥6 months during the year prior to study enrollment.  Ethanol exposure in 
grams/day was calculated and standardized across the different types of alcoholic beverages as 
previously reported (54).  Current alcohol consumption was defined as: no current use, <12 g/day 
(the equivalent of ~1 alcoholic beverage/day), ≥12 g/day.  A family history of breast cancer was 
defined as a report of breast cancer in a participant’s mother or sister.  Age at menarche (<12, 12-
13, ≥14) and age at first live birth (<30 vs. ≥30 or nulliparous) were categorized according to the 
Gail Model for 5-year risk of breast cancer (55).  Age at menopause was defined according to 
methods outlined by the Women’s Health Initiative (56), where age at menopause was the 
minimum age at which the participant last had any natural menstrual bleeding, had a bilateral 
oophorectomy, or began using HT.  For a hysterectomized woman without a bilateral 
oophorectomy, age at menopause was the earliest age at which she began using HT or first had 
menopausal symptoms.  If neither occurred and her age at hysterectomy was 50 years or older, 
then age at menopause was her age at hysterectomy (56).  In this report, one participant has a 
missing value for her age at menopause because she: 1) did not have a hysterectomy, and 2) has 
a missing value for age last had any menstrual bleeding, and 3) has a missing value for age of 
bilateral oophorectomy, and 4) has a missing value for age beginning HT.  An additional nine 
participants have a missing value for their age at menopause because they: 1) had a 
hysterectomy, but not a bilateral oophorectomy, and 2) had their hysterectomy when <50 years 
of age, and 3) had a missing value for age beginning HT, and 4) had a missing value for age at 
which she first experienced menopausal symptoms.  All ten women missing age at menopause 
were age 51 or greater at study enrollment.  Years since menopause was calculated by 
subtracting age at menopause from age at study enrollment.    
4.3.2 Non-steroidal anti-inflammatory drug exposure 
Non-steroidal anti-inflammatory drug use among MAMS participants was recorded in three 
different ways.  First, at study enrollment, trained clinical staff asked participants if they had 
used aspirin or another anti-inflammatory agent within the last 48 hours (yes/no).  Second, 
medication use was self-reported in the study questionnaire, with an open-ended question asking 
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participants to list all medications they were currently taking.  Lastly, in February 2005, IRB-
approval was obtained to send a follow-up questionnaire to capture medications participants may 
have taken for pain or inflammation prior to study enrollment.  The follow-up survey was sent to 
all MAMS participants who indicated on their study consent form that they agreed to be 
contacted by researchers at a future time to answer additional questions.  All 376 women included in 
the present study had agreed to follow-up.  To date, 304 (81%) of the follow-up surveys for 
participants included in this report have been returned, reviewed, and entered into the MAMS 
database.  Each mini-survey was accompanied with a personalized cover letter explaining that 
investigators were interested in learning about medications taken for pain or inflammation before 
study enrollment, and each woman’s enrollment date was clearly specified in the cover letter and 
throughout the mini-survey in bold face type.  Participants were asked to look at three lists of 
medications and then to answer the question, “During the year before you joined our study, did 
you ever take any of these products on a regular basis—that is, for at least once a week, every 
week, for 6 months or more?”  Separate lists were shown for aspirin (e.g. Aspirin, Anacin, 
Ascriptin, Bayer, Bufferin, Ecotrin, Emprin, Another Aspirin Product), acetaminophen (e.g. 
Tylenol, Anacin III, Acetaminophen, APAP), and non-aspirin NSAIDs (e.g. Advil, Nuprin, 
Ibuprofen, Motrin, Naproxen).  If the answer was yes, participants were asked to indicate for 
how many days per week (1, 2-4, or 5-7), on average, they took each type of medication.   
Participants were also asked for duration of use (in months) for each type of medication.  We 
used information from both questions to create a new variable indicating daily use of each 
medication for one year or more (yes/no).  In this report, “any NSAID” combines the use of 
aspirin and non-aspirin NSAIDs.  After editing study questionnaires for completeness and 
consistency, a trained research assistant telephoned subjects, when necessary, to retrieve missing 
information and to resolve inconsistencies.  
4.3.3 Mammographic density assessment 
Copies of screen-film mammograms completed within ~4.5 months of study enrollment (95% 
completed within 3 months; mean (SD) =33 (24) days), were assessed by a consultant expert 
reader (M Salane), initially trained by Wolfe in both Wolfe’s method and planimetry (6).  With 
respect to women enrolled through the Breast Biopsy Service, the unaffected side was sent for 
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evaluation, with the exception of five women, for whom only the affected side was available and 
assessed.  The cranio-caudal view of one breast chosen at random was evaluated for each 
participant.  For two women, only the medio-lateral view was available and assessed.  Density 
measurements from both sides and views have shown a high degree of symmetry (57).   
Both a qualitative method, Wolfe’s classification, and a quantitative method were used to 
assess breast density.  As Wolfe’s classification method is subjective and may vary between 
observers (58), the quantitative measurements have been deemed more effective in identifying 
women at increased risk for developing breast cancer (59, 60).  Indeed, the majority of studies 
have shown a stronger association with breast cancer risk for the quantitative methods than for 
those using Wolfe’s classification (8).  For this analysis, we therefore chose to examine the 
quantitative measures only.  Using the mammogram image and excluding biopsy scars, Cooper’s 
ligaments, and breast masses, the reader used a wax pencil to outline the entire breast and the 
portions of breast containing radio-densities. The reader used a compensating polar planimeter 
(LASICO, Los Angeles, CA) and traced the outline of the entire breast and outlines of dense 
breast to compute total breast area and dense breast area, respectively.  Percentage breast density 
was calculated by dividing the dense breast area by the total area.  Nondense area was calculated 
by subtracting dense breast area from total breast area.  All films were relabeled with a study ID 
so that the reader remained masked to the participant’s identity.  We assessed the internal 
reliability of the reader’s readings by randomly sending a masked set of 28 mammograms (8 
from the lowest tertile of percent breast density, and 10 each from the remaining two tertiles of 
percent breast density) for re-review.  The intraclass correlation coefficient (ICC) for intra-
observer agreement was ρ=0.86 for the continuous measurement of area of dense tissue, ρ=0.99 
for total area of the breast, and ρ=0.89 for the measurement of percent breast density.  Our ICC 
estimate for percent breast density is consistent with estimates reported by Boyd et al. (61), who 
observed an ICC of ρ=0.897 for 150 sets of films in the Canadian National Breast Screening 
Study, and Byrne et al. (62), who reported an ICC of ρ=0.93 for computer-assisted breast density 
measurements in the Nurses’ Health Study.  In addition, the reader’s reproducibility in our study 
is comparable to her reliability as evaluated in the Breast Cancer Detection Demonstration 
Project (BCDDP), with an ICC of ρ=0.915 (adjusted for case status, age, weight, and film type) 
for measurement of percent breast density in 193 sets of films (63).  
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4.3.4 Biological specimen collection 
At study enrollment, trained clinical staff drew 40 mL of peripheral blood using standardized 
phlebotomy procedures; 20 mL was collected with EDTA anticoagulant, which provided 4 mL 
of buffy coat and 8 mL of plasma. The blood was processed immediately according to 
standardized protocols at the Magee Womens Hospital Satellite Clinical Research Center.  Buffy 
coat and plasma were separated and placed into individually-labeled 1 mL cryovials and stored at 
–70°C until analyzed.     
4.3.5 Genotyping 
DNA extraction and genotyping were completed in the University of Pittsburgh GCRC 
Pharmacogenetics Core Laboratory (M Romkes).  High molecular weight DNA was isolated 
from EDTA buffy coat specimens using the PureGene DNA Isolation Kit (Gentra Systems, Inc. 
Minneapolis, MN), according to manufacturer’s instructions.  The TNFR2 –196 M/R genotypes 
were determined by restriction fragment length polymorphism (RFLP)-polymerase chain 
reaction (PCR).  The primer sequences used for the amplification of a 242-bp fragment of the 
TNFR2 exon 6 were as previously published (64):  flanking primer forward (F): 5’-ACT CTC 
CTA TCC TGC CTG CT-3’; and flanking primer reverse (R): 5’-TTC TGG AGT TGG CTG 
CGT GT-3’.  A total of 20ng of genomic DNA was used, along with 200µM of dNTP, 1.5mM of 
MgCl2, 396nM of primers, and 0.25µl of AmpliTaq Gold.  PCR was performed under the 
following conditions:  94°C for 10 min followed by 40 cycles at 96°C for 1 min, 64°C for 1 min 
and 72°C for 3 min.  A final extension step was carried out at 72°C for 7 min.  For the 
identification of 196M and 196R, 20µl of the PCR product were digested for 2 hours with 10U 
of Nla III (New England Biolabs) at 37°C followed by electrophoresis on an 8% acrylamide gel 
for separating the restriction fragments.  Gels were visualized on the Fotodyne Gel 
Documentation System (Hartland, WI).  Previously sequenced genomic DNA samples from 
healthy individuals were used as positive controls for the homozygous wild-type and 
homozygous mutant genotypes to verify reproducibility of the RFLP-PCR and to confirm 
accuracy of genotype classifications; these positive controls, along with a negative control 
containing no genomic DNA, were included with every PCR analysis.  Genotype assignments 
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were reviewed by two independent readers, and any disagreements were resolved by repeated 
typing.  Approximately 5% (n=20) of randomly selected samples were repeated in a masked 
fashion for verification of the results of the genotyping assays, with an 85% concordance rate.  
The three discordant results were for TG and GG, which we had determined a priori to group 
together for analysis purposes.   
4.3.6 Soluble TNFR2 assays 
We used the laboratory of RP Tracy and commercially available sTNFR1 and sTNFR2 antibody 
bead kits for human plasma (BioSource International, Camarillo, CA, USA) to measure sTNFR1 
and sTNFR2 plasma levels.  Multiplex immunoassays, combining the principle of a sandwich 
immunoassay with fluorescent-bead-based technology, were conducted according to the 
manufacturer’s specifications.  To minimize inter-assay variability, all assays were performed 
with a single lot of sTNFR kits for human plasma.  The plates were read on a Bio-Rad Bio-Plex 
instrument (Hercules, CA) using Bio-Plex Manager Software Version 3.0, with the instrument 
calibrated using a low RP1 setting, and gates adjusted to 3000 and 10000.  The standard curve 
range was 11,400 to 20 pg/mL for sTNFR2.  All samples read well within the standard curve 
range.  Assays were run in duplicate and were preformed by two different technicians, who were 
masked to the mammographic density and genotyping results.  Using control plasma, the 
laboratory reported a within-assay coefficient of variation of 17.4% for sTNFR2 concentrations.  
The inter-assay coefficient of variation calculated from the analytic results for 40 masked 
duplicate plasma samples was 22.4% for sTNFR2 concentrations. 
4.3.7 Statistical analysis 
Descriptive statistics for all baseline measures were calculated (means for continuous measures 
and frequencies for nominal variables) to assess the distribution of demographic variables and 
potential confounding variables.  Baseline characteristics were compared across genotypes using 
the Wilcoxon rank sum test for continuous measures and the chi-squared test for discrete 
measures.  Fisher’s exact test for discrete measures was used when expected cell counts are less 
than five.  Allele frequency departures from Hardy-Weinberg equilibrium were tested using the 
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chi-squared test.  Genotypes were modeled in a dichotomous manner, based upon the presence or 
absence of the variant allele.  The two-sample t-test was used to compare mean percent breast 
density in those women carrying the variant allele and those homozygous for the wild type allele.  
ANOVA was used to compare means of percent breast density between TNFR2 genotypes while 
controlling for potential confounding factors.  Since age and BMI have been previously shown to 
be positively associated with circulating sTNFR2 levels (65-67) and negatively associated with 
percent mammographic density (68-74), the multivariate models comparing mean percent breast 
density across TNFR2 genotypes were first adjusted for age at enrollment, and then for age and 
BMI (kg/m2).  Subsequent models added ever smoked cigarettes (yes/no), current alcohol use 
(yes/no), age at menarche (<12, 12-13, ≥14 years), nulliparity (yes/no), ever breast fed (yes/no), 
history of breast biopsy prior to study enrollment (yes/no), and aspirin or other anti-inflammatory 
drug use with 48 hrs of blood draw (yes/no), as these covariates were known to be associated 
with breast density or with sTNFR2, or they appeared to differ by TNFR2 –196 M/R genotype 
(p<0.10).  Although percent mammographic density was the primary focus of this study, the best 
method of utilizing the information obtained from the dense and nondense components of a 
mammogram is currently under debate (75).  We therefore report the associations between the 
comparisons across TNFR2 gentotypes for mean dense breast area, total breast area, and 
nondense breast area for descriptive purposes only, as we did not account for these multiple 
comparisons a priori.  To address our secondary aim, examining the effect of the TNFR2 –196 
M/R SNP on circulating TNFR2 levels, we used the two-sample t-test for independent samples 
to compare mean TNFR2 levels in those women carrying the variant allele vs. those homozygous 
for the wild type allele.  Transformations were not necessary to meet t-test and ANOVA 
assumptions, as both breast density and sTNFR2 were normally distributed.  Probability values 
of ≤ 0.05 were considered statistically significant.  All tests of statistical significance were two-
tailed.  Analyses were performed using SAS software release 8.02 (SAS Institute Inc., Cary, 
NC). 
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4.4 RESULTS 
Among the 376 MAMS participants in this report, the mean (SD) age was 62 (8) years, ranging 
from 42-85 (Table 25).  The majority of the population was Caucasian (94%) and attended post-
secondary education (75%).  The mean (SD) years since menopause was 14 (10), ranging from 
1-43.  The mean (SD) percent breast density was 29.7% (19.5), ranging from 0-94.9%.  One 
hundred sixty three (44%) of this population reported taking aspirin or another anti-inflammatory 
agent within 48 hours of blood draw, a proportion similar to those who reported current use of 
aspirin and non-aspirin NSAIDs medications in their original study questionnaire (40%), and 
slightly less than those who reported any NSAID use at least once a week in the 12 months prior 
to study enrollment in their follow-up questionnaire (51%) (Table 26).   
Previous reports from this population (Paper 2, unpublished data) have shown that 
percent mammographic density was associated with several breast cancer risk factors in the 
expected directions (8, 10-12, 14-21, 23, 68-74, 76, 77).  For instance, MAMS women with 
higher percent mammographic density were more likely to be nulliparous and/or have a later age 
at first birth, to be former hormone therapy users, and to report a history of breast biopsy; and 
were less likely to have taken aspirin or another anti-inflammatory agent at blood draw than 
women with lower percent mammographic density.  In addition, women with higher percent 
breast density were younger and had fewer years since menopause, had a lower BMI, were more 
likely to have attended post-secondary education and to report current consumption of alcohol.  
In contrast, women with higher sTNFR2 levels had a higher BMI and were older than women 
with lower sTNFR2 levels (also consistent with previous findings (65-67)).  Women with higher 
sTNFR2 levels had a greater number of years since menopause and were less educated than 
women with lower sTNFR2 levels (Paper 2, unpublished data).    
For the TNFR2 –196 M/R polymorphism, 206 (55%) had the T/T genotype, 134 (36%) 
had the T/G genotype, and 36 (10%) had the G/G genotype.  These proportions diverged from 
expectations under Hardy-Weinberg equilibrium (χ2 = 4.07, p=0.04), and genotypes (not alleles) 
were used in subsequent analyses.  The minor allele frequency (MAF) in this population was 
0.27, which is consistent with that observed in the HapMap European population (MAF=0.25, 
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HapMap data release #20, January 2006).  Table 25 depicts characteristics of the study 
population by TNFR2 genotype.  Women with the TT genotype had a lower BMI; were less 
likely to breastfeed and for a shorter duration; and were more likely to report current alcohol use 
and to be nulliparous.  These women also tended to be more likely to report a history of breast 
biopsy, a later age at menarche, and current cigarette smoking compared to women with the 
TG/GG genotypes.  Self-reported medication use by genotype is shown in Table 26.  Women 
with the TT genotype were less likely to report taking aspirin or another anti-inflammatory agent 
within 48 hours of blood draw (p=0.04).  No other self-reported medication use was related to 
TNFR2 genotype. 
 Table 27 provides mean percent mammographic density by TNFR2 genotype.  The 
unadjusted mean (SD) percent breast density was higher in women with the TT genotype (32.3% 
(21.0)) as compared to women with the TG/GG genotypes (26.6% (17.2)), p=0.003.  This 
difference remained statistically significant after adjustment for age and BMI; however, 
inclusion of additional covariates reduced the level of statistical significance, with an adjusted 
(least squares) mean percent density for women with the TT genotype of 31.1% vs. 27.9% in 
women with the TG/GG genotypes, p=0.08.  Mean dense breast area did not differ by TNFR2 
genotype, while age-adjusted mean total and nondense breast areas were significantly lower in 
women with the TT genotype (Table 28); these differences were no longer significant after 
adjustment for additional covariates.   There was no observable difference in circulating sTNFR2 
levels between the TNFR2 genotypes (Table 29), either before or after adjustment for covariates. 
4.5 DISCUSSION 
In this study of cancer-free, postmenopausal women, we investigated the association between 
percent mammographic density and a single-locus allelic variation with potential functional 
significance (49, 50) in the TNFR2 gene.  Compared to carriers of the variant allele, we observed 
higher mean percent breast density among women homozygous for the TT genotype, although 
this difference was attenuated after adjusting for potential confounding factors.  Further, mean 
circulating plasma levels of sTNFR2 did not differ by TNFR2 genotype in our population. 
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To our knowledge, this is the first study to examine the association between the –196 
M/R polymorphism and percent mammographic density.  Because carriers of the G allele have 
been found to have higher circulating levels of sTNFR2 in previous studies (49, 50), we chose to 
evaluate TT genotypes in comparison to TG/GG genotypes.  Our initial finding of lower mean 
percent mammographic density among women with the TG/GG genotypes was consistent with 
the idea that elevations in circulating sTNFRs in these women (49, 50) may block TNF-α activity 
(48), thereby preventing induction of COX-2 gene expression (78), resulting in decreased 
biosynthesis of estrogen and ultimately reducing mammographic density, a marker of breast 
cancer risk.  The differences in mean percent mammographic density remained after adjustment 
for age and BMI, which was significantly lower among women with the TT genotype, suggesting 
that the –196 M/R polymorphism influences percent mammographic density independent of an 
effect on BMI.   
Alcohol consumption, nulliparity, history of breast biopsy, and aspirin use within 48 hrs 
of blood draw were all related to both percent mammographic density and TNFR2 genotype in 
MAMS; while our findings adjusted for age and BMI seemed biologically plausible, the mean 
difference in breast density was no longer statistically significant after adjustment for these and 
other covariates, indicating that the association between percent mammographic density and 
TNFR2 genotype is not independent of these confounding factors.  Instead of focusing on 
percent mammographic density, investigators have recently argued for examination of the 
absolute area of dense breast tissue (75, 79).  Mean dense breast area did not significantly differ 
across TNFR2 genotypes, either before or after adjustment for potential confounding factors in 
our population.  In addition, our results are not consistent with the only study to have evaluated 
the –196 M/R polymorphism and its association with breast cancer risk (80).  In this recent study 
of 113 postmenopausal breast cancer cases and 157 pre- and postmenopausal controls in Tunisia, 
investigators demonstrated that the –196 M/R heterozygous genotype (TG) was associated with 
an increased risk, rather than having a  protective effect on incident breast cancer (OR=2.28, 
95% CI: 1.36-3.83) (80).  However, these results are to be interpreted with caution, as they might 
be specific to Tunisians (6 controls and 0 postmenopausal cases had the GG genotype), and the 
investigators did not attempt to control for potential confounding factors.   
Finally, we did not observe an association between the –196 M/R polymorphism and 
circulating sTNFR2 levels, nor did we observe a significant relationship between circulating 
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sTNFR2 levels and percent mammographic density in a previous analysis of this population 
(Paper 2, unpublished data).  To date, only one nested case-control study has prospectively 
examined the relationship between serum levels of sTNFR2 and breast cancer risk (81).  The 
investigators found no association between serum levels of the soluble TNFR2 receptor and 
breast cancer risk; however, this study had limited power to detect an association in 
postmenopausal women, with only 61 postmenopausal case-control pairs (81).   
Some limitations of this study deserve consideration.  Medication use was self-reported, 
and with the exception of a general question about use of “aspirin or anti-inflammatory agents in 
the last 48 hours” elicited by trained clinical staff, detailed use and dosage of specific 
medications were not recorded at the time of blood collection nor were they verified against pill 
bottles.  The lack of ethnic diversity within MAMS reduces the generalizability of our findings to 
other ethnic groups.  In addition, due to the relatively small size of this study and the limited 
prevalence of some covariates in this population, we were limited in the associations that could 
be evaluated.  For instance, the Women’s Health Study reported a significant interaction between 
cigarette smoking (current, former, never) and current NSAID use with respect to breast cancer 
risk (82); however, there were only 23 current smokers in our population, 4 of whom were 
carriers of the variant allele.  When current smokers were collapsed into the category with former 
smokers, ever smoking cigarettes did not differ by mammographic density or TNFR2 genotype 
in our population.  Strengths of the study include the use of a quantitative, highly reproducible 
measure of mammographic density, and reliable genotyping results.  Although we only used a 
single measure of circulating sTNFR2, measured with fair reproducibility, determination of 
sTNFR2 concentrations in healthy individuals at time lapses of one year demonstrated that the 
concentrations of sTNFR2 are stable in each individual (correlation coefficient of 0.90), possibly 
reflecting genetically determined differences (83); this observation is supported by studies of 
identical twins, who unlike discordant twins, are more likely to have similar levels of sTNFR2 
(83).   
 In conclusion, studies have demonstrated a strong heritability component for both 
mammographic density (7, 25-27) and circulating soluble TNF receptor levels (83).  While the 
present results do not offer compelling evidence for an association between the TNFR2 –196 
M/R polymorphism with percent mammographic density, and offer no evidence for an 
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association with circulating sTNFR2 levels in this population, these findings should be replicated 
in larger populations and with improved measurement of sTNFR2. 
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Table 25. Characteristics of the study population by genotype, Mammograms and Masses Study (2001-2005) 
   TNFR2 –196 M/R Genotype  
Variable n=376 
% or 
(range) 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Clinic, %       0.83 
   Biopsy 69 18 169 82 138 81  
   Screening clinic 307 82 37 18 32 19  
Age (years), mean (SD) 62 (8) (42-85) 62 (8) (45-83) 62 (8) (42-85) 0.89 
Race (%)       0.86 
   White 353 94 193 94 160 94  
   Other 23 6 13 6 10 6  
Education level (%)       0.66 
   High school 93 25 53 26 40 24  
   > High school 274 75 149 74 125 76  
   Missing 9  4  5   
Body mass index §, mean (SD) 28.4 (6.1) (16.8-46.6) 27.8 (5.9) (16.8-45.9) 29.1 (6.3) (17.3-46.6) 0.05 
Cigarette Smoking (%)       0.02 
  Never 219 58 119 58 100 59  
  Former 133 35 67 33 66 39  
  Current 23 6 19 9 4 2  
  Missing 1  1  0   
Cigarette Smoking (%)       0.88 
  Never 219 58 119 58 100 59  
  Ever 156 42 86 42 70 41  
  Missing 1  1     
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Table 25 (continued) 
   TNFR2 –196 M/R Genotype  
Variable n=376 
% or 
(range) 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Current alcohol consumption 
≥1/week for ≥6 months (%)       0.05 
  No 263 72 135 67 128 77  
  Yes 104 28 65 32 39 23  
   Missing 9  6  3   
Current alcohol use ≥ 1/week for 
≥ 6 months (%)       0.13 
  No 263 72 135 68 128 77  
   Yes        
   <12g/day 68 19 44 22 24 14  
   ≥12g/day 35 9 20 10 15 9  
   Missing 10  7  3   
Walks for exercise (%)       0.59 
  Rarely/1-3 times/month 148 40 84 42 64 39  
  At least 2-3 times/week 219 60 118 58 101 61  
  Missing 9  4  5   
Age at menarche (years), %       0.09 
  <12 72 19 31 15 41 24  
  12-13 223 59 128 62 95 56  
  ≥14 80 21 46 22 34 20  
   Missing 1  1  0   
Nulliparous (%)       0.05 
  No 295 78 154 75 141 83  
  Yes 81 21 52 25 29 17  
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Table 25 (continued) 
   TNFR2 –196 M/R Genotype  
Variable n=376 
% or 
(range) 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Parity (%)       0.39 
   Nulliparous 81 21 52 25 29 17  
  1 43 11 26 13 17 10  
  2 113 30 59 29 54 32  
  3 79 21 39 19 40 24  
  4 32 9 16 8 16 9  
  5+ 28 7 14 7 14 8  
Age at first birth (years), %       0.16 
  <30 249 66 130 63 119 70  
  ≥30 or nulliparous 127 34 76 37 51 30  
Breastfeeding (%)       0.01 
  Never or ≤1 month 226 60 136 66 90 53  
  Ever 149 40 69 34 80 47  
  Missing 1  1  0   
Breastfeeding (%)       0.03 
  Never or ≤1 month 
Ever
226 60 136 66 90 53  
          
    1-12 months 97 26 46 22 51 30  
    ≥13 months  52 14 23 11 29 17  
   Missing 1  1  0   
Age at menopause (years), mean 
(SD) 48 (5) (26-60) 48 (5) (30-60) 48 (5) (26-58) 0.42 
   Missing 10  5  5   
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Table 25 (continued) 
   TNFR2 –196 M/R Genotype  
Variable n=376 
% or 
(range) 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Years since menopause, mean 
(SD) 14 (10) (1-43) 14 (10) (1-43) 13 (10) (1-42) 0.88 
   Missing 10  5  5   
Surgical menopause (%)       0.26 
   No 340 93 184 91 156 95  
   Yes 26 7 17 8 9 5  
   Missing 10  5  5   
Hormone therapy (%)       0.95 
   Never use 151 40 83 40 68 40  
   Past use 225 60 123 60 102 60  
Family history of breast cancer † 
(%)       0.91 
  No 318 85 174 85 144 86  
  Yes 54 14 30 15 24 14  
   Missing 4  2  2   
Breast biopsy < enrollment (%)       0.23 
  Never 305 81 163 79 142 84  
  Ever 70 19 43 21 27 16  
  Missing 1  0  1   
Breast biopsy < enrollment (%)       0.09 
  0 305 81 163 79 142 84  
  1 48 13 26 13 22 13  
  2+ 22 6 17 8 5 3  
  Missing 1   0   1     
† History of breast cancer in a mother or sister; § Weight (kg)/height² (m²). 
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Table 26. Self-reported medication use by genotype in the Mammograms and Masses Study (MAMS), 2001-2005 
   TNFR2 –196 M/R Genotype  
Variable n=376 % 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Aspirin or other anti-inflammatory agent within 48 
hours of blood draw        
  % yes 163 44 80 39 83 49 0.04 
  Missing 2  0  2   
Self-reported current medication use in study 
questionnaire:        
Aspirin, % yes 111 29 59 29 52 31 0.68 
Non-aspirin NSAID, % yes 53 14 28 14 25 15 0.76 
Acetaminophen, % yes 22 6 10 5 12 7 0.36 
Any NSAID, % yes 150 40 79 38 71 42 0.50 
Cox-2 inhibitors, % yes 14 4 7 3 7 4 0.71 
Selective Estrogen Receptor Modulator (Raloxifene or 
Tamoxifen), % yes 31 8 15 7 16 9 0.45 
Bisphosphonates (Risedronate or Alendronate), %  yes 51 14 31 15 20 12 0.35 
Self-reported medication use in NSAIDs follow-up 
questionnaire:       0.19 
Aspirin ≥ 1/week in past 12 months, % yes 122 40 61 37 61 44 0.19 
  Missing 72  40  32   
Aspirin ~daily for 1 year or more, % yes 74 24 38 23 36 26 0.52 
  Missing 72  40  32   
Non-aspirin NSAID ≥ 1/week in past 12 months, % yes 69 23 36 22 33 24 0.64 
  Missing 72  40  32   
Non-aspirin NSAID ~daily for 1 year or more, % yes 19 6 11 7 8 6 0.77 
  Missing 72  40  32   
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Table 26 (continued) 
   TNFR2 –196 M/R Genotype  
Variable n=376 % 
TT  
(n=206) 
% or 
(range) 
TG/GG 
(n=170) 
% or 
(range) p-value 
Acetaminophen ≥ 1/week in past 12 months, % yes 79 26 40 24 39 28 0.39 
  Missing 73  40  33   
Acetaminophen ~daily for 1 year or more, % yes 15 5 7 4 8 6 0.52 
  Missing 73  40  33   
Any NSAID ≥ 1/week in past 12 months, % yes 155 51 80 48 75 54 0.28 
  Missing 72  40  32   
Any NSAID ~daily for 1 year or more, % yes 88 29 46 28 42 30 0.60 
  Missing 72   40   32     
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Table 27. Percent mammographic density by genotype, Mammograms and Masses Study (2001-2005) 
   TNFR2 –196 M/R Genotype     
   
TT  
(n=206) 
TG/GG  
(n=170)     
Variable Mean (SD) Range Mean (SD) Range Mean (SD) Range p1* p2 p3 p4§
% Mammographic 
density 29.7 (19.5) (0-94.9) 32.3 (21.0) (0-94.9) 26.6 (17.2) (0-84.5) 0.003 0.004 0.03 0.08 
*1. P-value for two-sample t-test with unequal variances comparing mean percent mammographic density by genotype. 
2. P-value based on analysis of variance (ANOVA) comparing mean % mammographic density by genotype while adjusting for age 
(continuous). 
3. ANOVA adjusting for age (continuous) and BMI (continuous). 
4. ANOVA adjusting for age (continuous), BMI (continuous), ever smoked cigarettes (yes/no), current alcohol consumption (yes/no), age at 
menarche (<12, 12-13, ≥14 years), nulliparous (yes/no), ever breast fed (yes/no), ever had breast biopsy prior to study enrollment (yes/no), and 
aspirin use within 48 hrs of blood draw (yes/no). 
§ Fourteen women are missing from this multivariate model (n=8 with the TT genotype; n=6 with the TG/GG genotype). 
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Table 28. Dense, total, and nondense breast area by genotype, Mammograms and Masses Study (2001-2005) 
   TNFR2 –196 M/R Genotype     
   
TT  
(n=206) 
TG/GG  
(n=170)     
Variable Mean (SD) Range Mean (SD) Range Mean (SD) Range p1* p2 p3 p4§
Dense 
breast area 40.9 (26.2) (0-188.1) 42.1 (27.0) (0-188.1) 39.6 (25.3) (0-114.7) 0.36 0.36 0.41 0.77 
           
Total  
breast area 162.5 (76.4) (31.6-442.0) 155.3 (77.8) (39.5-442.0) 171.1 (73.8) (31.6-386.0) 0.04 0.04 0.37 0.31 
           
Nondense 
breast area 121.5 (78.0) (3.6-389.0) 113.2 (80.0) (3.6-389.0) 131.6 (74.4) (4.9-369.5) 0.02 0.02 0.20 0.26 
*1. P-value for two-sample t-test with assumed equal variances comparing mean mammographic area by genotype. 
2. P-value based on analysis of variance (ANOVA) comparing mean mammographic area by genotype while adjusting for age (continuous). 
3. ANOVA adjusting for age (continuous) and BMI (continuous). 
4. ANOVA adjusting for age (continuous), BMI (continuous), ever smoked cigarettes (yes/no), current alcohol consumption (yes/no), age at 
menarche (<12, 12-13, ≥14 years), nulliparous (yes/no), ever breast fed (yes/no), ever had breast biopsy prior to study enrollment (yes/no), 
and aspirin use within 48 hrs of blood draw (yes/no). 
§ Fourteen women are missing from this multivariate model (n=8 with the TT genotype; n=6 with the TG/GG genotype). 
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Table 29. Circulating levels of sTNFR2 by genotype, Mammograms and Masses Study (2001-2005) 
   TNFR2 –196 M/R Genotype     
   
TT  
(n=206) 
TG/GG  
(n=170)     
Variable Mean (SD) Range Mean (SD) Range Mean (SD) Range p1* p2 p3 p4§
sTNFR2 
pg/mL 
2662.6 
(1202.8) (84.3-8517.8) 
2693.9 
(1249.5) (84.3-7402.7) 
2624.6 
(1146.2) (526.5-8517.8) 0.58 0.57 0.33 0.60 
*1. P-value for two-sample t-test with assumed equal variances comparing circulating sTNFR2 levels by genotype. 
2. P-value based on analysis of variance (ANOVA) comparing circulating sTNFR2 levels by genotype while adjusting for age (continuous). 
3. ANOVA adjusting for age (continuous) and BMI (continuous). 
4. ANOVA adjusting for age (continuous), BMI (continuous), ever smoked cigarettes (yes/no), current alcohol consumption (yes/no), age at 
menarche (<12, 12-13, ≥14 years), nulliparous (yes/no), ever breast fed (yes/no), ever had breast biopsy prior to study enrollment (yes/no), and 
aspirin use within 48 hrs of blood draw (yes/no). 
§ Fourteen women are missing from this multivariate model (n=8 with the TT genotype; n=6 with the TG/GG genotype). 
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5.0  GENERAL DISCUSSION 
Breast cancer is the most common cancer in women around the world; in the United States this 
year, it is expected that breast cancer alone will account for 31% (212,920) of all new cancer 
cases among women and 40,970 women are expected to die from the disease (1).  Breast density 
is a known risk factor for breast cancer (2, 3), and the risk associated with mammographic 
density is greater than that associated with almost all other risk factors for breast cancer (3, 4).  
Therefore, understanding factors that affect breast density and their underlying mechanism is an 
important research question.  Endogenous and exogenous estrogen exposures have been 
associated with breast density (3, 5) and have been implicated in breast cancer (6-9).  Most breast 
tumors are initially dependent on estrogen for survival; paradoxically, the highest incidence of 
breast cancer occurs in postmenopausal women when ovarian production of estrogens is 
minimal.  In postmenopausal women, estrogens continue to be produced in non-ovarian sites, 
such as adipose tissue, as well as in normal and cancerous breast tissues (10).  In fact, 
postmenopausal breast cancer is largely estrogen receptor (ER) or progesterone receptor (PR) 
positive, and is more responsive to anti-estrogen therapy and aromatase inhibitors, even after 
controlling for stage and other prognostic factors (11).  In addition, recent studies have 
demonstrated a protective effect of nonsteroidal anti-inflammatory drugs (NSAIDs) with respect 
to postmenopausal breast cancer risk, suggesting that inflammation and cytokines may play a 
role in postmenopausal breast cancer (12-14).   
Cytokines may be associated with breast cancer risk independently.  However, it is also 
biologically plausible that cytokines may alter breast cancer risk through their relationship with 
breast density; no prior study has investigated this possibility.  Hence, we sought explore to the 
association between inflammation and breast cancer risk in two populations of postmenopausal 
women: the Study of Osteoporotic Fractures (SOF), and the Mammograms and Masses Study 
(MAMS). 
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5.1 ARTICLE 1 
In the first article, we tested reported use of NSAIDs for their effect on incident breast cancer 
within the Study of Osteoporotic Fractures (SOF) cohort.  We further investigated whether the 
relationship between NSAIDs and breast cancer incidence differed by hormone receptor status 
and tumor type at diagnosis.  The Study of Osteoporotic Fractures is a multi-center, prospective 
cohort study of white women recruited from four U.S. centers, 1986-1988.  Complete NSAID 
medication and breast cancer risk factor information was available for 6695 women, mean (SD) 
age 73 (5) years.  During a mean (SD) of 13.2 (3.8) years of follow-up, there were no differences 
in the risk of incident breast cancer (n=372 cases) by use of aspirin, non-aspirin NSAID, or any 
NSAID, before and after adjustment for potential confounding factors.  Further, we observed no 
difference in breast cancer risk by frequency and duration of NSAID use.   
Our results are consistent with seven prior large prospective studies finding no 
association (15-21), and with null results from a randomized controlled trial of alternate-day low-
dose aspirin (22).  However, our results are not consistent with five prospective studies 
demonstrating a protective effect from use of NSAIDs (12, 23-26) and one suggesting an 
increased risk (27).  Although the reason for these differing results is unclear, one explanation 
may be due to differences in exposure assessment across studies.  In SOF, a medication 
inventory was not conducted until visit 4, at which time patients were asked to bring all 
medications to the clinic for verification of use; however, the questions regarding frequency and 
duration of aspirin and non-aspirin NSAID use were only asked at visit two.  Further, at visit two 
only non-prescription NSAID use was captured.  This is an important limitation, especially given 
that a recent case-control study observed a 71% reduction in breast cancer risk associated with 
use of selective COX-2 inhibitors (28).  If in SOF users of prescription NSAIDs were included in 
the referent group (i.e. non-NSAID users), results would be biased toward the null.  Our results 
do not support a protective effect of nonprescription NSAIDs among older postmenopausal, 
white women. 
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5.2 ARTICLE 2 
The second article describes an ancillary study we conducted within the Mammograms and 
Masses Study (MAMS), an ongoing cross-sectional study of correlates of breast density.  In 376 
MAMS participants, we measured plasma levels of two soluble receptors for TNF-alpha 
(sTNFR1 and sTNFR2) and examined their association with percent mammographic breast 
density.  We chose to measure receptors for the cytokine TNF-alpha, because TNF-alpha is 
believed to have a central role in regulating estrogen synthesis in the breast (29-31).  Circulating 
TNF receptors may block TNF-α activity (32), thereby preventing induction of COX-2 gene 
expression (33, 34) and ultimately estrogen biosynthesis in the breast.  In MAMS, we found that 
mean percent mammographic density was lower among women in the highest quartiles of 
circulating levels of sTNFR1 and sTNFR2.  After adjustment for BMI, the inverse association 
initially observed between the circulating sTNFRs and percent mammographic density 
disappeared.   
This is the first study to examine the association between circulating sTNFRs and percent 
mammographic density.  Our initial findings of an inverse correlation between the sTNFRs and 
percent breast density were consistent with the idea that circulating sTNFRs may block TNF-α 
activity, thereby preventing induction of COX-2 gene expression, resulting in decreased 
biosynthesis of estrogen and ultimately reducing mammographic density, a marker of breast 
cancer risk.  However, since body mass index correlates strongly and positively with both the 
nondense and total breast areas (35), and thus correlates inversely with percent breast density 
(36-38), potential confounding by adiposity is of particular concern when studying factors, such 
as circulating sTNFRs, which are positively correlated with BMI.  We therefore examined the 
absolute area of dense breast tissue, instead of percent breast density (35, 39).  Indeed, 
circulating sTNFRs were not associated with dense breast area, both before and after adjustment 
for potential confounding factors in our population.  Interestingly, MAMS participants who 
reported use of aspirin or another anti-inflammatory agent within 48 hours of blood collection 
were significantly more likely to have lower percent mammographic density.  Consistent with 
this biologic mechanism is the epidemiologic evidence supporting and association between use 
of NSAIDs and reduced breast cancer risk (reviewed in (40) and (14)).  Thus, in spite of the lack 
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of an independent association between sTNFRs and mammographic density in this study, we 
cannot rule out the hypothesis that inflammation plays a role in mammographic density.   
5.3 ARTICLE 3 
Our interest in the third article was to expand upon our ancillary study in MAMS, by evaluating 
a non-synonymous SNP in the TNFR2 gene, known as the –196 M/R polymorphism (T to G 
transition), with respect to both percent mammographic density and circulating sTNFR2 levels.  
Compared to carriers of the variant allele, we observed higher mean percent breast density 
among women homozygous for the TT genotype, although this difference was attenuated after 
adjusting for potential confounding factors.   
To our knowledge, this is the first study to examine the association between the –196 
M/R polymorphism and percent mammographic density.  Because carriers of the G allele have 
been found to have higher circulating levels of sTNFR2 in previous studies (41, 42), we chose to 
evaluate TT genotypes in comparison to TG/GG genotypes.  Our initial finding of lower mean 
percent mammographic density among women with the TG/GG genotypes was consistent with 
the idea that elevations in circulating sTNFRs in these women (41, 42) may block TNF-α activity 
(32), thereby preventing induction of COX-2 gene expression (34), resulting in decreased 
biosynthesis of estrogen and ultimately reducing mammographic density, a marker of breast 
cancer risk.  The differences in mean percent mammographic density remained after adjustment 
for age and BMI, which was significantly lower among women with the TT genotype, suggesting 
that the –196 M/R polymorphism influences percent mammographic density independent of an 
effect on BMI.  However, inclusion of additional confounding factors reduced this difference 
(p=0.08).  Further, mean circulating plasma levels of sTNFR2 did not differ by TNFR2 genotype 
in our population, failing to confirm the previous literature that demonstrated functional 
significance for this polymorphism.  Since, in MAMS, the inter-assay coefficient of variation 
calculated from the analytic results for 40 masked duplicate plasma samples did not indicate 
good reproducibility for sTNFR2 concentrations (CV=22.4%), the lack of association observed 
in our study may be due to inadequate measurement of sTNFR2.  In fact, studies have 
demonstrated a strong heritability component for both mammographic density (2, 43-45) and 
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circulating soluble TNF receptor levels (46).  Hence, while the present results do not offer 
compelling evidence for an association between the TNFR2 –196 M/R polymorphism with 
percent mammographic density, and offer no evidence for an association with circulating 
sTNFR2 levels in this population, these findings should be replicated in larger populations and 
with improved sTNFR2 measures (i.e. enzyme-linked immunosorbent assay). 
5.4 SUMMARY AND FUTURE DIRECTIONS 
This project has provided us with a unique opportunity to explore the potential association 
between inflammation and breast cancer risk in two populations of postmenopausal women.  We 
used two different exposures known to be associated with inflammation (NSAID use and 
cytokines) and tested their association with incident breast cancer and mammographic density, a 
well-established risk factor for breast cancer.  Despite the evidence that NSAIDs consistently 
inhibit COX-2 (34), resulting in decreased biosynthesis of estrogen and thereby hindering breast 
tumor cell growth in vitro and in animal models (28, 47-50), our results do not support a 
protective effect of nonprescription NSAIDs among older postmenopausal women participating 
in the Study of Osteoporotic Fractures.  However, given the potential public health impact should 
NSAIDs be successful chemopreventive agents for breast cancer, these findings warrant further 
investigation in larger populations with carefully defined exposure assessment, for instance in a 
randomized clinical trial.  Furthermore, as we did not assess prescription NSAID use, we could 
not rule out the possibility that other NSAIDs, such as selective COX-2 inhibitors, might reduce 
the risk of breast cancer.  Finally, evidence suggests that inter-individual variation in metabolism 
of NSAIDs occurs by two major enzymes, CYP2C9 and UGT1A6, which may explain some of 
the inconsistencies seen in the epidemiologic literature (51-53).  No prior study has investigated 
the association between breast cancer risk (and breast density) with both NSAID use and 
genotypic variations in NSAID metabolizing genes. 
We did not observe strong support for an independent association between sTNFRs and 
the TNFR2 polymorphism with respect to percent mammographic density among 
postmenopausal women in the Mammograms and Masses Study.  However, we did confirm that 
percent mammographic density is associated with several breast cancer risk factors (3, 9, 36-38, 
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54-70).  For instance, MAMS women with higher percent mammographic density were more 
likely to be nulliparous and/or have a later age at first birth, to be former hormone therapy users, 
and to report a history of breast biopsy than women with lower percent mammographic density.  
In addition, women with higher percent breast density were younger and had fewer years since 
menopause, had a lower BMI, were more likely to have attended post-secondary education and 
to report current consumption of alcohol.  In addition, we confirmed that women with higher 
sTNFR levels had a higher BMI and were older than women with lower sTNFR levels (71-73).  
While not the primary aim of the study, recent aspirin use reported at blood collection was 
associated with lower percent mammographic density.   
While the mechanism by which mammographic density increases breast cancer risk 
remains unknown, it is thought that dense areas may be associated with increased cell 
proliferation (74).  A recent retrospective study of diagnostic mammograms from women 
diagnosed with DCIS demonstrated that DCIS lesions occurred overwhelmingly in areas of 
mammographically dense tissue, suggesting that some characteristic of the dense tissue is 
directly influencing the carcinogenic process in the breast (75).  Thus, we hope our findings will 
encourage other investigators to further examine potential mechanisms by which inflammation 
may be related to mammographic density and breast cancer risk. 
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6.0  PUBLIC HEALTH SIGNIFICANCE 
In these collective studies, we attempted to explore whether breast cancer risk may be 
significantly decreased by reducing inflammation.  It is well known that mammograms provide 
early detection of breast cancer and a 20-30% reduction in breast carcinoma mortality.  However, 
breast density has been shown to affect mammographic sensitivity and specificity, with greater 
breast density being associated with a reduction in the technical performance of mammography.  
Breast density is also predictive of breast cancer risk.  Extensive areas of light appearing, 
mammographically dense tissue on a mammogram have been associated with a 4-6 fold increase 
in breast cancer risk after adjusting for other known risk factors for the disease.  Thus, women 
who are at higher risk of the disease may not be as well served by mammograms.   
Increased understanding of factors that affect breast density and their underlying 
mechanisms is needed, and inflammatory cytokines may be involved.  While we did not observe 
a reduction in incident breast cancer with NSAID use, we did find an inverse association 
between aspirin use and breast density.  Such findings could provide the impetus for 
investigating NSAIDs as potential chemopreventive agents for breast cancer.  Confirmation of 
this finding in additional studies would have important pubic health implications.  
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APPENDIX A 
NONSTEROIDAL ANTI-INFLAMMATORY DRUG USE AND BREAST CANCER IN 
OLDER WOMEN: THE STUDY OF OSTEOPOROTIC FRACTURES 
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Table 30. Visit 2 analysis: Incident breast cancer among participants in the Study of 
Osteoporotic Fractures, 1986-2003 
Total Cohort 9704 
Total with available Visit 2 data 9339 
Prevalent breast cancer self-reported in first annual questionnaire (year 1) 470 
Additional prevalent breast cancer diagnosed before visit 2 52 
Censored before visit 2 1 
No available data on breast cancer status during follow-up 113 
Confirmed cases 443 
Non-cases 8260 
Total with confirmed breast cancer information, eligible for V2 analysis 8703 
Total with missing covariate data 2008 
     Aspirin or Ibuprofen at visit 2 438 
     Potential confounding factors at visit 2 1570 
Final sample for V2 analysis 6695 
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Table 31. Characteristics of women by breast cancer status in the Study of Osteoporotic 
Fractures 
  
 Controls (n=6323) Cases (n=372)  
Variable n % n % p-value 
Clinic*     0.34 
   A 1670 26 111 30  
   B 1540 24 95 25  
   C  1412 22 77 21  
   D 1701 27 89 24  
Age (±SD), years 73 (5) 72 (4) 0.0004 
Age (years)      
   ≤72 3307 52 221 59 0.008 
   73+ 3016 48 151 41  
Education*     0.17 
   <High school 1362 21 69 19  
   High school graduate 4961 78 303 81  
Family history of breast cancer*     0.03 
  No 5500 87 309 83  
  Yes 823 13 63 17  
Age at first Menses     0.22 
     <12 745 12 49 14  
    12-13 3337 54 204 57  
     14+ 2086 34 106 30  
  Missing 155  13   
Parity*     0.99 
   Nulliparous 1179 19 67 18  
   1 871 14 51 14  
   2 1726 27 102 27  
   3 1284 20 79 21  
   4 660 10 37 10  
   5+ 603 9 36 10  
Nulliparous*     0.76 
   No 5144 81 305 82  
   Yes 1179 19 67 18  
Age at first live birth     0.78 
   ≤20 791 15 45 15  
   >20 4344 85 259 85  
  Missing 1188  68   
Age (years) at menopause*     0.63 
   ≤40 550 10 30 9  
   41-45 1017 19 65 21  
   46-50 2034 38 110 35  
   ≥51 1726 32 108 34  
  Missing 996  59   
Surgical menopause*     0.18 
   No 5555 88 318 85  
   Yes 768 12 54 14  
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Table 31 (continued) 
  
 Controls (n=6323) Cases (n=372)  
Variable n % n % p-value 
Estrogen only therapy (Oral)*     0.003 
   Never use 3645 58 190 51  
   Past use 1777 28 106 28  
   Current use 901 14 76 20  
Estrogen only therapy (Any Current)*     0.001 
   No 5422 86 296 80  
   Yes 901 14 76 20  
Average no. of alcoholic drinks/week (±SD)* 2 (4) 2 (4) 0.96 
Average no. of alcoholic drinks/week*     0.59 
   None 1830 29 102 27  
   <1 2134 34 131 35  
   1-2 780 12 50 13  
   2-7 1041 16 65 17  
   >7 538 9 24 6  
Cigarette Smoking     0.09 
  Never 3802 60 245 66  
  Former 2026 32 102 27  
  Current 495 8 25 7  
Walks for exercise*     0.37 
  No 3006 47 168 45  
  Yes 3317 52 204 55  
Body mass index §     0.07 
   <25 2849 45 150 40  
   25+ 3474 55 222 60  
Hypertension*     0.3 
   Never 3944 62 242 65  
   Ever 2379 38 130 35  
Hip bone mineral density (±SD), g/cm² 0.76 (0.13) 0.79 (0.12) <0.0001 
Stroke     0.7 
   Never 6020 96 358 96  
   Ever 262 4 14 4  
  Missing 41  0   
Heart Attack     0.52 
   Never 5076 93 299 94  
   Ever 377 7 19 6  
  Missing 870  54   
Mammogram at visit 3     0.03 
   No 839 20 36 15  
   Yes 3275 80 209 85  
  Missing 2209   127     
*Information collected at baseline clinical visit.    
† History of breast cancer in a mother or sister.    
§ Weight (kg)/height² (m²).      
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Table 32. Clinical characteristics of breast cancer cases by regular aspirin use, SOF (1986-1993) 
 Regular use of asiprin in past 12 mos  Daily use of aspirin for at least 1 year  
 No (n=229) Yes (n=143)  No (n=297) Yes (n=75)  
Characteristics n % n % p-value n % n % p-value 
Age at diagnosis, mean (SD), y 78 (5)  79 (6)  0.38 78 (5)  78 (6)  0.75 
Estrogen receptor status, No. (%)†     §     § 
   Positive 168 73 101 71  211 71 58 77  
   Negative 20 9 17 12  32 11 5 7  
   Borderline 0 0 1 1  1 0.3 0 0  
   Unknown 41 18 24 17  53 18 12 16  
Estrogen receptor status, No. (%)†     0.34     0.26 
   Positive ║ 168 89 102 86  212 87 58 8  
   Negative 20 11 17 14  32 13 5 92  
   missing 41  24   53  12   
Progesterone receptor status, No. (%)†     §     § 
   Positive 131 57 78 55  169 57 40 53  
   Negative 49 21 39 27  66 22 22 29  
   Borderline 5 2 2 1  6 2 1 1  
   Unknown 44 19 24 17  56 19 12 16  
Progesterone receptor status, No. (%)†     0.24     0.24 
   Positive ║ 136 74 80 67  175 73 41 65  
   Negative  49 26 39 33  66 27 22 35  
   missing 44  24   56  12   
Cancer stage at diagnosis, No. (%)‡     0.92     0.88 
  O (in situ) 33 14 19 13  41 14 11 15  
   I 127 55 79 55  167 56 39 52  
  II (no nodes) 27 12 14 10  35 12 6 8  
  II (+ nodes) 23 10 13 9  25 8 11 15  
  III 6 3 8 6  11 4 3 4  
  IV 1 0 3 2  4 1 0 0  
  Unknown 12 5 7 5   14 5 5 7   
†Women with unknown estrogen receptor status were excluded in statistical tests.      
‡The p value compares women with stage II cancer or greater at diagnosis with other cases.  Women with unknown cancer stage at diagnosis were 
excluded from this analysis. 
 ║ Borderline recoded to positive; § Cell sizes too sparse to use chi square test to compare clinical characteristic by medication use. 
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Table 33. Clinical characteristics of breast cancer cases by regular non-aspirin NSAID use, SOF (1986-1993) 
 
Regular use of a non-aspirin NSAID 
in past 12 months  
Daily use of a non-aspirin NSAID for 
at least 1 year  
 No (n=273) Yes (n=99)  No (n=323) Yes (n=49)  
Characteristics n % n % p-value n % n % p-value 
Age at diagnosis, mean (SD), y 78 (5)  79 (6)  0.47 78 (5)  78 (6)  0.37 
Estrogen receptor status, No. (%)†     §     § 
   Positive 194 71 75 76  231 71 38 78  
   Negative 30 11 7 7  32 10 5 10  
   Borderline 1 0 0 0  1 0 0 0  
   Unknown 48 17 17 17  59 18 6 12  
Estrogen receptor status, No. (%)†     0.25     0.93 
   Positive ║ 195 87 75 91  232 88 38 88  
   Negative 30 13 7 8  32 12 5 12  
   missing 48  17   59  6   
Progesterone receptor status, No. (%)†     §     § 
   Positive 149 54 60 61  181 56 28 57  
   Negative 68 25 20 20  73 23 15 31  
   Borderline 5 2 2 2  7 2 0 0  
   Unknown 51 19 17 17  62 19 6 12  
Progesterone receptor status, No. (%)†     0.29     0.35 
   Positive ║ 154 69 62 76  188 72 28 65  
   Negative  68 31 20 24  73 28 15 35  
   missing 51  17   62  6   
Cancer stage at diagnosis, No. (%)‡     0.87     § 
  O (in situ) 40 15 12 12  48 15 4 8  
   I 151 55 55 55  179 55 27 55  
  II (no nodes) 31 11 10 10  34 11 7 14  
  II (+ nodes) 30 11 6 6  33 10 3 6  
  III 8 3 6 6  12 4 2 4  
  IV 1 0 3 3  3 1 1 2  
  Unknown 12 4 7 7   14 4 5 10   
†Women with unknown estrogen receptor status were excluded in statistical tests.      
‡The p value compares women with stage II cancer or greater at diagnosis with other cases.  Women with unknown cancer stage at diagnosis were 
excluded from this analysis. 
 ║ Borderline recoded to positive; § Cell sizes too sparse to use chi square test to compare clinical characteristic by medication use. 
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Table 34. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use by estrogen receptor (ER) status in the Study of Osteoporotic 
Fractures, 1986-1993 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
ER+ 
(ER+/PR+  
or  
ER+/PR-)  
(n=270) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Aspirin ≥ 1/week in past 
12 months         
   No 168 1.00  1.00  1.00  
   Yes 102 0.95 0.74, 1.22 0.95 0.75, 1.22 0.93 0.72, 1.19 
Aspirin frequency: §          
        No regular use 168 1.00  1.00  1.00  
        1-4 days/week 44 0.99 0.71, 1.38 0.98 0.71, 1.37 0.97 0.69, 1.35 
        5-7 days/week 51 0.86 0.63, 1.18 0.87 0.63, 1.19 0.83 0.61, 1.14 
        Missing 7       
Aspirin ~daily for 1 year 
or more §          
   No 212 1.00  1.00  1.00  
   Yes 58 1.00 0.75, 1.34 1.01 0.75, 1.35 0.97 0.72, 1.30 
Aspirin duration: §          
        No regular use 212 1.00  1.00  1.00  
        < 5 years 29 0.91 0.62, 1.35 0.92 0.62, 1.35 0.89 0.60, 1.32 
        5+ years 29 1.12 0.76, 1.65 1.13 0.76, 1.66 1.07 0.72, 1.58 
        Missing 0       
Non-aspirin NSAID ≥ 
1/week in past 12 
months §          
   No 195 1.00  1.00  1.00  
   Yes 75 1.07 0.82, 1.40 1.07 0.82, 1.40 1.02 0.78, 1.34 
Non-aspirin NSAID 
frequency: §          
        No regular use 195 1.00  1.00  1.00  
        1-4 days/week 28 1.21 0.81, 1.80 1.21 0.81, 1.79 1.18 0.79, 1.76 
        5-7 days/week 45 1.00 0.72, 1.39 1.01 0.73, 1.39 0.94 0.68, 1.31 
        Missing 2       
Non-aspirin NSAID 
~daily for 1 year or 
more §          
   No 232 1.00  1.00  1.00  
   Yes 38 1.10 0.78, 1.55 1.10 0.78, 1.55 1.03 0.72, 1.45 
Non-aspirin NSAID 
duration: §          
        No regular use 232 1.00  1.00  1.00  
        < 5 years 26 1.13 0.75, 1.70 1.14 0.76, 1.70 1.09 0.72, 1.63 
        5+ years 12 1.06 0.59, 1.89 1.05 0.59, 1.88 0.94 0.52, 1.68 
        Missing 0       
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Table 34 (continued) 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
ER+ 
(ER+/PR+  
or  
ER+/PR-)  
(n=270) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs ≥ 1/week in 
past 12 months         
   No 129 1.00  1.00  1.00  
   Yes 141 0.92 0.73, 1.17 0.93 0.73, 1.18 0.88 0.69, 1.13 
Any NSAIDs frequency: 
§          
        No regular use 129 1.00  1.00  1.00  
        1-4 days/week 75 0.86 0.65, 1.15 0.87 0.65, 1.16 0.81 0.61, 1.09 
        5-7 days/week 60 0.97 0.71, 1.31 0.96 0.71, 1.31 0.93 0.69, 1.27 
        Missing 6       
Any NSAIDs ~daily for 1 
year or more §          
   No 189 1.00  1.00  1.00  
   Yes 81 0.98 0.76, 1.27 0.99 0.76, 1.28 0.94 0.72, 1.22 
NSAIDs duration: §          
        No regular use 189 1.00  1.00  1.00  
        < 5 years 45 0.95 0.69, 1.32 0.96 0.69, 1.32 0.92 0.66, 1.28 
        5+ years 36 1.03 0.72, 1.47 1.04 0.73, 1.48 0.96 0.67, 1.38 
        Missing 0       
Acetaminophen ≥ 
1/week in past 12 
months §          
   No 211 1.00  1.00  1.00  
   Yes 58 0.95 0.71, 1.27 0.94 0.71, 1.26 0.92 0.68, 1.23 
   Missing 1       
Acetaminophen 
frequency: §          
        No regular use 211 1.00  1.00  1.00  
        1-4 days/week 36 0.98 0.69, 1.40 0.98 0.69, 1.40 0.95 0.67, 1.36 
        5-7 days/week 14 0.70 0.41, 1.20 0.70 0.41, 1.21 0.69 0.40, 1.18 
        Missing 9       
Acetaminophen ~daily 
for 1 year or more § †         
   No 261 1.00  1.00  1.00  
   Yes 9       
   Missing 0       
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Table 34 (continued) 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
ER+ 
(ER+/PR+  
or  
ER+/PR-)  
(n=270) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Acetaminophen 
duration: § †         
        No regular use 261 1.00  1.00  1.00  
        < 5 years 4       
        5+ years 5       
        Missing 0             
*Proportional hazards regression models. 
**Age-adjusted hazard 
ratio        
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval. 
§ Too few hormone receptor-negative breast cancer cases to estimate HR associated with medication use. 
† Too few hormone receptor-positive breast cancer cases to estimate HR associated with medication use. 
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Table 35. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use by progesterone receptor status (PR+) in SOF (1986-1993)  
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
PR+ 
(ER+/PR+ 
or  
ER-/PR+) 
(n=216) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Aspirin ≥ 1/week in past 12 
months         
   No 136 1.00  1.00  1.00  
   Yes 80 0.92 0.70, 1.22 0.93 0.70, 1.22 0.89 0.67, 1.18 
Aspirin frequency: §          
        No regular use 136 1.00  1.00  1.00  
        1-4 days/week 40 1.11 0.78, 1.58 1.10 0.77, 1.57 1.08 0.76, 1.53 
        5-7 days/week 35 0.73 0.50, 1.06 0.74 0.51, 1.07 0.70 0.48, 1.01 
        Missing 5       
Aspirin ~daily for 1 year 
or more §          
   No 175 1.00  1.00  1.00  
   Yes 41 0.86 0.61, 1.21 0.87 0.62, 1.22 0.82 0.58, 1.15 
Aspirin duration: §          
        No regular use 175 1.00  1.00  1.00  
        < 5 years 21 0.81 0.51, 1.27 0.81 0.51, 1.27 0.78 0.49, 1.22 
        5+ years 20 0.94 0.59, 1.49 0.94 0.59, 1.50 0.87 0.55, 1.39 
        Missing 0       
Non-aspirin NSAID ≥ 
1/week in past 12 months §          
   No 154 1.00  1.00  1.00  
   Yes 62 1.12 0.83, 1.50 1.12 0.83, 1.50 1.06 0.78, 1.42 
Non-aspirin NSAID 
frequency: §          
        No regular use 154 1.00  1.00  1.00  
        1-4 days/week 26 1.42 0.94, 2.15 1.42 0.93, 2.14 1.38 0.91, 2.10 
        5-7 days/week 34 0.96 0.66, 1.39 0.96 0.66, 1.39 0.89 0.61, 1.29 
        Missing 2       
Non-aspirin NSAID ~daily 
for 1 year or more §          
   No 188 1.00  1.00  1.00  
   Yes 28 1.00 0.67, 1.49 1.00 0.67, 1.49 0.91 0.61, 1.37 
Non-aspirin NSAID 
duration: §          
        No regular use 188 1.00  1.00  1.00  
        < 5 years 18 0.97 0.60, 1.57 0.97 0.60, 1.58 0.92 0.56, 1.49 
        5+ years 10 1.09 0.57, 2.05 1.08 0.57, 2.05 0.93 0.49, 1.77 
        Missing 0       
Any NSAIDs ≥ 1/week in 
past 12 months         
   No 102 1.00  1.00  1.00  
   Yes 114 0.94 0.72, 1.23 0.95 0.73, 1.24 0.89 0.68, 1.17 
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Table 35 (continued) 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
PR+ 
(ER+/PR+ 
or  
ER-/PR+) 
(n=216) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs frequency: §          
        No regular use 102 1.00  1.00  1.00  
        1-4 days/week 55 0.80 0.58, 1.11 0.81 0.58, 1.12 0.74 0.53, 1.03 
        5-7 days/week 55 1.12 0.80, 1.55 1.11 0.80, 1.55 1.07 0.77, 1.49 
        Missing 4       
Any NSAIDs ~daily for 1 
year or more §          
   No 158 1.00  1.00  1.00  
   Yes 58 0.84 0.62, 1.14 0.85 0.63, 1.15 0.78 0.58, 1.07 
NSAIDs duration: §          
        No regular use 158 1.00  1.00  1.00  
        < 5 years 32 0.81 0.56, 1.19 0.82 0.56, 1.20 0.77 0.53, 1.13 
        5+ years 26 0.89 0.59, 1.35 0.90 0.59, 1.36 0.81 0.53, 1.23 
        Missing 0       
Acetaminophen ≥ 1/week 
in past 12 months §          
   No 167 1.00  1.00  1.00  
   Yes 48 0.99 0.72, 1.36 0.99 0.72, 1.36 0.95 0.69, 1.31 
   Missing 1       
Acetaminophen frequency: 
§          
        No regular use 167 1.00  1.00  1.00  
        1-4 days/week 34 1.17 0.81, 1.69 1.17 0.81, 1.69 1.13 0.78, 1.64 
        5-7 days/week 7 0.44 0.21, 0.94 0.45 0.21, 0.95 0.43 0.20, 0.91 
        Missing 8       
Acetaminophen ~daily for 
1 year or more § †         
   No 211 1.00  1.00  1.00  
   Yes 5       
   Missing 0       
Acetaminophen duration: 
§ †         
        No regular use 211 1.00  1.00  1.00  
        < 5 years 2       
        5+ years 3       
        Missing 0             
*Proportional hazards regression models. 
**Age-adjusted hazard ratio        
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval. 
§ Too few hormone receptor-negative breast cancer cases to estimate HR associated with medication use. 
† Too few hormone receptor-positive breast cancer cases to estimate HR associated with medication use. 
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Table 36. Estimated relative hazard of breast cancer associated with history of NSAID and 
acetaminophen use by progesterone receptor status (PR-) in SOF (1986-1993) 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
PR-  
(ER-/PR- or 
ER+/PR-) 
(n=88) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Aspirin ≥ 1/week in past 
12 months        
   No 49 1.00  1.00  1.00  
   Yes 39 1.25 0.82, 1.90 1.25 0.82, 1.91 1.24 0.81, 1.89 
Aspirin frequency: §         
        No regular use 49 1.00  1.00  1.00  
        1-4 days/week 12 0.93 0.49, 1.74 0.92 0.49, 1.73 0.90 0.48, 1.70 
        5-7 days/week 24 1.38 0.85, 2.25 1.40 0.86, 2.28 1.39 0.85, 2.27 
        Missing 3       
Aspirin ~daily for 1 year 
or more §         
   No 66 1.00  1.00  1.00  
   Yes 22 1.21 0.75, 1.97 1.23 0.76, 1.99 1.22 0.75, 1.98 
Aspirin duration: §         
        No regular use 66 1.00  1.00  1.00  
        < 5 years 11 1.11 0.58, 2.10 1.11 0.59, 2.11 1.10 0.58, 2.09 
        5+ years 11 1.35 0.72, 2.57 1.38 0.73, 2.60 1.37 0.72, 2.62 
        Missing 0       
Non-aspirin NSAID ≥ 
1/week in past 12 
months §         
   No 68 1.00  1.00  1.00  
   Yes 20 0.82 0.50, 1.36 0.83 0.50, 1.36 0.79 0.48, 1.32 
Non-aspirin NSAID 
frequency: §         
        No regular use 68 1.00  1.00  1.00  
        1-4 days/week 4       
        5-7 days/week 15       
        Missing 1       
Non-aspirin NSAID 
~daily for 1 year or 
more §         
   No 73 1.00  1.00  1.00  
   Yes 15 1.38 0.79, 2.40 1.38 0.79, 2.41 1.35 0.77, 2.38 
Non-aspirin NSAID 
duration: §         
        No regular use 73 1.00  1.00  1.00  
        < 5 years 12       
        5+ years 3       
        Missing 0       
Any NSAIDs ≥ 1/week in 
past 12 months        
   No 40 1.00  1.00  1.00  
   Yes 48 1.02 0.67, 1.55 1.02 0.67, 1.55 0.99 0.65, 1.52 
185 
Table 36 (continued) 
 Cases  Unadjusted* Adjusted** Adjusted*** 
Risk Factor 
PR-  
(ER-/PR- or 
ER+/PR-) 
(n=88) HR‡ 95% CI HR‡ 95% CI HR‡ 95% CI 
Any NSAIDs frequency: §         
        No regular use 40 1.00  1.00  1.00  
        1-4 days/week 32 1.18 0.74, 1.88 1.20 0.75, 1.91 1.16 0.72, 1.87 
        5-7 days/week 13 0.68 0.36, 1.27 0.68 0.36, 1.26 0.66 0.35, 1.24 
        Missing 3       
Any NSAIDs ~daily for 1 
year or more §         
   No 55 1.00  1.00  1.00  
   Yes 33 1.37 0.89, 2.10 1.38 0.90, 2.13 1.39 0.90, 2.16 
NSAIDs duration: §         
        No regular use 55 1.00  1.00  1.00  
        < 5 years 20 1.44 0.86, 2.40 1.46 0.87, 2.43 1.46 0.87, 2.45 
        5+ years 13 1.27 0.70, 2.33 1.29 0.70, 2.36 1.30 0.71, 2.41 
        Missing 0       
Acetaminophen ≥ 1/week 
in past 12 months §         
   No 71 1.00  1.00  1.00  
   Yes 17 0.83 0.49, 1.40 0.82 0.48, 1.40 0.83 0.49, 1.41 
   Missing 0       
Acetaminophen frequency: 
§         
        No regular use 71 1.00  1.00  1.00  
        1-4 days/week 8       
        5-7 days/week 7       
        Missing 2       
Acetaminophen ~daily for 
1 year or more § †        
   No 83 1.00  1.00  1.00  
   Yes 5       
   Missing 0       
Acetaminophen duration: 
§ †        
        No regular use 83 1.00  1.00  1.00  
        < 5 years 2       
        5+ years 3       
        Missing 0             
*Proportional hazards regression models. 
**Age-adjusted hazard ratio        
***Data were controlled for age, current use of estrogen therapy, BMI, surgical menopause, total hip BMD, 
smoking, family history of breast cancer, study center, walking for exercise, nulliparity, and hypertension. 
‡HR, hazard ratio; CI, confidence interval. 
§ Too few hormone receptor-negative breast cancer cases to estimate HR associated with medication use. 
† Too few hormone receptor-positive breast cancer cases to estimate HR associated with medication use. 
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APPENDIX B 
THE MAMMOGRAMS AND MASSES STUDY (MAMS) 
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Number approached = 100
Number, without personal cancer history,  
consenting, and providing interview data 
and blood sample = 86 (86%)
Subject recruitment through direct solicitiation of women who visited the 
mammography screening facility
Number with non-cancer outcome 
from screening = 85 (99%)
Number with cancer outcome from 
screening = 1 (1%)
Number postmenopausal, not 
taking hormone therapy at blood 
draw = 43 (51%)
Number with breast density and 
cytokine results = 30 (70%)
Number excluded from final analysis = 13 
(30%)
1.) Unable to obtain mammogram or questionnaire (n=6)
2.) No available unthawed plasma (n=3) or buffy coat (n=1)
4.) Requested no further contact (n=3)
 
Figure 2. Recruitment in the mammography screening facility, MAMS 
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Number approached = 856
Number, without personal cancer history,  
consenting, and providing interview data 
and blood sample = 573 (67%)
Subject recruitment through direct solicitiation of women who visited the 
breast biopsy facility or surgical clinic
Number with non-cancer outcome  
= 311 (54% of 573)
Number with incident breast cancer 
= 262 (46% of 573)
Number postmenopausal, not taking 
hormone therapy at blood draw = 109 
(35% of 311)
Number with breast density and 
cytokine results = 69 (63%)
Number excluded from final analysis = 40 
(37%)
1.) Unable to obtain mammogram or questionnaire (n=24)
2.) ≥ 4.5 months between date of blood draw and 
mammogram (n=8)
3.) No available unthawed plasma (n=2) or buffy coat (n=1)
4.) Requested no further contact (n=5)
 
Figure 3. Recruitment in the biopsy facility or surgical clinic, MAMS 
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Number of solicitations mailed = 21,606
Number responding = 1025 (5%)
Number eligible (no personal cancer history) = 
857 (84%)
Number postmenopausal, not taking hormone 
therapy at blood draw = 297 (66%)
Number scheduling visit = 559 (65%)
Subject recruitment through solicitiations mailed to women with negative 
screening mammography results
Number, without personal cancer history, 
consenting, and providing interview data and 
blood sample = 451 (81%)
Number excluded from final analysis 
= 20 (7%)
1.) Unable to obtain mammogram or 
questionnaire (n=15)
2.) ≥ 4.5 months between date of blood draw 
and mammogram (n=5)
Number with breast density and 
cytokine results = 277 (93%)
 
Figure 4. Recruitment by flyer, MAMS 
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Figure 5. Mean % mammographic density by quartiles of sTNFR1, unadjusted and 
adjusted for age and BMI 
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Figure 6. Mean % mammographic density by quartiles of sTNFR2, unadjusted and 
adjusted for age and BMI 
 
192 
BIBLIOGRAPHY 
Abeloff, M. D., A. S. Lichter, et al. (2000). Breast. Clinical Oncology. M. D. Abeloff, J. O. 
Armitage, A. S. Lichter and J. E. Niederhuber. Philadelphia, Churchill Livingstone. 
Adams, E. F., B. Rafferty, et al. (1991). "Interleukin 6 is secreted by breast fibroblasts and 
stimulates 17 beta-oestradiol oxidoreductase activity of MCF-7 cells: possible paracrine 
regulation of breast 17 beta-oestradiol levels." Int J Cancer 49(1): 118-21. 
Aderka, D. (1996). "The potential biological and clinical significance of the soluble tumor 
necrosis factor receptors." Cytokine Growth Factor Rev 7(3): 231-40. 
Aderka, D., H. Engelmann, et al. (1992). "Stabilization of the bioactivity of tumor necrosis factor 
by its soluble receptors." J Exp Med 175(2): 323-9. 
Aderka, D., H. Engelmann, et al. (1992). "Variation in serum levels of the soluble TNF receptors 
among healthy individuals." Lymphokine and Cytokine Research 11(3): 157-9. 
Aderka, D., H. Englemann, et al. (1991). "Increased serum levels of soluble receptors for tumor 
necrosis factor in cancer patients." Cancer Research 51(20): 5602-7. 
Aiello, E. J., D. S. M. Buist, et al. (2005). "Association between Mammographic Breast Density 
and Breast Cancer Tumor Characteristics." Cancer Epidemiol Biomarkers Prev 14(3): 
662-668. 
Aiello, E. J., S. S. Tworoger, et al. (2005). "Associations among Circulating Sex Hormones, 
Insulin-Like Growth Factor, Lipids, and Mammographic Density in Postmenopausal 
Women." Cancer Epidemiol Biomarkers Prev 14(6): 1411-1417. 
Al-Ansari, A. S., W. E. R. Ollier, et al. (2000). "Tumor necrosis factor receptor II (TNFRII) exon 
6 polymorphism in systemic lupus erythematosus." Tissue Antigens 55(1): 97-99. 
Alberg, A. J. and S. Singh (2001). "Epidemiology of breast cancer in older women: implications 
for future healthcare." Drugs & Aging 18(10): 761-72. 
Amir, H., C. Makwaya, et al. (2001). "Breast cancer during the HIV epidemic in an African 
population." Oncology Reports 8(3): 659-61. 
Atkinson, C., R. Warren, et al. (1999). "Mammographic patterns as a predictive biomarker of 
breast cancer risk: effect of tamoxifen." Cancer Epidemiol Biomarkers Prev 8(10): 863-6. 
193 
Band, P. R., N. D. Le, et al. (2002). "Carcinogenic and endocrine disrupting effects of cigarette 
smoke and risk of breast cancer.[comment]." Lancet 360(9339): 1044-9. 
Barton, A., S. John, et al. (2001). "Association between rheumatoid arthritis and polymorphism 
of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in 
Caucasians." Arthritis and Rheumatism 44(1): 61-5. 
Bazzoni, F. and B. Beutler (1996). "The tumor necrosis factor ligand and receptor families." N 
Engl J Med 334(26): 1717-25. 
Beltinger, C. P., P. S. White, et al. (1996). "Physical mapping and genomic structure of the 
human TNFR2 gene." Genomics 35(1): 94-100. 
Benichou, J., C. Byrne, et al. (2003). "Secular stability and reliability of measurements of the 
percentage of dense tissue on mammograms." Cancer Detection and Prevention 27(4): 
266-274. 
Bergkvist, L., L. Tabar, et al. (1987). "Epidemiologic determinants of the mammographic 
parenchymal pattern. A population-based study within a mammographic screening 
program." American Journal of Epidemiology 126(6): 1075-81. 
Berube, S., C. Diorio, et al. (2004). "Vitamin D, calcium, and mammographic breast densities." 
Cancer Epidemiol Biomarkers Prev 13(9): 1466-72. 
Boyd, N. F., J. W. Byng, et al. (1995). "Quantitative classification of mammographic densities 
and breast cancer risk: results from the Canadian National Breast Screening Study." J 
Natl Cancer Inst 87(9): 670-5. 
Boyd, N. F., G. S. Dite, et al. (2002). "Heritability of mammographic density, a risk factor for 
breast cancer." New England Journal of Medicine 347(12): 886-94. 
Boyd, N. F., C. Greenberg, et al. (1997). "Effects at two years of a low-fat, high-carbohydrate 
diet on radiologic features of the breast: results from a randomized trial. Canadian Diet 
and Breast Cancer Prevention Study Group." J Natl Cancer Inst 89(7): 488-96. 
Boyd, N. F., G. A. Lockwood, et al. (1998). "Mammographic densities and breast cancer risk." 
Cancer Epidemiol Biomarkers Prev 7(12): 1133-44. 
Boyd, N. F., G. A. Lockwood, et al. (2001). "Mammographic density as a marker of 
susceptibility to breast cancer: a hypothesis." IARC Scientific Publications 154: 163-9. 
Boyd, N. F., B. O'Sullivan, et al. (1982). "Mammographic signs as risk factors for breast cancer." 
Br J Cancer 45(2): 185-93. 
Boyd, N. F., B. O'Sullivan, et al. (1984). "Mammographic patterns and breast cancer risk: 
methodologic standards and contradictory results." J Natl Cancer Inst 72(6): 1253-9. 
194 
Boyd, N. F., J. M. Rommens, et al. (2005). "Mammographic breast density as an intermediate 
phenotype for breast cancer." The Lancet Oncology 6(10): 798-808. 
Boyd, N. F., J. Stone, et al. (2002). "The association of breast mitogens with mammographic 
densities." British Journal of Cancer 87(8): 876-82. 
Bright, R. A., A. S. Morrison, et al. (1988). "Relationship between mammographic and 
histologic features of breast tissue in women with benign biopsies." Cancer 61(2): 266-
71. 
Brisson, J., B. Brisson, et al. (2000). "Tamoxifen and mammographic breast densities." Cancer 
Epidemiol Biomarkers Prev 9(9): 911-5. 
Brisson, J., F. Merletti, et al. (1982). "Mammographic features of the breast and breast cancer 
risk." Am J Epidemiol 115(3): 428-37. 
Brisson, J., A. S. Morrison, et al. (1984). "Height and weight, mammographic features of breast 
tissue, and breast cancer risk." Am J Epidemiol 119(3): 371-81. 
Brisson, J., R. Verreault, et al. (1989). "Diet, mammographic features of breast tissue, and breast 
cancer risk." Am J Epidemiol 130(1): 14-24. 
Brooks-Asplund, E. M., C. E. Tupper, et al. (2002). "Hormonal modulation of interleukin-6, 
tumor necrosis factor and associated receptor secretion in postmenopausal women." 
Cytokine 19(4): 193-200. 
Brueggemeier, R. W., A. L. Quinn, et al. (1999). "Correlation of aromatase and cyclooxygenase 
gene expression in human breast cancer specimens." Cancer Letters 140(1-2): 27-35. 
Buist, D. S. M., P. L. Porter, et al. (2004). "Factors Contributing to Mammography Failure in 
Women Aged 40-49 Years." J Natl Cancer Inst 96(19): 1432-1440. 
Byng, J. W., N. F. Boyd, et al. (1996). "Automated analysis of mammographic densities." Phys 
Med Biol 41(5): 909-23. 
Byng, J. W., N. F. Boyd, et al. (1996). "Symmetry of projection in the quantitative analysis of 
mammographic images." Eur J Cancer Prev 5(5): 319-27. 
Byng, J. W., M. J. Yaffe, et al. (1998). "Analysis of mammographic density and breast cancer 
risk from digitized mammograms." Radiographics 18(6): 1587-98. 
Byrne, C., G. A. Colditz, et al. (2000). "Plasma insulin-like growth factor (IGF) I, IGF-binding 
protein 3, and mammographic density." Cancer Research 60(14): 3744-8. 
Byrne, C., S. E. Hankinson, et al. (2000). "Insulin-like growth factors and mammographic 
density." Growth Horm IGF Res 10 Suppl A: S24-5. 
195 
Byrne, C., C. Schairer, et al. (1995). "Mammographic features and breast cancer risk: effects 
with time, age, and menopause status." Journal of the National Cancer Institute 87(21): 
1622-9. 
Carlile, T., K. J. Kopecky, et al. (1985). "Breast cancer prediction and the Wolfe classification of 
mammograms." Jama 254(8): 1050-3. 
Cauley, J. A., S. R. Cummings, et al. (1990). "Prevalence and determinants of estrogen 
replacement therapy in elderly women." Am J Obstet Gynecol 163(5 Pt 1): 1438-44. 
Cauley, J. A., F. L. Lucas, et al. (1999). "Elevated serum estradiol and testosterone 
concentrations are associated with a high risk for breast cancer. Study of Osteoporotic 
Fractures Research Group.[comment]." Annals of Internal Medicine. 130(4 Pt 1): 270-7. 
Cauley, J. A., F. L. Lucas, et al. (1996). "Bone mineral density and risk of breast cancer in older 
women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research 
Group." Jama 276(17): 1404-8. 
Chandrasekharan, N. V., H. Dai, et al. (2002). "From the Cover: COX-3, a cyclooxygenase-1 
variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, 
structure, and expression." PNAS 99(21): 13926-13931. 
Chaudary, M. A., I. H. Gravelle, et al. (1983). "Breast parenchymal patterns in women with 
bilateral primary breast cancer." Br J Radiol 56(670): 703-6. 
Chen, W. Y., G. A. Colditz, et al. (2002). "Use of postmenopausal hormones, alcohol, and risk 
for invasive breast cancer.[summary for patients in Ann Intern Med. 2002 Nov 
19;137(10):I43; PMID: 12435234]." Annals of Internal Medicine Online 137(10): 798-
804. 
Chen, Z., M. Maricic, et al. (2005). "Fracture Risk Among Breast Cancer Survivors: Results 
From the Women's Health Initiative Observational Study." Arch Intern Med 165(5): 552-
558. 
Chow, C. K., D. Venzon, et al. (2000). "Effect of tamoxifen on mammographic density." Cancer 
Epidemiol Biomarkers Prev 9(9): 917-21. 
Christodoulakos, G. E., I. V. Lambrinoudaki, et al. (2003). "The effect of various regimens of 
hormone replacement therapy on mammographic breast density." Maturitas 45(2): 109-
18. 
Christodoulakos, G. E., I. V. Lambrinoudaki, et al. (2006). "The effect of low dose hormone 
therapy on mammographic breast density." Maturitas 54: 78-85. 
Ciotti, M., A. Marrone, et al. (1997). "Genetic polymorphism in the human UGT1A6 (planar 
phenol) UDP-glucuronosyltransferase: pharmacological implications." Pharmacogenetics 
7(6): 485-95. 
196 
Clavel-Chapelon, F. and M. Gerber (2002). "Reproductive factors and breast cancer risk. Do 
they differ according to age at diagnosis?" Breast Cancer Research & Treatment 72(2): 
107-15. 
“Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity 
in Adults: The Evidence Report,” 1998. NIH Publication No. 98-4083. 
Collaborative Group on Hormonal Factors in Breast, C. (1996). "Breast cancer and hormonal 
contraceptives: collaborative reanalysis of individual data on 53 297 women with breast 
cancer and 100 239 women without breast cancer from 54 epidemiological 
studies.[comment]." Lancet 347(9017): 1713-27. 
Collaborative Group on Hormonal Factors in Breast, C. (1997). "Breast cancer and hormone 
replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 
52,705 women with breast cancer and 108,411 women without breast cancer. 
[comment][erratum appears in Lancet 1997 Nov 15;350(9089):1484]." Lancet. 
350(9084): 1047-59. 
Collaborative Group on Hormonal Factors in Breast, C. (2002). "Breast cancer and 
breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies 
in 30 countries, including 50302 women with breast cancer and 96973 women without 
the disease.[comment]." Lancet 360(9328): 187-95. 
Constantin, A., P. Dieude, et al. (2004). "Tumor necrosis factor receptor II gene polymorphism 
and severity of rheumatoid arthritis." Arthritis Rheum 50(3): 742-7. 
Coogan, P. F., S. R. Rao, et al. (1999). "The Relationship of Nonsteroidal Anti-inflammatory 
Drug Use to the Risk of Breast Cancer,." Preventive Medicine 29(2): 72-76. 
Cook, N. R., I. M. Lee, et al. (2005). "Low-Dose Aspirin in the Primary Prevention of Cancer: 
The Women's Health Study: A Randomized Controlled Trial." JAMA 294(1): 47-55. 
Cotterchio, M., N. Kreiger, et al. (2001). "Nonsteroidal Anti-inflammatory Drug Use and Breast 
Cancer Risk." Cancer Epidemiol Biomarkers Prev 10(11): 1213-1217. 
Crandall, C., S. Palla, et al. (2005). "Positive association between mammographic breast density 
and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study." 
Breast Cancer Research 7(6): R922 - R928. 
Cummings, S. R., D. M. Black, et al. (1990). "Appendicular bone density and age predict hip 
fracture in women. The Study of Osteoporotic Fractures Research Group." JAMA 263(5): 
665-8. 
Cuzick, J., J. Warwick, et al. (2004). "Tamoxifen and Breast Density in Women at Increased 
Risk of Breast Cancer." J Natl Cancer Inst 96(8): 621-628. 
197 
Danforth, D. N., Jr. and M. K. Sgagias (1993). "Tumour necrosis factor-alpha modulates 
oestradiol responsiveness of MCF-7 breast cancer cells in vitro." J Endocrinol 138(3): 
517-28. 
de Jong, P. C., M. A. Blankenstein, et al. (2001). "Importance of local aromatase activity in 
hormone-dependent breast cancer: a review." The Breast 10(2): 91-99. 
de Stavola, B. L., I. H. Gravelle, et al. (1990). "Relationship of mammographic parenchymal 
patterns with breast cancer risk factors and risk of breast cancer in a prospective study." 
International Journal of Epidemiology 19(2): 247-54. 
de Waard, F., J. J. Rombach, et al. (1984). "Breast cancer risk associated with reproductive 
factors and breast parenchymal patterns." J Natl Cancer Inst 72(6): 1277-82. 
Deapen, D., L. Liu, et al. (2002). "Rapidly rising breast cancer incidence rates among Asian-
American women." International Journal of Cancer 99(5): 747-50. 
Deb, S., S. Amin, et al. (2004). "Estrogen Regulates Expression of Tumor Necrosis Factor 
Receptors in Breast Adipose Fibroblasts." J Clin Endocrinol Metab 89(8): 4018-4024. 
Dieudé, P., E. Petit, et al. (2002). "Association between tumor necrosis factor receptor II and 
familial, but not sporadic, rheumatoid arthritis: Evidence for genetic heterogeneity." 
Arthritis & Rheumatism 46(8): 2039-2044. 
Diorio, C., M. Pollak, et al. (2005). "Levels of C-Peptide and Mammographic Breast Density." 
Cancer Epidemiol Biomarkers Prev 14(11): 2661-2664. 
Diorio, C., M. Pollak, et al. (2005). "Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and 
Mammographic Breast Density." Cancer Epidemiol Biomarkers Prev 14(5): 1065-1073. 
Dite, G., J. Wark, et al. (2006). "Is there a positive association between mammographic density 
and bone mineral density?" Breast Cancer Research 8(1): 401. 
Dite, G. S., J. D. Wark, et al. (2005). "Is there overlap between the genetic determinants of 
mammographic density and bone mineral density?" Cancer Epidemiol Biomarkers Prev 
14(9): 2266-8. 
Dror, Y., T. Hahn, et al. (1998). "Soluble tumor necrosis factor receptor levels in familial 
Mediterranean fever." Journal of Rheumatology 25(12): 2481-2. 
DuBois, R. N. (2004). "Aspirin and breast cancer prevention: the estrogen connection." Jama 
291(20): 2488-9. 
Duncan, L. J., N. G. Coldham, et al. (1994). "The interaction of cytokines in regulating 
oestradiol 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells." J Steroid 
Biochem Mol Biol 49(1): 63-8. 
198 
"Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in 
postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) 
Trial. The Writing Group for the PEPI Trial." (1995). Jama 273(3): 199-208. 
Egan, K., M. Stampfer, et al. (1996). "Prospective study of regular aspirin use and the risk of 
breast cancer." J Natl Cancer Inst 88(14): 988a-993. 
Egan, R. L. and R. C. Mosteller (1977). "Breast cancer mammography patterns." Cancer 40(5): 
2087-90. 
Ellison, R. C., Y. Zhang, et al. (2001). "Exploring the Relation of Alcohol Consumption to Risk 
of Breast Cancer. ." American Journal of Epidemiology 154(8): 740-747. 
Ernster, V. L., S. T. Sacks, et al. (1980). "Mammographic parenchymal patterns and risk factors 
for breast cancer." Radiology 134(3): 617-20. 
Erren, T. C. (2001). "A meta-analysis of epidemiologic studies of electric and magnetic fields 
and breast cancer in women and men." Bioelectromagnetics Suppl(5): S105-19. 
Fabris, M., B. Tolusso, et al. (2002). "Tumor necrosis factor-alpha receptor II polymorphism in 
patients from southern Europe with mild-moderate and severe rheumatoid arthritis." J 
Rheumatol 29(9): 1847-50. 
Fisher, B., J. P. Costantino, et al. (1998). "Tamoxifen for prevention of breast cancer: report of 
the National Surgical Adjuvant Breast and Bowel Project P-1 Study." Journal of the 
National Cancer Institute 90(18): 1371-88. 
Fisher, E. R., A. Palekar, et al. (1978). "The histopathology of mammographic patterns." 
American Journal of Clinical Pathology 69(4): 421-6. 
Friedenreich, C. M. and M. R. Orenstein (2002). "Physical activity and cancer prevention: 
etiologic evidence and biological mechanisms." Journal of Nutrition 132(11 Suppl): 
3456S-3464S. 
Friis, S., H. T. Sorensen, et al. (2003). "A population-based cohort study of the risk of colorectal 
and other cancers among users of low-dose aspirin." Br J Cancer 88(5): 684-8. 
Gadducci, A., M. Ferdeghini, et al. (1995). "Serum Levels of Tumor Necrosis Factor (TNF), 
Soluble Receptors for TNF (55- and 75-kDa sTNFr), and Soluble CD14 (sCD14) in 
Epithelial Ovarian Cancer." Gynecologic Oncology 58(2): 184-188. 
Gadducci, A., M. Ferdeghini, et al. (1996). "Serum levels of soluble receptors for tumor necrosis 
factor (p55 and p75 sTNFr) in endometrial cancer." Anticancer Res 16(5B): 3125-8. 
Gail, M. H., L. A. Brinton, et al. (1989). "Projecting individualized probabilities of developing 
breast cancer for white females who are being examined annually.[comment]." Journal of 
the National Cancer Institute 81(24): 1879-86. 
199 
Gammon, M. D., M. S. Wolff, et al. (2002). "Environmental toxins and breast cancer on Long 
Island. II. Organochlorine compound levels in blood." Cancer Epidemiology Biomarkers 
& Prevention 11(8): 686-97. 
Garcia Rodriguez, L. A. and A. Gonzalez-Perez (2004). "Risk of breast cancer among users of 
aspirin and other anti-inflammatory drugs." Br J Cancer 91(3): 525-9. 
Gasparini, G., R. Longo, et al. (2003). "Inhibitors of cyclo-oxygenase 2: a new class of 
anticancer agents?" Lancet Oncol 4(10): 605-15. 
Gierach, G. and V. Vogel (2004). Epidemiology of Breast Cancer. Advanced Therapy of Breast 
Disease, 2nd Edition. S. E. Singletary, G. L. Robb and G. N. Hortobagyi. Hamilton, 
Ontario, BC Decker, Inc.: 58-74. 
Glenn, C. L., W. Y. Wang, et al. (2000). "Linkage and association of tumor necrosis factor 
receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor." 
Human Molecular Genetics 9(13): 1943-9. 
Gram, I., Y. Bremnes, et al. (2005). "Percentage density, Wolfe's and Tabar's mammographic 
patterns: agreement and association with risk factors for breast cancer." Breast Cancer 
Research 7(5): R854 - R861. 
Gram, I. T., E. Funkhouser, et al. (1995). "Reproductive and menstrual factors in relation to 
mammographic parenchymal patterns among perimenopausal women." British Journal of 
Cancer 71(3): 647-50. 
Gravelle, I. H., J. C. Bulstrode, et al. (1986). "A prospective study of mammographic 
parenchymal patterns and risk of breast cancer." Br J Radiol 59(701): 487-91. 
Greendale, G. A., S. L. Palla, et al. (2005). "The Association of Endogenous Sex Steroids and 
Sex Steroid Binding Proteins with Mammographic Density: Results from the 
Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study." Am J 
Epidemiol 162(9): 826-34. 
Grosen, E. A., G. A. Granger, et al. (1993). "Measurement of the soluble membrane receptors for 
tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic 
malignancy." Gynecol Oncol 50(1): 68-77. 
Grove, J. S., M. J. Goodman, et al. (1985). "Factors associated with mammographic pattern." 
British Journal of Radiology 58(685): 21-5. 
Guo, Y. P., L. J. Martin, et al. (2001). "Growth factors and stromal matrix proteins associated 
with mammographic densities." Cancer Epidemiology, Biomarkers and Prevention 10(3): 
243-8. 
Haars, G., P. A. H. van Noord, et al. (2005). "Measurements of Breast Density: No Ratio for a 
Ratio." Cancer Epidemiol Biomarkers Prev 14(11): 2634-2640. 
200 
Habel, L. A., J. J. Dignam, et al. (2004). "Mammographic Density and Breast Cancer After 
Ductal Carcinoma In Situ." J Natl Cancer Inst 96(19): 1467-1472. 
Haiman, C. A., L. Bernstein, et al. (2002). "Genetic determinants of mammographic density." 
Breast Cancer Research 4(3): R5. 
Haiman, C. A., S. E. Hankinson, et al. (2003). "Polymorphisms in steroid hormone pathway 
genes and mammographic density." Breast Cancer Research and Treatment 77(1): 27-36. 
Hancock, S. L., M. A. Tucker, et al. (1993). "Breast cancer after treatment of Hodgkin's disease." 
Journal of the National Cancer Institute 85(1): 25-31. 
Hankinson, S. E., G. A. Colditz, et al. (1997). "A prospective study of oral contraceptive use and 
risk of breast cancer (Nurses' Health Study, United States)." Cancer Causes & Control 
8(1): 65-72. 
Hankinson, S. E., W. C. Willett, et al. (1998). "Circulating concentrations of insulin-like growth 
factor-I and risk of breast cancer.[comment]." Lancet 351(9113): 1393-6. 
Harris, R., J. Beebe-Donk, et al. (2006). "Reduction in the risk of human breast cancer by 
selective cyclooxygenase-2 (COX-2) inhibitors." BMC Cancer 6(1): 27. 
Harris, R. E., J. Beebe-Donk, et al. (2005). "Aspirin, ibuprofen, and other non-steroidal anti-
inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 
blockade (review)." Oncol Rep 13(4): 559-83. 
Harris, R. E., R. T. Chlebowski, et al. (2003). "Breast Cancer and Nonsteroidal Anti-
Inflammatory Drugs: Prospective Results from the Women's Health Initiative." Cancer 
Res 63(18): 6096-6101. 
Harris, R. E., S. Kasbari, et al. (1999). "Prospective study of nonsteroidal anti-inflammatory 
drugs and breast cancer." Oncol Rep 6(1): 71-3. 
Harris, R. E., Namboodiri K., et al. (1995). "Breast Cancer and NSAID Use: Heterogeneity of 
Effect in a Case-Control Study." Preventive Medicine 24(2): 119-120. 
Harris, R. E., K. K. Namboodiri, et al. (1996). "Nonsteroidal antiinflammatory drugs and breast 
cancer." Epidemiology 7(2): 203-5. 
Harrison, D. A., S. W. Duffy, et al. (2002). "Deterministic models for breast cancer progression::  
Application to the association between mammographic parenchymal pattern and 
histologic grade of breast cancers." Journal of Clinical Epidemiology 55(11): 1113-1118. 
Harvey, J., C. Scheurer, et al. (2005). "Hormone replacement therapy and breast density 
changes." Climacteric 8(2): 185-92. 
Harvey, J. A. and V. E. Bovbjerg (2004). "Quantitative Assessment of Mammographic Breast 
Density: Relationship with Breast Cancer Risk." Radiology 230(1): 29-41. 
201 
Hasegawa, Y., M. Sawada, et al. (2000). "Increased soluble tumor necrosis factor receptor levels 
in the serum of elderly people." Gerontology 46(4): 185-8. 
Hauner, H., M. Bender, et al. (1998). "Plasma concentrations of soluble TNF-alpha receptors in 
obese subjects." Int J Obes Relat Metab Disord 22(12): 1239-43. 
Heller, R. A., K. Song, et al. (1992). "The p70 tumor necrosis factor receptor mediates 
cytotoxicity." Cell 70(1): 47-56. 
Heng, D., F. Gao, et al. (2004). "Risk Factors for Breast Cancer Associated with Mammographic 
Features in Singaporean Chinese Women." Cancer Epidemiol Biomarkers Prev 13(11): 
1751-1758. 
Higuchi, M. and B. B. Aggarwal (1993). "P80 form of the human tumor necrosis factor receptor 
is involved in DNA fragmentation." FEBS Letters 331(3): 252-5. 
Hilakivi-Clarke, L., A. Cabanes, et al. (2002). "Do estrogens always increase breast cancer risk?" 
Journal of Steroid Biochemistry & Molecular Biology 80(2): 163-74. 
Hill, D., S. Preston-Martin, et al. (2002). "Medical radiation, family history of cancer, and benign 
breast disease in relation to breast cancer risk in young women, USA." Cancer Causes 
Control 13(8): 711-8. 
Hohmann, H., R. Remy, et al. (1989). "Two different cell types have different major receptors 
for human tumor necrosis factor (TNF alpha)." J Biol Chem 264(25): 14927-14934. 
Hong, C. C., H. J. Thompson, et al. (2003). "Val158Met Polymorphism in catechol-O-
methyltransferase gene associated with risk factors for breast cancer." Cancer 
Epidemiology, Biomarkers and Prevention 12(9): 838-47. 
Hong, C. C., H. J. Thompson, et al. (2004). "Association between the T27C polymorphism in the 
cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer." Breast 
Cancer Res Treat 88(3): 217-30. 
Horn-Ross, P. L., E. M. John, et al. (2001). "Phytoestrogen Consumption and Breast Cancer Risk 
in a Multiethnic Population - The Bay Area Breast Cancer Study." American Journal of 
Epidemiology 154(5): 434-441. 
Hoshaw, S. J., P. J. Klein, et al. (2001). "Breast implants and cancer: causation, delayed 
detection, and survival." Plastic & Reconstructive Surgery 107(6): 1393-407. 
Hotamisligil, G. S., P. Arner, et al. (1997). "Differential regulation of the p80 tumor necrosis 
factor receptor in human obesity and insulin resistance." Diabetes 46(3): 451-5. 
Howe, L. R., K. Subbaramaiah, et al. (2001). "Cyclooxygenase-2: a target for the prevention and 
treatment of breast cancer." Endocrine-Related Cancer 8(2): 97-114. 
202 
Hube, F., M. Birgel, et al. (1999). "Expression pattern of tumour necrosis factor receptors in 
subcutaneous and omental human adipose tissue: role of obesity and non-insulin-
dependent diabetes mellitus." European Journal of Clinical Investigation 29(8): 672-8. 
Huo, Z., M. L. Giger, et al. (2002). "Computerized analysis of digitized mammograms of 
BRCA1 and BRCA2 gene mutation carriers." Radiology 225(2): 519-26. 
Il'yasova, D., L. H. Colbert, et al. (2005). "Circulating Levels of Inflammatory Markers and 
Cancer Risk in the Health Aging and Body Composition Cohort." Cancer Epidemiol 
Biomarkers Prev 14(10): 2413-2418. 
Ininns, E. K., M. Gatanaga, et al. (1992). "Growth of the endometrial adenocarcinoma cell line 
AN3 CA is modulated by tumor necrosis factor and its receptor is up-regulated by 
estrogen in vitro." Endocrinology 130(4): 1852-6. 
Innes, K. E. and T. E. Byers (1999). "Preeclampsia and breast cancer risk." Epidemiology 10(6): 
722-32. 
Ip, M. M., C. Mazzer, et al. (1989). "The effect of eicosanoid synthesis inhibitors on DMBA-
induced rat mammary carcinogenesis." Proc Am Assoc Cancer Res 30: 182. 
Irwin, M., E. Aiello, et al. (2005). "Pre-diagnosis physical activity and mammographic density in 
breast cancer survivors." Breast Cancer Research and Treatment: 1-8. 
Jablonska, E., M. Kiluk, et al. (1998). "Soluble TNF receptors release by polymorphonuclear 
cells and the serum levels in breast cancer patients before and after treatment." 
Neoplasma 45(1): 17-20. 
Jacobs, E. J., M. J. Thun, et al. (2005). "Aspirin and Other Nonsteroidal Anti-inflammatory 
Drugs and Breast Cancer Incidence in a Large U.S. Cohort." Cancer Epidemiol 
Biomarkers Prev 14(1): 261-264. 
Jeffreys, M., R. Warren, et al. (2004). "Life course breast cancer risk factors and adult breast 
density (United Kingdom)." Cancer Causes and Control 15(9): 947-955. 
Jemal, A., R. Siegel, et al. (2006). "Cancer Statistics, 2006." CA Cancer J Clin 56(2): 106-130. 
Johnson, J. W. (2001). "Transactions of the sixty-third annual meeting of the South Atlantic 
Association of Obstetricians and Gynecologyists. The millennial mark: presidential 
address." American Journal of Obstetrics & Gynecology 185(2): 261-7. 
Johnson, T. W., K. E. Anderson, et al. (2002). "Association of Aspirin and Nonsteroidal Anti-
inflammatory Drug Use with Breast Cancer." Cancer Epidemiol Biomarkers Prev 11(12): 
1586-1591. 
Kaaks, R., C. Diorio, et al. (2005). "Insulin-Like Growth Factor-I and Mammographic Breast 
Density." Cancer Epidemiol Biomarkers Prev 14(12): 3019-. 
203 
Kaaks, R., E. Lundin, et al. (2002). "Prospective study of IGF-I, IGF-binding proteins, and breast 
cancer risk, in northern and southern Sweden." Cancer Causes & Control 13(4): 307-16. 
Kadar, D. (1998). Anti-inflammatory analgesics. Principles of Medical Pharmacology. H. Kalant 
and W. H. E. Roschlau. New York, Oxford University Press: 410-30. 
Kaminska, J., M. P. Nowacki, et al. (2005). "Clinical significance of serum cytokine 
measurements in untreated colorectal cancer patients: soluble tumor necrosis factor 
receptor type I--an independent prognostic factor." Tumour Biol 26(4): 186-94. 
Kato, I., C. Beinart, et al. (1995). "A nested case-control study of mammographic patterns, breast 
volume, and breast cancer (New York City, NY, United States)." Cancer Causes Control 
6(5): 431-8. 
Kaufman, Z., W. I. Garstin, et al. (1991). "The mammographic parenchymal patterns of 
nulliparous women and women with a family history of breast cancer." Clinical 
Radiology 43(6): 385-8. 
Kelsey, J. L., M. D. Gammon, et al. (1993). "Reproductive factors and breast cancer." 
Epidemiologic Reviews 15(1): 36-47. 
Kerlikowske, K., D. Grady, et al. (1995). "Efficacy of screening mammography. A meta-
analysis." Jama 273(2): 149-54. 
Kerlikowske, K., J. Shepherd, et al. (2005). "Are Breast Density and Bone Mineral Density 
Independent Risk Factors for Breast Cancer?" J Natl Cancer Inst 97(5): 368-374. 
Kharfi, A., Y. Labelle, et al. (2003). "Deficient expression of tumor necrosis factor receptor type 
2 in the endometrium of women with endometriosis." Am J Reprod Immunol 50(1): 33-
40. 
Khuder, S. A. and A. B. Mutgi (2001). "Breast cancer and NSAID use: a meta-analysis." British 
Journal of Cancer 84(9): 1188-92. 
Komata, T., N. Tsuchiya, et al. (1999). "Association of tumor necrosis factor receptor 2 (TNFR2) 
polymorphism with susceptibility to systemic lupus erythematosus." Tissue Antigens 
53(6): 527-33. 
Krajcik, R. A., S. Massardo, et al. (2003). "No association between serum levels of tumor 
necrosis factor-alpha (TNF-alpha) or the soluble receptors sTNFR1 and sTNFR2 and 
breast cancer risk." Cancer Epidemiol Biomarkers Prev 12(9): 945-6. 
Lacey, J. V., Jr., S. S. Devesa, et al. (2002). "Recent trends in breast cancer incidence and 
mortality." Environmental & Molecular Mutagenesis 39(2-3): 82-8. 
Lai, J. H., D. Vesprini, et al. (2004). "A Polymorphic Locus in the Promoter Region of the 
IGFBP3 Gene Is Related to Mammographic Breast Density." Cancer Epidemiol 
Biomarkers Prev 13(4): 573-582. 
204 
Lam, P. B., P. M. Vacek, et al. (2000). "The association of increased weight, body mass index, 
and tissue density with the risk of breast carcinoma in Vermont." Cancer 89(2): 369-75. 
Langman, M. J. S., K. K. Cheng, et al. (2000). "Effect of anti-inflammatory drugs on overall risk 
of common cancer: case-control study in general practice research database." BMJ 
320(7250): 1642-1646. 
Lee, P. P. and M. M. Ip (1992). "Regulation of proliferation of rat mammary tumor cells by 
inhibitors of cyclooxygenase and lipoxygenase." Prostaglandins Leukot Essent Fatty 
Acids 45: 21-31. 
Li, T., L. Sun, et al. (2005). "The Association of Measured Breast Tissue Characteristics with 
Mammographic Density and Other Risk Factors for Breast Cancer." Cancer Epidemiol 
Biomarkers Prev 14(2): 343-349. 
Lillie, E. O., L. Bernstein, et al. (2004). "Polymorphism in the Androgen Receptor and 
Mammographic Density in Women Taking and Not Taking Estrogen and Progestin 
Therapy." Cancer Res 64(4): 1237-1241. 
Lipworth, L., H. O. Adami, et al. (1996). "Serum steroid hormone levels, sex hormone-binding 
globulin, and body mass index in the etiology of postmenopausal breast cancer." 
Epidemiology 7(1): 96-100. 
Lopez, P., L. Van Horn, et al. (2003). "Physical inactivity and percent breast density among 
Hispanic women." International Journal of Cancer 107(6): 1012-6. 
Lord, S., W. Mack, et al. (2005). "Polymorphisms in genes involved in estrogen and 
progesterone metabolism and mammographic density changes in women randomized to 
postmenopausal hormone therapy: results from a pilot study." Breast Cancer Research 
7(3): R336 - R344. 
Macdiarmid, F., D. Wang, et al. (1994). "Stimulation of aromatase activity in breast fibroblasts 
by tumor necrosis factor alpha." Mol Cell Endocrinol 106(1-2): 17-21. 
Madhusudan, S., M. Foster, et al. (2004). "A Phase II Study of Etanercept (Enbrel), a Tumor 
Necrosis Factor {alpha} Inhibitor in Patients with Metastatic Breast Cancer." Clin Cancer 
Res 10(19): 6528-6534. 
Marshall, S. F., L. Bernstein, et al. (2005). "Nonsteroidal Anti-Inflammatory Drug Use and 
Breast Cancer Risk by Stage and Hormone Receptor Status." J Natl Cancer Inst 97(11): 
805-812. 
Martin, J. H., E. J. Begg, et al. (2001). "Is cytochrome P450 2C9 genotype associated with 
NSAID gastric ulceration?" Br J Clin Pharmacol 51(6): 627-30. 
Masala, G., D. Ambrogetti, et al. (2006). "Dietary and lifestyle determinants of mammographic 
breast density. A longitudinal study in a Mediterranean population." International Journal 
of Cancer 118(7): 1782-1789. 
205 
Maskarinec, G., G. Lurie, et al. (2004). "An investigation of mammographic density and gene 
variants in healthy women." Int J Cancer 112(4): 683-8. 
Maskarinec, G. and L. Meng (2000). "A case-control study of mammographic densities in 
Hawaii." Breast Cancer Res Treat 63(2): 153-61. 
Maskarinec, G., I. Pagano, et al. (2005). "Mammographic Density and Breast Cancer Risk." Am. 
J. Epidemiol.: kwi270. 
Maskarinec, G., Y. Takata, et al. (2006). "Alcohol consumption and mammographic density in a 
multiethnic population." Int J Cancer 118(10): 2579-83. 
Maskarinec, G., A. E. Williams, et al. (2003). "Mammographic densities in a one-year isoflavone 
intervention." European Journal of Cancer Prevention 12(2): 165-9. 
Maskarinec, G., A. E. Williams, et al. (2003). "A cross-sectional investigation of breast density 
and insulin-like growth factor I." International Journal of Cancer 107(6): 991-6. 
McCormack, V. A., I. dos Santos Silva, et al. (2003). "Life-course body size and perimenopausal 
mammographic parenchymal patterns in the MRC 1946 British birth cohort." Br J Cancer 
89(5): 852-9. 
Medvedev, A. E., T. Espevik, et al. (1996). "Distinct Roles of the Two Tumor Necrosis Factor 
(TNF) Receptors in Modulating TNF and Lymphotoxin alpha Effects." J Biol Chem 
271(16): 9778-9784. 
Meier, C. R., S. Schmitz, et al. (2002). "Association between acetaminophen or nonsteroidal 
antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer." 
Pharmacotherapy 22(3): 303-9. 
Meilahn, E. N., B. De Stavola, et al. (1998). "Do urinary oestrogen metabolites predict breast 
cancer? Guernsey III cohort follow-up." British Journal of Cancer 78(9): 1250-5. 
Melbye, M., J. Wohlfahrt, et al. (1997). "Induced abortion and the risk of breast 
cancer.[comment]." New England Journal of Medicine 336(2): 81-5. 
Mestiri, S., N. Bouaouina, et al. (2005). "A functional polymorphism of the tumor necrosis factor 
receptor-II gene associated with the survival and relapse prediction of breast carcinoma." 
Cytokine 30(4): 182-187. 
Miller, W. R. and A. P. Forrest (1974). "Oestradiol synthesis by a human breast carcinoma." 
Lancet 2(7885): 866-8. 
Miners, J. O. and D. J. Birkett (1998). "Cytochrome P4502C9: an enzyme of major importance 
in human drug metabolism." Br J Clin Pharmacol 45(6): 525-38. 
Modugno, F., R. B. Ness, et al. (2003). "Alcohol Consumption and the Risk of Mucinous and 
Nonmucinous Epithelial Ovarian Cancer." Obstet Gynecol 102(6): 1336-1343. 
206 
Modugno, F., D. Ngo, et al. (2005). "Breast cancer risk factors and mammographic breast 
density in women over age 70." Breast Cancer Research and Treatment: 1-10. 
Mohamed-Ali, V., S. Goodrick, et al. (1999). "Production of soluble tumor necrosis factor 
receptors by human subcutaneous adipose tissue in vivo." Am J Physiol 277(6 Pt 1): 
E971-5. 
Moorman, P., J. Grubber, et al. (2003). "Association between non-steroidal anti-inflammatory 
drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast." Cancer 
Causes and Control 14(10): 915-922. 
Morimoto, L., E. White, et al. (2002). "Obesity, body size, and risk of postmenopausal breast 
cancer: the Women's Health Initiative (United States)." Cancer Causes Control 13(8): 
741-51. 
Morita, C., T. Horiuchi, et al. (2001). "Association of tumor necrosis factor receptor type II 
polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and 
functional analysis." Arthritis Rheum 44(12): 2819-27. 
Morita, I. (2002). "Distinct functions of COX-1 and COX-2." Prostaglandins Other Lipid Mediat 
68-69: 165-75. 
Mulhall, C., R. A. Hegele, et al. (2005). "Pituitary Growth Hormone and Growth Hormone-
Releasing Hormone Receptor Genes and Associations with Mammographic Measures 
and Serum Growth Hormone." Cancer Epidemiol Biomarkers Prev 14(11): 2648-2654. 
Muti, P., H. L. Bradlow, et al. (2000). "Estrogen metabolism and risk of breast cancer: a 
prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and 
postmenopausal women." Epidemiology 11(6): 635-40. 
Neugut, A., D. Rosenberg, et al. (1998). "Association between coronary heart disease and 
cancers of the breast, prostate, and colon." Cancer Epidemiol Biomarkers Prev 7(10): 
869-873. 
Newcomb, P. A., A. Trentham-Dietz, et al. (2001). "Fracture History and Risk of Breast and 
Endometrial Cancer." American Journal of Epidemiology 153(11): 1071-1078. 
Noh, J. J., G. Maskarinec, et al. (2006). "Mammographic densities and circulating hormones: A 
cross-sectional study in premenopausal women." The Breast 15(1): 20-28. 
Paganini-Hill, A., A. Chao, et al. (1989). "Aspirin use and chronic diseases: a cohort study of the 
elderly." Bmj 299(6710): 1247-50. 
Page, D. L. and A. C. Winfield (1986). "The dense mammogram." AJR. American Journal of 
Roentgenology 147(3): 487-9. 
207 
Pankow, J. S., C. M. Vachon, et al. (1997). "Genetic analysis of mammographic breast density in 
adult women: evidence of a gene effect." Journal of the National Cancer Institute 89(8): 
549-56. 
Pawluczyk, O., B. J. Augustine, et al. (2003). "A volumetric method for estimation of breast 
density on digitized screen-film mammograms." Med Phys 30(3): 352-64. 
Peral, B., J. L. San Millan, et al. (2002). "Comment: the methionine 196 arginine polymorphism 
in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic 
ovary syndrome and hyperandrogenism." Journal of Clinical Endocrinology and 
Metabolism 87(8): 3977-83. 
Pfeilschifter, J., R. Koditz, et al. (2002). "Changes in Proinflammatory Cytokine Activity after 
Menopause." Endocr Rev 23(1): 90-119. 
Pike, M. C., M. D. Krailo, et al. (1983). "'Hormonal' risk factors, 'breast tissue age' and the age-
incidence of breast cancer." Nature 303(5920): 767-70. 
Purohit, A., L. J. Duncan, et al. (1997). "Paracrine control of oestrogen production in breast 
cancer." Endocr Relat Cancer 4: 323-330. 
Purohit, A., S. Newman, et al. (2002). "The role of cytokines in regulating estrogen synthesis: 
implications for the etiology of breast cancer." Breast Cancer Res 4(2): 65 - 69. 
Rahme, E., J. Ghosn, et al. (2005). "Association between frequent use of nonsteroidal anti-
inflammatory drugs and breast cancer." BMC Cancer 5(1): 159. 
Rainsford, K. D. (2003). "Discovery, mechanisms of action and safety of ibuprofen." Int J Clin 
Pract Suppl(135): 3-8. 
Reed, M. J. and A. Purohit (1997). "Breast cancer and the role of cytokines in regulating 
estrogen synthesis: an emerging hypothesis." Endocr Rev 18(5): 701-15. 
Reed, M. J. and A. Purohit (2001). "Aromatase regulation and breast cancer." Clinical 
Endocrinology 54(5): 563-71. 
Riza, E., I. dos Santos Silva, et al. (2001). "Urinary estrogen metabolites and mammographic 
parenchymal patterns in postmenopausal women." Cancer Epidemiol Biomarkers Prev 
10(6): 627-34. 
Riza, E., I. dos Santos Silva, et al. (2005). "Correlates of high-density mammographic 
parenchymal patterns by menopausal status in a rural population in Northern Greece." 
European Journal of Cancer 41(4): 590-600. 
Rosenberg, L. (1995). "Nonsteroidal Anti-inflammatory Drugs and Cancer." Preventive 
Medicine 24(2): 107-109. 
208 
Roubidoux, M. A., J. E. Bailey, et al. (2004). "Invasive Cancers Detected after Breast Cancer 
Screening Yielded a Negative Result: Relationship of Mammographic Density to Tumor 
Prognostic Factors." Radiology 230(1): 42-48. 
Saftlas, A. F., R. N. Hoover, et al. (1991). "Mammographic densities and risk of breast cancer." 
Cancer 67(11): 2833-8. 
Sala, E., R. Warren, et al. (1998). "Mammographic parenchymal patterns and mode of detection: 
implications for the breast screening programme." J Med Screen 5(4): 207-12. 
Santee, S. M. and L. B. Owen-Schaub (1996). "Human tumor necrosis factor receptor p75/80 
(CD120b) gene structure and promoter characterization." Journal of Biological Chemistry 
271(35): 21151-9. 
Sato, R., K. J. Helzlsouer, et al. (2002). "Prospective study of carotenoids, tocopherols, and 
retinoid concentrations and the risk of breast cancer." Cancer Epidemiology Biomarkers 
& Prevention 11(5): 451-7. 
Schreinemachers, D. M. and R. B. Everson (1994). "Aspirin use and lung, colon, and breast 
cancer incidence in a prospective study." Epidemiology 5(2): 138-46. 
"SEER*Stat Database: 9 SEER Incidence Registries for Public-Use, National Cancer Institute, 
DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2003, 
based on the November 2002 data (for the years 1973-2000)."    Retrieved November 11, 
2004. 
Sellers, T. A., L. H. Kushi, et al. (2001). "Dietary folate intake, alcohol, and risk of breast cancer 
in a prospective study of postmenopausal women." Epidemiology 12(4): 420-8. 
Sharpe, C. R., J. P. Collet, et al. (2000). "Nested case-control study of the effects of non-steroidal 
anti-inflammatory drugs on breast cancer risk and stage." Br J Cancer 83(1): 112-20. 
Sites, C. K., M. J. Toth, et al. (2002). "Menopause-related differences in inflammation markers 
and their relationship to body fat distribution and insulin-stimulated glucose disposal." 
Fertil Steril 77(1): 128-35. 
Smith-Warner, S. A., D. Spiegelman, et al. (2001). "Types of dietary fat and breast cancer: a 
pooled analysis of cohort studies." International Journal of Cancer 92(5): 767-74. 
Sorensen, H. T., S. Friis, et al. (2003). "Risk of cancer in a large cohort of nonaspirin NSAID 
users: a population-based study." Br J Cancer 88(11): 1687-92. 
Soysal, S., M. E. Soysal, et al. (2006). "The basal and TRH stimulated levels of prolactin in low 
risk climacteric patients with increased breast density: A matched pair case control trial." 
Maturitas In Press. 
209 
Steele, V. E., R. C. Moon, et al. (1994). "Preclinical efficacy evaluation of potential 
chemopreventive agents in animal carcinogenesis models: methods and results from the 
NCI Chemoprevention Drug Development Program." J Cell Biochem Suppl 20: 32-54. 
Suijkerbuijk, K. P. M., F. J. B. Van Duijnhoven, et al. (2006). "Physical Activity in Relation to 
Mammographic Density in the Dutch Prospect-European Prospective Investigation into 
Cancer and Nutrition Cohort." Cancer Epidemiol Biomarkers Prev 15(3): 456-460. 
Swede, H., A. L. Mirand, et al. (2005). "Association of Regular Aspirin Use and Breast Cancer 
Risk." Oncology 68(1): 40-47. 
Tabar, L. and P. B. Dean (1982). "Mammographic parenchymal patterns. Risk indicator for 
breast cancer?" Jama 247(2): 185-9. 
Tamimi, R. M., S. E. Hankinson, et al. (2005). "Endogenous Sex Hormone Levels and 
Mammographic Density among Postmenopausal Women." Cancer Epidemiol Biomarkers 
Prev 14(11): 2641-2647. 
Terry, M. B., M. D. Gammon, et al. (2004). "Association of Frequency and Duration of Aspirin 
Use and Hormone Receptor Status With Breast Cancer Risk." JAMA 291(20): 2433-
2440. 
Tesarova, P., J. Kvasnicka, et al. (2000). "Soluble TNF and IL-2 receptors in patients with breast 
cancer." Med Sci Monit 6(4): 661-7. 
The Endogenous Hormones and Breast Cancer Collaborative Group (2002). "Endogenous Sex 
Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective 
Studies." JNCI Cancer Spectrum 94(8): 606-616. 
Thun, M., M. Namboodiri, et al. (1993). "Aspirin use and risk of fatal cancer." Cancer Res 53(6): 
1322-1327. 
Tolusso, B., S. Sacco, et al. (2004). "Relationship between the tumor necrosis factor receptor II 
(TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in 
rheumatoid arthritis." Human Immunology 65(12): 1420-1426. 
Torres-Mejia, G., B. De Stavola, et al. (2005). "Mammographic Features and Subsequent Risk of 
Breast Cancer: A Comparison of Qualitative and Quantitative Evaluations in the 
Guernsey Prospective Studies." Cancer Epidemiol Biomarkers Prev 14(5): 1052-1059. 
Ursin, G., L. Hovanessian-Larsen, et al. (2005). "Greatly increased occurrence of breast cancers 
in areas of mammographically dense tissue." Breast Cancer Research 7(5): R605 - R608. 
Ursin, G., H. Ma, et al. (2003). "Mammographic density and breast cancer in three ethnic 
groups." Cancer Epidemiol Biomarkers Prev 12(4): 332-8. 
210 
Vacek, P. M. and B. M. Geller (2004). "A Prospective Study of Breast Cancer Risk Using 
Routine Mammographic Breast Density Measurements." Cancer Epidemiol Biomarkers 
Prev 13(5): 715-722. 
Vachon, C. M., R. A. King, et al. (1999). "Preliminary sibpair linkage analysis of percent 
mammographic density." Journal of the National Cancer Institute 91(20): 1778-9. 
Vachon, C. M., C. C. Kuni, et al. (2000). "Association of mammographically defined percent 
breast density with epidemiologic risk factors for breast cancer (United States)." Cancer 
Causes and Control 11(7): 653-62. 
Vachon, C. M., L. H. Kushi, et al. (2000). "Association of diet and mammographic breast density 
in the Minnesota breast cancer family cohort." Cancer Epidemiol Biomarkers Prev 9(2): 
151-60. 
van den Brandt, P. A., D. Spiegelman, et al. (2000). "Pooled analysis of prospective cohort 
studies on height, weight, and breast cancer risk." American Journal of Epidemiology 
152(6): 514-27. 
van Duijnhoven, F. J. B., I. D. Bezemer, et al. (2005). "Polymorphisms in the Estrogen Receptor 
{alpha} Gene and Mammographic Density." Cancer Epidemiol Biomarkers Prev 14(11): 
2655-2660. 
van Duijnhoven, F. J. B., P. H. M. Peeters, et al. (2006). "Influence of Estrogen Receptor {alpha} 
and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on 
Mammographic Density." Cancer Epidemiol Biomarkers Prev 15(3): 462-467. 
van Gils, C. H., J. H. Hendriks, et al. (1999). "Changes in mammographic breast density and 
concomitant changes in breast cancer risk." European Journal of Cancer Prevention 8(6): 
509-15. 
van Gils, C. H., J. D. Otten, et al. (1995). "Short communication: breast parenchymal patterns 
and their changes with age." British Journal of Radiology 68(814): 1133-5. 
Varela, L. M., K. M. Darcy, et al. (1997). "The Epidermal Growth Factor Receptor Is Not 
Required for Tumor Necrosis Factor-{alpha} Action in Normal Mammary Epithelial 
Cells." Endocrinology 138(9): 3891-3900. 
Verthelyi, D. and D. M. Klinman (2000). "Sex hormone levels correlate with the activity of 
cytokine-secreting cells in vivo." Immunology 100(3): 384-390. 
Vogel, V. G. (1998). Breast cancer risk factors and preventive approaches to breast cancer. 
Cancer in Women. S. S. Kavanagh J, Einhorn N, DePetrillo AD, Eds. Cambridge, MA, 
Blackwell Scientific Publications, Inc.: 58-91. 
Wellings, S. R. and J. N. Wolfe (1978). "Correlative studies of the histological and radiographic 
appearance of the breast parenchyma." Radiology 129(2): 299-306. 
211 
White, E., P. Velentgas, et al. (1998). "Variation in mammographic breast density by time in 
menstrual cycle among women aged 40-49 years." Journal of the National Cancer 
Institute 90(12): 906-10. 
Whitehead, J., T. Carlile, et al. (1985). "Wolfe mammographic parenchymal patterns. A study of 
the masking hypothesis of Egan and Mosteller." Cancer 56(6): 1280-6. 
Whitehouse, G. H. and S. J. Leinster (1985). "The variation of breast parenchymal patterns with 
age." British Journal of Radiology 58(688): 315-8. 
Wolfe, J. N. (1976). "Risk for breast cancer development determined by mammographic 
parenchymal pattern." Cancer 37(5): 2486-92. 
Wolfe, J. N., A. F. Saftlas, et al. (1987). "Mammographic parenchymal patterns and quantitative 
evaluation of mammographic densities: a case-control study." AJR. American Journal of 
Roentgenology 148(6): 1087-92. 
Writing Group for the Women's Health Initiative, I. (2002). "Risks and benefits of estrogen plus 
progestin in healthy postmenopausal women: principal results From the Women's Health 
Initiative randomized controlled trial." Jama 288(3): 321-33. 
Zhang, Y., P. F. Coogan, et al. (2005). "Use of Nonsteroidal Antiinflammatory Drugs and Risk 
of Breast Cancer: The Case-Control Surveillance Study Revisited." Am J Epidemiol 
162(2): 165-170. 
Zhao, Y., V. R. Agarwal, et al. (1996). "Estrogen biosynthesis proximal to a breast tumor is 
stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 
(aromatase) gene." Endocrinology 137(12): 5739-42. 
Ziv, E., J. Cauley, et al. (2001). "Association between the T29-->C polymorphism in the 
transforming growth factor beta1 gene and breast cancer among elderly white women: 
The Study of Osteoporotic Fractures." JAMA 285(22): 2859-63. 
Ziv, E., J. Shepherd, et al. (2003). "Mammographic breast density and family history of breast 
cancer." J Natl Cancer Inst 95(7): 556-8. 
Zmuda, J. M., J. A. Cauley, et al. (2001). "Bone mass and breast cancer risk in older women: 
differences by stage at diagnosis." Journal of the National Cancer Institute 93(12): 930-6. 
 
212 
